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Major Depressive Disorder (MDD) is a disabling, common psychiatric 
disorder and the leading cause of global disability. A complex combination of genetic 
and environmental factors gives rise to MDD, although the exact aetiology has not 
been identified. Genome-wide association studies (GWAS) have established that 
MDD has a moderate heritability of approximately 37%. MDD has in the past also 
been associated with abnormalities of white matter microstructure, which represents 
the brain’s connectivity network. This network is also moderately heritable, providing 
rationale to investigate its relationship to MDD genetic risk.  
Over recent years, there has been considerable progress in establishing genetic 
contributions to MDD. These advances can be harnessed, in combination with 
neuroimaging and epigenomics, to understand the neurobiology of the disorder. This 
has only recently become possible at sufficient scale with the availability of large 
publicly available datasets including genomic, epigenomic, and neuroimaging data. 
In the current thesis, I therefore aimed to leverage genetic, epigenetic, and 
neuroimaging data in two large datasets, UK Biobank (N range: 6,400 – 14,800) and 
Generation Scotland: Scottish Family Health Study (N = 625). Specifically, I aimed to 
uncover links between white matter microstructure, as measured by fractional 
anisotropy and mean diffusivity, and (i) differential gene expression as indexed by 
expression quantitative trait loci (eQTLs) scores in chapter 2; here, decreased white 
matter integrity was found to be associated with 6 scores regulating genes previously 
reported to be implicated in neurological and neuropsychiatric disorders, while 2 
scores regulating neurodevelopment-linked genes were associated with increased 
white matter integrity; (ii) MDD genetic risk stratified by the NETRIN1 Signalling 
Pathway, previously implicated in MDD, indexed by polygenic risk scores (PRS) in 
chapter 3; results indicated novel associations between the pathway-focussed PRS and 
decreased white matter integrity in thalamic radiations, as well as several association 
fibres, including superior and inferior longitudinal fasciculus; (iii) a novel whole-
genome epigenetic risk score for MDD, which uncovered an association with MDD, 
but no significant associations with changes in white matter microstructure (chapter 




genetic function and risk and explore epigenetic risk for MDD in order to identify 
novel links to structural brain connectivity. 
Overall, the three studies provide a strong rationale for integrating 
neuroimaging, genomic and epigenomic data. Specifically, findings in chapter 2 
indicate the importance of DCAKD, SLC35A4, SEC14L4, SRA1, PLEKHM1, UBE3C, 
NMT1, and CPNE1, not previously found by conventional GWAS approaches. This 
suggests that integrating neuroimaging and genetic expression data may uncover novel 
associations that inform disease- or trait-specific genetic links to brain connectivity. 
Chapter 3 results provide a rationale for investigating the NETRIN1 Signalling 
Pathway and emphasise the role of thalamic connections in MDD within this biological 
pathway, indicating that novel associations with brain connectivity may be uncovered 
at a more focused level when stratifying MDD risk by biology. Finally, results from 
chapter 4 indicate that epigenetics play an important role in MDD risk, although further 
analysis including larger-scale epigenetic and neuroimaging data should be carried out 

















Major Depressive Disorder (MDD) is a common psychiatric disorder affecting 
approximately 4.4% of the world’s population. Although a complex mixture of 
environmental and genetic factors plays a role in MDD, an exact cause has not been 
identified. MDD has been linked to changes in the wiring of the brain, which is also 
known to have a genetic component, making it a valid target in the investigation of 
MDD. 
Combining neuroimaging and genetic data is useful in the investigation of 
MDD, as it may provide novel insights into disease mechanisms, ultimately leading to 
disorder categorisation and novel treatments. Despite this, large-scale studies 
combining both types of data have only recently become available. 
The current thesis therefore presents three studies using two large datasets that 
comprise both genetic and neuroimaging data. In chapter 2, I looked at the genetics 
behind protein production, which is carried out by genes. I found that poorer 
connectivity was associated with genes previously known to play a role in brain-related 
disorders, while better connectivity was linked to those implicated in developmental 
processes. In chapter 3, genetic risk for MDD aggregated in a specific biological 
process was linked to poor connectivity between the thalamus and other parts of the 
brain, as well as to connections linking homologous parts of the two brain 
hemispheres. In chapter 4, two types of MDD risk, one coming from multiple genetic 
mutations, and one which may be modified by environmental factors called 
“epigenetic risk”, were shown to additively increase risk of having MDD, but were not 
linked to brain connectivity in this sample, though larger studies with this specific type 
of “epigenetic” data are required. 
The three studies show that using analysis methods that link different forms of 
genetic data to neuroimaging variables may elucidate the role played by a large number 
of genetic mutations in MDD, as well as identify specific biomarkers, improving 
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Chapter 1: Introduction 
 
1. Major Depressive Disorder (MDD) 
 
1.1 Definition and diagnosis 
Major Depressive Disorder (MDD) is a common psychiatric disorder and the 
leading cause of disability worldwide. According to a report by the World Health 
Organization (2017), it is estimated that over 300 million individuals are affected 
globally, which is equivalent to 4.4% of the world’s population (World Health 
Organization, 2017).  
MDD is mainly characterized by at least one depressive episode of at least a 2-
week duration, with symptoms persisting for most of the day, nearly every day. 
According to the Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V), 
for a diagnosis of MDD, at least 5 of 9 symptoms must be present (Table 1). At least 
one of the symptoms must be either depressed mood or loss of interest or pleasure in 
daily activities. In addition, MDD may be further characterized using specifiers, which 
describe the nature of an episode (e.g. severity of episode, with mixed, melancholic, 
atypical, mood-congruent psychotic or mood-incongruent psychotic features, with 
catatonia, with peripartum onset or with a seasonal pattern). These symptoms must 
mark a significant change from previous functioning, such as impairment in social, 
educational or occupational domains, and may not be attributable to another medical 
condition (APA, 2013).  
Due to the classification system of MDD, there are over 200 ways in which 
patients can meet diagnostic criteria for MDD. This means that 2 patients diagnosed 
with MDD can have completely different symptom profiles (Zimmerman et al., 2015). 
Moreover, some symptoms are alternative or opposite: a patient presenting with 
psychomotor agitation and insomnia meets criteria in the same way as a patient 
presenting with psychomotor retardation and hypersomnia (Goldberg, 2011). These 
factors make MDD a highly heterogeneous disorder, which may lead to difficulty in 




To address this inherent heterogeneity, stratification of the disorder is needed. 
For instance, patients may form sub-groups comprised of different biological 
mechanisms. Kunugi et al. (2015) discuss three distinct biological mechanisms which 
may act as sub-groups of MDD. Briefly, different classes of antidepressants inhibit the 
reuptake of neurotransmitters in the monoamine system (serotonin, noradrenaline, 
dopamine), which are thought to be important biomarkers for MDD; secondly, the 
hypothalamic-pituitary-adrenal (HPA) axis has been shown to be disrupted in MDD, 
with patients showing both hyper- and hypo-cortisolism; lastly, MDD has been 
proposed as a chronic inflammatory disease, as shown by inflammatory markers linked 
to the disorder. However, research has been inconclusive and often showed opposite 
results when investigating these three, and other, mechanisms in MDD patients (Hodes 
et al., 2015; Kunugi et al., 2015), suggesting the importance for potential biological 
stratification of patients in future analyses. 
In addition, studies suggest stratification of symptoms when assessing their 
association with traits of interest. Pearson et al. (2017) investigated the extent to which 
variation in single nucleotide polymorphism (SNPs) explained variation in 4 MDD 
symptom dimensions in 1,345 cases. They found that core depressives symptoms such 
as sad mood and anhedonia had a lower SNP heritability (14%) than symptoms such 
as insomnia and appetite (30% for both), although replication is needed for a more 
robust conclusion of this study (Pearson et al., 2017).  
The approach of stratifying patients through biological systems or phenotypic 
similarity allows for more homogeneity within MDD when investigating specific links 
to biologically relevant mechanisms. This may lead to a more effective personalised 
medicine approach, such as tailoring treatment options to specific sub-groups 











1. Depressed mood most of the day, nearly every day, as indicated by either 
subjective report (e.g., feels sad, empty, hopeless) or observation made by others 
(e.g., appears tearful). (Note: In children and adolescents, can be irritable mood) 
2. Markedly diminished interest or pleasure in all, or almost all, activities most of 
the day, nearly every day (as indicated by either subjective account or 
observation) 
3. Significant weight loss when not dieting or weight gain (e.g., a change of more 
than 5% of body weight in a month) or decrease or increase in appetite nearly 
every day. (Note: In children, consider failure to make expected weight gain) 
4. Insomnia or hypersomnia nearly every day 
5. Psychomotor agitation or retardation nearly every day (observable by others, 
not merely subjective feelings of restlessness or being slowed down) 
6. Fatigue or loss of energy nearly every day 
7. Feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being sick) 
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day 
(either by subjective account or as observed by others) 
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing 
suicide 
Table 1. DSM-V diagnostic criteria for MDD (APA, 2013).  
1.2 Epidemiology 
The average 12-month prevalence of MDD is approximately 6%, with 1 in 6 
individuals affected. Although limited by recall bias and underestimation, reports 
show that approximately 20% of all individuals fulfill diagnosis criteria for MDD at 
some point in their life (Otte et al., 2016). MDD typically affects twice as many women 
(5.1%) as men (3.6%), at any age (WHO, 2017), with the number of MDD episodes 
also being more frequent in women than men (Otte et al., 2016). Moreover, the median 
age of onset is 25 years for both men and women, although MDD may appear at any 
age, and the risk period for MDD appearance ranges from mid-adolescence to mid-life 
(early 40s) (Otte et al., 2016). 
Between 2005 and 2015, it is estimated that the number of people with an MDD 
diagnosis increased by 18.4%, reflecting both a growing population and an increase in 
the possible age groups which receive an MDD diagnosis (WHO, 2017). Briefly, 





 A recent WHO report indicated that there are some regional differences in the 
prevalence of MDD, ranging from 2.6% affected males in the Western Pacific region, 
to 5.9% affected females in the African region. Moreover, from a total of 322 million 
affected individuals worldwide, 9% of these are in the African region while 27% are 
in the South-East Asia Region (WHO, 2017). MDD also affects individuals 
irrespective of income. Bromet et al. (2011) investigated data from 18 countries 
categorized by income (N = 89,037) and found that the lifetime and 12-month 
prevalence was 14.6% and 5.5% in 10 high-income and 11.1% and 5.9% in 8 low-
income countries, respectively, indicating that the manifestation of MDD is similar 
across countries, independent of income (Bromet et al., 2011).  
 
1.3 MDD impact on everyday functioning and treatment options 
The economic burden of MDD has increased through the years, with 5% 
attributable to suicide-related costs, 48-50% to workplace costs, and a significant 45-
47% accounting for direct medical costs (Greenberg et al., 2015). MDD has a 
substantial impact on workplace performance, with MDD individuals missing 
approximately one month of work per year (McIntyre et al., 2015) Moreover, 
approximately 60% of individuals with MDD report impairment of functioning (Fried 
& Nesse, 2014). Furthermore, MDD has an effect on a range of domains which may 
impact individuals’ capability for self-care and independent living, including homelife, 
social activities and relationships (Beblo et al., 2010; Rot et al., 2012; Fried & Nesse, 
2014). 
Given the far-reaching negative impact of MDD, numerous treatment options 
have been investigated in order to establish which is the most efficacious. Gartlehner 
et al. (2017) looked at 140 pharmacological and non-pharmacological treatment 
options in a review of systematic reviews and identified only 5 treatment options for 
which the general efficacy for MDD in an acute phase is supported by reliable 
evidence. Of these, cognitive-behavioural therapy seems to be the only non-
pharmacological treatment with similar efficacy to second generation antidepressants, 
based on moderate strength evidence (Gartlehner et al., 2017). Khan et al. (2012) 




psychotherapy, pharmacotherapy, a combination of those two, and alternative 
therapies. Although further research is needed, they concluded that a combination of 
psychotherapy and pharmacotherapy provided a slight advantage as compared to only 
taking antidepressants or participating in therapy.  
 Lastly, Cipriani et al. (2018) carried out a review and meta-analysis 
investigating the efficacy and acceptability of 21 antidepressant drugs in the acute 
treatment of adults with MDD, which included 116,477 participants across 522 trials. 
All 21 antidepressants were more efficacious than placebo in adults with MDD with 
modest effect sizes, although there was variability in their efficacy and acceptability, 
which indicates heterogeneity of acting drugs.  
The variability in treatment for MDD mentioned above suggests that empirical 
research is needed in order to uncover novel targets for intervention. Genetic studies 
targeting specific biological pathways and genes, as well as neuroimaging studies 
focusing on specific brain regions associated with MDD will be needed in order to 
address the need for novel optimal treatment options. 
 
1.4 Major risk factors 
MDD arises as a result of a complex combination of environmental and genetic 
risk factors. The sections below outline some of the major risk factors, and it is 
important to note that these do not act in isolation. In MDD, gene-environment 
interactions are complex, and cumulatively act to predispose individuals to the 
development of the disorder throughout their lifetime (Lopizzo et al., 2015).  
 
1.4.1 Environmental risk factors 
A majority of epidemiological studies find that gender and age are highly 
associated with depression (Stordal et al., 2001; Brodaty et al., 2005).  As indicated 
above, women have a two-fold increased risk of MDD, and MDD risk is known to 
increase with age (WHO, 2017). In addition, a variety of other sociodemographic 
factors increase the risk of depression. For instance, childhood is a period in life when 




2012). Therefore, early-life stressors such as early adversity (e.g. sexual, physical, and 
emotional abuse and maltreatment), parental loss due to separation or death, poor 
paternal relationships, or maternal overprotection have all been reported to lead to an 
increased risk of depression (Gibb et al., 2001; Gibb, Chelminski & Zimmerman, 
2007; Heim & Binder, 2012). Other environmental risk factors later in life include 
stressful life events, such as moving to a new house (Bhugra & Ayonrinde, 2004), a 
lower socio-economic status (Gavin et al., 2010), and a stressful work environment 
(Theorell et al., 2015). 
 
1.4.2 Health risk factors 
In addition to environmental risk factors, multiple health factors may increase 
the risk for depression. For instance, researchers have found that a family history of 
depression and co-morbidity with other psychiatric disorders (e.g. schizophrenia, 
bipolar disorder, anxiety disorders) may lead to an increased risk of depression. 
Individuals who have already experienced an episode of depression are also at 
increased likelihood of experiencing further episodes (Kendler et al., 2001).  
Brook et al. (2002) showed that cumulative use and frequency of drug use, such 
as alcohol and marijuana, in childhood and early adolescence, was associated with 
episodes of MDD in the late 20s (Brook et al., 2002), a link uncovered in other studies 
as well (Nemeroff & Vale, 2005; Neupane, 2016). Moreover, food addiction has 
previously been linked to both MDD and depressive symptom severity (Mills et al., 
2020). 
Lastly, previous evidence has shown that physical conditions, such as 
cardiovascular disorders and type 2 diabetes, may also lead to an increased risk of 
depression (Beekman et al., 2000; Heim & Binder, 2012). Chronic inflammatory states 
and chronic pain have been consistently associated with depression prevalence 
(Dantzer et al., 2007; Ohayon & Schatzberg, 2003; Ohayon & Schatzberg, 2012). 
During system infections for instance, continual activation of the peripheral immune 
system may lead to the development of depressive symptoms, marking inflammation 
as an important risk factor for depression (Dantzer et al., 2007). Furthermore, in their 




Ohayon and Schatzberg (2010) found that 73.3% of participants who met criteria for 
MDD also reported chronic pain (Ohayon & Schatzberg, 2010). The studies above 
therefore indicate the importance of both physical and psychological health factors in 
MDD prevalence. 
 
1.4.3 Genetic risk factors 
Twin, adoption, and family studies 
In an early meta-analysis of studies investigating genetic contributions to 
MDD, Sullivan et al. (2000) concluded that MDD is a heritable trait, stating that 
genetic effects are the most important contributor to familial aggregation. Twin studies 
investigating concordance rates for MDD indicate a heritability of approximately 37%, 
and family studies indicate that first-degree relatives of probands have a two-fold to 
three-fold increase in lifetime risk of developing MDD (Lohoff, 2010).  
Linkage and candidate gene studies 
 Family, twin, and adoption studies have also provided support for the genetic 
contribution to MDD, and a number of linkage and candidate gene studies were 
conducted in the 2000s in order to identify specialised loci and genes conferring risk 
to MDD. However, although this type of approach was successful in the investigation 
of rare, Mendelian disorders with high penetrance, no major loci of large effect were 
reported for MDD. These studies were largely underpowered, which may have played 
a role in the unsuccessful results. Border et al. (2019) recently investigated 18 genes 
that were empirically identified by such studies to have had an association with MDD. 
Using new well-powered samples (Nrange = 62,138 – 443,264), the authors showed that 
none of the most highly investigated polymorphisms within these 18 genes 
demonstrated a significant genetic contribution to the liability of MDD (Border et al., 
2019).  
This, and additional studies described below, has provided additional support 
to the hypothesis that MDD is likely to be a polygenic disorder, with thousands of loci 
of minor effect contributing a fraction to the liability of the disorder. Moreover, MDD 




genes, interacting with environmental risk factors, confer risk of MDD (Flint & 
Kendler, 2014). 
Rare genetic variants and MDD 
 Aided by recent rapid advances in genetic analysis techniques, rare genetic 
variants have been increasingly investigated in relation to psychiatric disorders (Cook 
& Scherer, 2008; Dunn et al., 2015). Specifically, previous evidence indicates that 
copy-number variants (CNVs), inherited or de-novo segments of DNA that may affect 
gene function through deletion or duplication, may play a role in MDD.  
In a study examining CNVs in 1,693 MDD cases and 4,506 controls, Glessner 
et al. (2010) found 12 CNV regions that occurred more frequently in MDD cases. 
Among these, the most significant locus was harboring the SLIT3 gene, which is 
known to be implicated in axon guidance. Rucker et al. (2013) analysed copy number 
variation in 2,723 individuals with recurrent depression and 5,176 controls. They 
found that rare deletion CNVs, specifically genic and exonic, are enriched in recurrent 
depression cases as compared to controls (Rucker et al., 2013). 
More recently, Kendall et al. (2019) investigated 53 CNVs previously 
associated with neurodevelopmental disorders in 407,074 individuals (23,979 MDD 
cases and 383,095 controls). They found that all 53 CNVs were associated with self-
reported depression, however this association was partly explained by variables such 
as smoking status, physical health, and alcohol consumption. Zhang et al. (2019) 
conducted the largest genome-wide CNV study to date in a meta-analysis of four 
cohorts comprised of 5,780 MDD cases and 6,626 controls, finding an enrichment of 
short intergenic deletions in MDD patients. This suggests that CNVs may confer risk 
to MDD through the deletion of regulatory mechanisms. 
The studies above indicate a role played by rare genetic variants in MDD. 
However, the association between CNVs and MDD risk remains largely unclear and 
CNVs do not replicate across studies, which may be due to small sample sizes in 
previous studies. As such, the study of rare genetic variants in relation to MDD is still 





Genome-wide association studies and MDD 
Genome-wide association studies (GWAS) have been an important tool in 
investigating the genetic architecture of MDD, as they allow researchers to identify 
the genetic underpinnings of MDD by investigating the association between millions 
of SNPs across the genome without any a priori hypothesis about the function of a 
gene and the phenotype of interest (McCarthy et al., 2008).  
MDD is a complex genetic trait with thousands of variants each contributing a 
small amount to the risk for disease. Until recently, MDD GWAS did not have 
sufficient sample sizes to detect what is now known to be the polygenic architecture 
of the trait. A GWAS mega-analysis for MDD found no genome-wide significant hits 
in the discovery sample (9,240 cases and 9,519 controls), replication sample (6,783 
cases and 50,695 controls), or any other secondary analyses (Ripke et al., 2013). In 
2015, Cai et al. (2015) found two genome-wide significant loci in 5,303 MDD 
recurrent cases and 5,337 controls.  
The success of MDD GWAS only came to be realized once sample sizes 
massively increased. Wray et al. (2018) found 44 risk variants associated with MDD, 
using 135,458 cases and 344,901 controls (Wray et al., 2018). The most recent GWAS 
of MDD to date, a genome-wide meta-analysis of 807,553 individuals, has identified 
102 independent variants associated with depression (Howard et al., 2019). An 
independent replication sample of 1,306,354 individuals showed that 87 of the 102 
variants continued to be significant after multiple testing correction. Genes and gene-
sets uncovered in this analysis showed an association with synaptic structure and 
neurotransmission, highlighting prefrontal brain regions as an important area for the 
study of MDD (Howard et al., 2019).  
Downstream genetic and epigenetic analysis approaches 
The increasing power of GWAS and large number of hits have allowed for 
further downstream analyses, and a number of cutting-edge approaches can be used to 
identify the underlying biology of MDD. Given the notorious heterogeneity of MDD, 
there is a need for disorder stratification in order to gain a deeper understanding of the 
environmental and genetic impacts on the disorder. A novel way to stratify MDD is 
through employing genetic approaches to investigate specific links to MDD. These 




expression quantitative trait loci analysis. Moreover, DNA methylation analysis may 
be carried out to examine the impact of environmental insults on the biology of MDD.  
Given that most posited biological mechanisms implicated in MDD involve 
neural mechanisms and brain regions, there is a need to understand the impact of MDD 
genetic risk factors on the brain in order to identify neurobiological markers. As such, 
the approaches mentioned above and discussed in more detail in the sections below, 
may be explored in association with neuroimaging traits. Early literature did not 
initially provide conclusive evidence for an association between genetic risk factors 
for MDD and brain phenotypes, mainly due to scarce genetic-MDD associations and 
limited sample sizes (Reus et al., 2017; Wigmore et al., 2017). With increasing sample 
sizes, associations are becoming more evident (Schmaal et al., 2016; Elliott et al., 
2018; Shen et al., 2019), which further highlights heterogeneous findings. This 
emphasizes the importance of leveraging other genetic approaches to examine these 
associations. Imaging phenotypes typically studied include white matter 
microstructure, subcortical volumes, cortical volume, surface area, and thickness, of 
which white matter demonstrates moderate heritability (Elliott et al., 2018). White 
matter microstructure, which forms the brain’s connectivity network, may be a key 
neurobiological marker for MDD, although findings have so far been unclear and 
inconsistent (Whalley et al., 2013; Shen et al., 2017; Reus et al., 2017). A description 
and summary of white matter microstructure and its relationship with MDD as well as 
genetic risk for MDD to date is presented in the next section. 
 
2. White matter microstructure 
2.1 White matter microstructure 
White matter, located beneath the grey matter cortex, comprises millions of 
myelinated axon bundles which connect neurons in different areas of the brain, 
travelling along tracts (Fields, 2010). These white matter tracts are structurally 
classified in terms of spatial connection within the brain. More specifically, projection 
fibres connect higher cortical areas to subcortical regions of the brain, such as limbic 
system structures (e.g. amygdala, thalamus), as well as the brain stem, cerebellum and 
spinal cord; association fibres connect cortical areas within the same hemisphere; and 




et al., 2004).  
The myelin surrounding the axons, which gives these nerve fibres a white 
colour, is necessary for high-speed transmission of electrical signals. Review articles 
report that damage to this may result in impaired cognitive, sensory, and motor 
functions (Fields, 2010). Furthermore, changes in white matter microstructure have 
been previously associated with both normal functioning, such as learning complex 
tasks (Scholz et al., 2009), and psychiatric and neurological disorders, such as 
schizophrenia, MDD, and Alzheimer's Disease (Nasrabady et al., 2018). These 
findings implicate white matter microstructure in behavioural changes, indicating that 
perhaps psychiatric disorders arise as a result of a connection deficit within the brain, 
rather than being confined to a single brain region. 
Diffusion tensor imaging (DTI), a specialised Magnetic Resonance Imaging 
(MRI) technique, is the most common method used to measure white matter 
microstructure. DTI allows for the measurement of both architecture and integrity of 
white matter tracts in both healthy and disordered brains (Assaf & Pasternak, 2008). It 
does this by applying a tensor which measures the three-dimensional distribution of 
water molecule diffusion within voxels. Temperature, presence of large molecules, 
myelination, and microstructural barriers such as cell membranes and axon 
compaction all influence the mobility of water molecules (Beaulieu et al., 2002; Jones 
et al., 2013). Unlike cerebrospinal fluid, in which water diffusion is isotropic (i.e. water 
diffusion occurs equally in any direction), water diffusion in white matter occurs along 
tracts, meaning it is anisotropic. As opposed to a sphere indicating an isotropic 
diffusion distribution, the diffusion distribution in white matter then becomes an 
ellipsoid, in which the main axis is the principal eigenvector, while the second and 
third eigenvectors are oriented perpendicularly to it (ε 1-3). The amount of diffusion 
along each of these eigenvectors is quantified as eigenvalues (λ 1-3) (Figure 1) 






Figure 1. The diffusion tensor as a model of white matter microstructure. The figure 
was adapted from Jellison et al. (2004). 
 
Two common DTI scalars are fractional anisotropy (FA) and mean diffusivity 
(MD), which can both be calculated using eigenvalues (Figure 2). FA measures the 
directionality of water diffusion from 0 (complete diffusion isotropy) to 1 (complete 
diffusion anisotropy). Generally, therefore, lower FA indicates decreased 
microstructural integrity of white matter and directionality, while higher FA represents 
increased white matter microstructural integrity. A major limitation of FA is crossing 
fibres, where different tracts with distinct orientations are present within an imaging 
voxel, which hamper accurate deterministic tractography of different tracts (Jbabdi et 
al., 2011). MD is calculated as an average of the eigenvalues and measures the 
magnitude of water molecule diffusion. Generally, higher MD indicates decreased 
white matter microstructural integrity, while lower MD indicates increased white 
matter microstructural integrity. Although crossing fibres affect FA more than they do 
MD, the scalar is sensitive to partial volume contamination in certain cases. For 
instance, ageing or specific disorders lead to loss of white and grey matter, which in 
turn may lead to cerebrospinal fluid contamination in white matter tracts which are 
spatially close to the ventricles (Metzler-Baddeley et al., 2011; Berlot et al., 2014). 
Two additional DTI scalars providing more specific measurements of water 
diffusion are axial diffusivity (AD; (λ1), which is the measurement of water molecule 
diffusion parallel to the tract, and radial diffusivity (RD; ( (λ2 + λ3)/2 ), which 
measures water diffusion perpendicular to the tract (Winklewski et al., 2018). The two 




and demyelination (RD) and are also sensitive to issues such as crossing fibres and 
anisotropy decrease as a result of disorders (Alexander et al., 2008).  
However, structural changes, such as demyelination, changes in neurite 
morphology, or increase/decrease in the dispersion of neurite orientation distribution, 
may contribute independently to variation within both FA and MD (Timmers et al., 
2016). Newly developed measures such as neurite orientation dispersion and density 
imaging (NODDI) may provide additional information with regards to cellular 
contributors to FA and MD. NODDI provides estimates of neurite density through 
intra-cellular volume fraction (ICVF); extra-cellular water diffusion through isotropic 
volume fraction (ISOVF); and tract complexity or fanning and bending of axon 
bundles through orientation dispersion index (OD) (Zhang et al., 2012).  
As NODDI measures may uncover additional sources of variation within FA 
and MD that cannot be distinguished using conventional DTI measures, there is 
increasing interest in using this method alongside FA and MD. Previous studies have 
shown they are sensitive in both healthy (Cox et al., 2016; Edwards et al., 2017) and 
clinical populations (Timmers et al., 2016; Rae et al., 2017), and may therefore provide 
more specific information with regards to changes in white matter microstructure. 
Despite the limitations outlined above, FA and MD are microstructure 
variances that provide a more general measurement of water diffusion and 
directionality within white matter tracts, and have been shown to be valid and effective 
methods of white matter microstructure measurement (Jones et al., 2013; Shen et al., 
2017). As the two DTI scalars are the most commonly reported measurements in 
previous studies (Jones et al., 2013), in the current thesis, findings concerning both FA 
and MD are presented. 
Previous studies indicate that white matter microstructure is consistently 
heritable across tracts. Kochunov et al. (2015) investigated the heritability of FA in 
481 participants, finding white matter tracts to be highly heritable, with approximately 
70 – 80% of the total variance being explained by genetic factors in an additive 
manner. In addition, Vuoksimaa et al. (2017) examined the proportion of genetic and 
environmental influence on white matter microstructure, as measured by FA, MD, AD 
and RD, in 393 middle-aged twins, and found that genetic effects explained between 




between individual tracts. This evidence suggests that white matter microstructure 
formation and maintenance is partially explained by genetic factors, enabling it as an 
important phenotype in downstream analyses of brain-related traits and disorders in 
relation to genetic information. 
 
𝑀𝐷 =	
λ1 + 	λ2 + 	λ3
3  
𝐹𝐴 =	,
(λ1 − MD)2 +	(λ2 − MD)2	+	(λ3 − MD)2		
2(λ12 +	λ22 +	λ32)  
 
Figure 2. Calculation of FA and MD (Alexander et al., 2007). 
2.2 Probabilistic tractography and tract-based spatial statistics 
Tractography is a non-invasive method used to measure the apparent 
orientation and trajectory of white matter tracts in vivo. There exist numerous methods 
that allow for the characterisation of anatomical microstructure of white matter. In the 
present thesis, white matter tracts derived from two methods, probabilistic 
tractography and tract-based spatial statistics (TBSS), are presented.  
Probabilistic tractography probes probability distribution of fibre orientations 
at each voxel. This allows for observing the probability of a given fibre moving along 
a specific path (Hagler et al., 2009). This method accounts for uncertainty in local fibre 
orientation and can reconstruct crossing fibres in a reliable way (Behrens et al., 2003; 
Hagler et al., 2009); however, the method is computationally demanding as it requires 
a large number of iterations, and prior anatomical knowledge of white matter 
microstructure organisation is required (Hagler et al., 2009). AutoPtx 
(https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/AutoPtx), which is a set of scripts used to run 
probabilistic tractography, outputs 27 white matter tracts, 3 unilateral and 12 bilateral 
(Figure 3). In chapters 2 and 3, white matter tracts derived from probabilistic 
tractography were analysed. 
Tract-based spatial statistics (TBSS; 
https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/TBSS) aims to combine strengths of both voxel-




subjects’ FA raw images are non-linearly aligned to a standard brain space; the mean 
of the aligned images is then used to create a mean FA skeleton representing the centre 
of major white matter tracts which are common in all participants; lastly, each 
participant’s FA data is then projected onto the mean FA skeleton, where their 
projected FA values are taken from the local centre of the tract in the original FA image 
(Smith et al., 2006). In addition to the method being less computationally intensive by 
reducing the number of tests it carries out (Smith et al., 2006), it also attempts to take 
into account issues such as tract alignment and pre-specification of tracts. Potential 
limitations include crossing fibres, as well as disease states, which might lead to 
exclusion or skewness of FA values due to, for example, reduction in grey matter 
volume, although images should be carefully examined during pre-processing stages 
in order to avoid this (Smith et al., 2006). In chapter 4, TBSS was used to derive 43 
white matter tracts, 5 unilateral and 19 bilateral (Figure 4).  
Although the two methods output different sets of white matter tracts, both are 
computationally valid and are based on connectivity and anatomical knowledge of the 





















Figure 3. White matter tracts grouped in three tract categories output by AutoPtx. The 






Figure 4. White matter tracts output by TBSS. The images were created using Mango 
(http://ric.uthscsa.edu/mango/).  
 
2.3 White matter microstructure and MDD 
White matter microstructural changes indicated by lower FA and higher MD 
have been associated with MDD in the past (Tham et al., 2011; Shen et al., 2017). In 
2011, Tham et al. reviewed post-mortem, genetic, and neuroimaging studies of white 
matter microstructure abnormalities in MDD. Previous post-mortem studies mainly 
found white matter abnormalities in prefrontal brain regions characterised by decreases 
in oligodendrocyte density, a glial cell responsible for myelin production. In addition, 
myelin-associated genes important for processes such as axon guidance and growth, 
and synaptic function, were generally related to white matter abnormalities (Tham et 
al., 2011). 
Neuroimaging studies generally reported lower FA within cortical and 
subcortical regions; in Tham et al.’s (2011) review, the frontal gyrus, superior 
longitudinal fasciculus (SLF), and the striatum were marked as specific affected tracts 
(Tham et al., 2011). A meta-analysis investigating DTI studies in connection to MDD 
found the SLF to be consistently abnormal in MDD patients as opposed to healthy 
individuals across studies (Murphy & Frodl, 2011). A further meta-analysis of DTI 
studies in MDD patients looked at research including case-control samples only. The 
authors found that tracts connecting the prefrontal cortex with cortical and sub-cortical 





These studies however were typically limited by sample size and heterogeneity, 
which hinders generalisability to wider population samples. All studies described 
above concluded that further analysis using much larger sample sizes would be needed 
in order to uncover links between genetic factors and specialised white matter tracts in 
MDD, as well as to identify genes which are implicated in white matter formation, 
maintenance, and pathology. 
More recent empirical studies have attempted to address the above-mentioned 
limitations, and evidence exists linking lower FA and higher MD in numerous white 
matter tracts to MDD, both in affected individuals and those at high risk of the disorder. 
Whalley et al. (2013) investigated the association between white matter microstructure 
as measured by FA and individuals at high risk for mood disorders, quantified by a 
polygenic risk score (PRS) for bipolar disorder and MDD. With regards to MDD, they 
found a significant association between higher polygenic risk of MDD and lower FA 
within the parietal region of the superior and inferior longitudinal fasciculus, as well 
as thalamic radiations, uncinate fasciculus, and inferior fronto-occipital fasciculus 
(Whalley et al., 2013). In a case-control study, Shen et al. (2017) found global 
measures of FA, as well as thalamic radiations and association fibres, to be reduced in 
MDD patients as opposed to healthy individuals in a sample size of 1,087. Lower FA 
was also localised to individual white matter tracts, such as the left SLF, superior 
thalamic radiation, and forceps major. Van Velzen et al. (2019) investigated white 
matter anisotropy and diffusivity in 1,305 MDD cases and1,602 healthy controls 
across 20 samples worldwide as part of the MDD Working Group of the Enhancing 
Neuroimaging Genetics through Meta-Analysis (ENIGMA). Within adult samples, 
they found significantly lower FA in MDD cases (N = 921) compared to healthy 
controls (N = 1,265) in 16 of the total 25 white matter tracts investigated, including 
parts of the corona radiata, corpus callosum, and superior and inferior fronto-occipital 
fasciculi. While no differences were found for AD and MD, global RD was found to 
be higher in MDD cases (Van Velzen et al., 2019). 
Shen et al. (2019) also investigated cross-sectional and longitudinal measures 
of depressive symptoms and their association with white matter microstructure as 




radiation was associated with all measures of depressive symptoms; several 
association fibre tracts, including superior and inferior longitudinal fasciculus, and 
projection fibre tracts, including acoustic radiation and corticospinal tract, were 
associated with cross-sectional measures of depressive symptoms (Shen et al., 2019). 
In summary, the main findings to date indicate connections between the 
prefrontal cortex and sub-cortical areas, most notably the SLF and thalamic radiations. 
The SLF connects the frontal lobe to parietal, occipital, and temporal lobes 
(Schmahmann et al., 2007). As a result, it is associated with numerous higher-order 
cognitive functions, such as language, spatial working memory, attention, and emotion 
regulation (Vestergaard et al., 2011; Madhavan et al., 2014; Parkinson & Wheatly, 
2014). Thalamic radiations connect the thalamus to anterior, superior, and posterior 
regions of the brain (Jones, 2002). The thalamus is a subcortical structure which plays 
an important role in sleep regulation, as well as cognitive processes such as attention, 
speed of information processing, and memory (Van Der Werf et al., 2001; Fama & 
Sullivan, 2015). White matter tracts connecting the thalamus with other cortical areas 
of the brain may therefore be implicated in these processes. 
Deficits in these tracts may therefore reflect MDD symptomatology profiles 
such as insomnia or hypersomnia, inability to concentrate, mood disruptions and 
suicidal tendencies, providing a strong rationale for the investigation of white matter 
microstructure in relation to MDD (Coenen et al., 2012; Jia et al., 2014). Numerous 
causative paths may contribute to these symptoms, and novel opportunities allowing 
the combination of genetic approaches with neuroimaging traits may provide a deeper 
mechanistic understanding of the disorder. An overview of the genetic approaches 
used in this thesis is presented below. 
 
3. Expression quantitative trait loci (eQTL) 
Gene expression is the process by which genetic information is used to direct 
product synthesis, such as proteins for protein-coding genes, or transfer RNA, for non-
protein coding genes. Within this process, some genes that produce proteins involved 
in important functions (i.e. breaking down glucose) are continuously expressed, while 
others may only be expressed as part of a specific process and at a particular time (e.g. 




process that increases or represses gene expression, is vital in all living organisms, as 
it allows for the cell’s control of structure and function, as well as cell differentiation. 
Moreover, it facilitates organisms’ adaptability and evolution, as the cell has control 
over the amount of gene expression at a specific time and location (Wray, 2007).  
Gene expression is one of the primary processes in converting information 
within the genome to observable phenotypes (Storey et al., 2007). As such, levels of 
expression may act as an intermediate phenotype between genetic information and 
observable traits, such as common diseases (McKenzie et al., 2014). Therefore, 
understanding the genetics of gene expression allows researchers to gain insight into 
the genetics of complex traits (Lee, 2018). 
Expression quantitative trait loci (eQTL) are genetic variants that explain 
variation in gene expression, and have been characterised as cis (loci within 1 
megabase from a gene’s transcription start site) or trans (loci at least 5 megabases 
downstream or upstream of a gene’s transcription start site, or on a different 
chromosome) (Nica & Dermitzakis, 2013) (Figure 5). GWAS of gene expression have 
been developed in order to identify polymorphic genetic loci influencing gene 
expression across the genome. Essentially, if a genotype at a specific locus is 
associated with an increase or decrease in the expression of a gene, this locus may act 
as a regulator, or eQTL (Michaelson et al., 2009), and different genotypes will lead to 
variation in phenotypes. 
 
Figure 5. Cis and trans eQTL gene expression regulation. 1 Mb and 10 Mb represent 
the physical distance of the genome region and indicate the distance from each gene’s 
transcription start site; the two types of eQTL regulate gene expression which in turn 
give rise to traits / diseases. 
 
Findings from these methods indicate that eQTL may play a role in 




pathways and gene sets in the manifestation of specific disorders. GWAS findings 
have identified significant associations between genetic variants and disease 
phenotypes, but our understanding of the molecular mechanisms underlying these 
associations is scarce. Numerous variants lie in non-protein coding regions of the 
genome, and therefore it could be that they influence traits through the regulation of 
gene expression (Fagny et al., 2017). Therefore, gaining insight into the links between 
eQTL and disease phenotypes may further the understanding of the causation, 
formation, and manifestation of these traits.  
Previous studies have indicated that genetic variation may explain variance in 
level of gene expression in a tissue-specific manner. For example, O’Brien et al. (2018) 
mapped eQTL by performing deep RNA sequencing and genome-wide genotyping in 
120 post-mortem foetal human brains in the second trimester, and identified eQTL 
conferring risk and gene expression changes mediating susceptibility to 
neuropsychiatric disorders, such as attention deficit hyperactivity disorder, 
schizophrenia, and bipolar disorder (O’Brien et al., 2018). In addition, Bhalala et al. 
(2018) conducted a multi-region meta-analysis to investigate whether SNPs previously 
associated with schizophrenia, bipolar disorder, and MDD are associated with gene 
expression in human brain tissue. To do this, they investigated SNPs associated with 
the three disorders in 11 GWAS of gene expression levels in post-mortem neurotypical 
brain tissue from two independent datasets, and identified 2,224 cis eQTL associated 
with expression of 40 genes (Bhalala et al., 2018). 
Lastly, Zhong et al. (2019) integrated genetic associations from a recent MDD 
GWAS (Wray et al., 2018) and brain eQTL data to identify genes whose expression 
alteration may contribute to susceptibility of MDD. They found 18 genes whose 
perturbations may play a role in susceptibility to MDD, including FLOT1, whose 
expression was further upregulated in the brain and peripheral blood of a European 
sample of MDD cases, as compared to controls (Zhong et al., 2019). As shown by 
these studies, eQTL analysis may uncover putatively novel associations between gene 
expression and brain-related disorders, paving the way for further analyses implicating 
potentially new therapeutic targets.   
However, using brain tissue in eQTL analysis poses several issues due to the 




levels of expression throughout the brain are not likely to be uniform. Moreover, the 
brain is not accessible ante-mortem, and the use of tissue post-mortem introduces 
issues such as small sample sizes, cause of death, post-mortem interval, and gene 
expression differences in post-mortem as opposed to ante-mortem brains (McKenzie 
et al., 2014). These issues have led researchers to consider alternative approaches of 
investigating eQTL in relation to brain-related traits in more accessible tissues, such 
as whole blood (Qi et al., 2018).  
Hernandez et al. (2012) sought to observe whether it is possible to use 
peripheral tissues such as blood to infer expression levels in the central nervous 
system. They examined 399 brain samples (frontal lobe and cerebral cortex) and 501 
blood samples and found a small number of eQTL to be shared between the two tissues 
(brain and blood). They also found that some eQTL differed between the two tissues, 
which might be due to differences in pattern of gene expression (e.g. neuron-specific 
proteins being expressed). McKenzie et al. (2014) analysed eQTL overlap between 8 
published brain studies and eQTL measured in blood in a large meta-analysis, finding 
that between 13 – 23% of eQTL overlapped between the two tissues. These studies 
suggest that where it is not possible to directly access the tissue of relevance, it is 
appropriate, with caution and an awareness of possible limitations, to use whole blood 
as a proxy. 
Using peripheral samples to investigate gene expression levels in the brain 
introduces additional limitations that should be considered. Firstly, gene expression is 
tissue- and cell-specific, and evidence suggests that there is limited commonality 
among different tissue types. For instance, gene expression may be altered in both a 
tissue- and timing-specific manner, leading to different expression levels in peripheral 
tissues compared to brain (Hernandez et al., 2012). To address this, it is necessary to 
identify which gene expression patterns and biological processes are conserved 
between brain and peripheral tissues (Glatt et al., 2005).  
Secondly, it is difficult to determine the overlap between brain and peripheral 
tissue eQTL, as data is often taken from different subjects; moreover, while brain 
samples are collected post-mortem, blood samples are collected in life. This in turn 
introduces further limitations, such as number of samples used, presence or absence of 




differential expression pattern, whose gene expression levels have been measured 
using different protocols (McKenzie et al., 2014).  
Lastly, Sullivan et al. (2006) found a 0.5 correlation between transcripts present 
in whole blood and central nervous system tissues, arguing that whole blood gene 
expression may not be suitable for specific applications that require high tissue or 
transcription specificity, but may be applicable for specific sets of genes or biological 
pathways that are arguably expressed at a similar level across brain and peripheral 
tissues, or in the investigation of more general tissue-gene expression approaches 
(Sullivan et al., 2006). 
Neuroimaging phenotypes, as measured by MRI, provide a unique opportunity 
to examine eQTL in association with in vivo brain phenotypes. Uncovering novel 
associations between gene expression patterns and brain structure may lead to further 
analysis and identification of loci that are of importance in psychiatric and neurological 
disorders, by linking genetic information to both specific brain regions and brain-
related disorders. As both white matter microstructure and MDD are moderately 
heritable (Kochunov et al., 2015; Lohoff, 2010) and linked to each other (Shen et al., 
2017), in Chapter 2, using genetic and neuroimaging data, the relationship between 
white matter phenotypes and eQTL genetic scores, previously measured in whole 
blood, is explored and analysed. The analysis provides evidence of changes in gene 
expression in relation to white matter microstructure, allowing for an insight into the 
relationship between previous brain- and disease-associated genes, their expression, 
and brain connectivity.  
 
4. Polygenic risk scores, biological pathways, and MDD 
4.1 Polygenic risk scores 
GWAS allow for the identification of the genetic underpinnings of MDD 
reflected by the effect of multiple common genetic variants, lending support to further 
studies attempting to uncover the heritability of the disorder. Studies have attempted 
to uncover the functional impact of these variants, but a major issue in uncovering 
genetic links to MDD is that the variance explained by a single genetic variant is minor 
(Gandal et al., 2016). As such, a method of aggregating risk variants into a single 




given trait, known as a PRS (Wray et al., 2008). 
A PRS for a given trait is calculated from GWAS summary statistics, by 
summing the number of risk alleles carried by an individual in an independent dataset 
and weighting them by the effect size from the discovery GWAS (Euesden et al., 
2015). The score can be calculated at any p-value threshold, which is chosen based on 
the trait it is calculated for (Euesden et al., 2015), and is described as a single 
continuous variable measuring genetic liability of a disorder. PRS may be used to 
predict an individual’s risk of disease, differentiating between higher-risk and lower-
risk individuals, with the average PRS being higher in cases than controls (Lewis & 
Vassos, 2017). PRS may also be used to investigate genetic links between two traits, 
by associating PRS for one trait with the phenotype for another trait. The International 
Schizophrenia Consortium (2009), for instance, calculated PRS for schizophrenia 
(3,322 cases and 3,587 controls) and were able to show that genetic risk for 
schizophrenia may explain some variance in bipolar disorder (1.9% and 1.4% in two 
independent samples).  
The most direct application of PRS is to follow-up GWAS results by testing 
the prediction of case / control status in an independent study. However, PRS may be 
limited by the power of the original GWAS (Gandal et al., 2016). In MDD, GWAS 
results have increased in robustness and power over time, as described earlier. In the 
most recent MDD GWAS, Howard et al. (2019) found that PRS calculated from more 
than 800K individuals (246,363 cases and 561,190 controls) explained between 1.5 – 
3.2% of the variance in MDD. Although this is a small proportion of the total variance 
explained, it is in line with previous findings concerning psychiatric disorders 
(Reginsson et al., 2018), and will likely further increase as sample sizes become larger 
and statistical methods improve. 
In addition to being influenced by the original GWAS, there are a number of 
additional factors that may influence PRS accuracy. Firstly, heterogeneity between 
training and testing samples may have an effect on the accuracy of PRS. Secondly, 
there may be a lack of diversity in populations used to derive PRS, as the majority of 
genetic studies used for GWA consist of European populations. As disease-associated 
risk alleles may significantly differ in frequency between populations, this may lead 




the derivation of PRS (De La Vega & Bustamante, 2018). 
Moreover, GWAS are typically only used to identify common genetic variants 
with a small contribution to disease risk. However, as mentioned previously, other 
genetic variants, such as copy number variants of high penetrance, may contribute to 
disease risk. Thus, individuals carrying rare, but not common risk alleles, may not 
show high genetic risk for a disorder according to PRS (Fullerton & Nurnberg, 2019). 
Lastly, PRS assumes that genetic risk conferred by common alleles of small effect is 
additive and does not yet consider complex epistatic relationships between risk 
variants, which may differ between individuals based on their genetic profile 
(Fullerton & Nurnberg, 2019). 
Even with the success of recent GWAS, at the moment, PRS are unlikely to 
have clinical utility as a single variable. However, their usefulness may increase when 
associated and combined with environmental or other genetic risk factors, such as rare 
risk variants or DNA methylation (Lewis & Vassos, 2017). PRS calculated for MDD 
have previously been associated with traits of importance in MDD, including 
childhood trauma (Peyrot et al., 2014), depressive symptoms and psychological 
distress (Musliner et al., 2015), body mass index and obesity (Clarke et al., 2015), and 
the personality trait neuroticism (De Moor et al., 2015). These studies show that 
combining PRS for MDD with other known environmental risk factors may aid in 
increasing the variance explained in MDD, as well as uncovering interaction effects 
between genetic and environmental risk factors. 
To date, there is scarce evidence of the association between PRS for MDD and 
brain-related phenotypes. This may be in part due to unsuccessful results from past 
GWAS, as well as the lack of, until recently, large datasets consisting of both genetic 
and neuroimaging data. Large cohorts such as UK Biobank (Sudlow et al., 2015) and 
Generation Scotland (Smith et al., 2006; Smith et al., 2013), which contain both types 
of data in a large number, have allowed researchers to gain novel insights into the 
association between the two.  
The fact that white matter microstructure is moderately heritable and the most 
recent GWAS shows an enrichment of risk loci in brain regions (Howard et al., 2019) 
points to the importance of relating this phenotype to MDD genetic risk in order to 




between polygenic risk for individuals at high risk of mood disorders (MDD and 
bipolar disorder) and FA in 70 high-risk cases and 62 controls. They found a negative 
association between PRS for MDD and several white matter tracts, including SLF, 
inferior longitudinal fasciculus, and inferior fronto-occipital fasciculus (IFOF). Shen 
et al. (2019) provided a comprehensive analysis of PRS for MDD associated with 210 
behavioural and 278 neuroimaging traits in a discovery (N = 10,674) and replication 
sample (N = 11,214). For white matter tracts as measured by FA and MD, they found 
MDD PRS to be associated with lower global white matter integrity, as well as regional 
tracts within association fibres and thalamic radiation. Several individual white matter 
tracts were also associated with higher MDD PRS, including lower FA in the SLF, 
posterior thalamic radiation, and forceps major; and higher MD in anterior and 
superior thalamic radiation, SLF, IFOF, cingulate gyrus, and forceps minor (Shen et 
al., 2019).  
Findings from the above studies indicate that white matter microstructure is 
globally and regionally disrupted in those at higher genetic risk of MDD (Shen et al., 
2017; Whalley et al., 2013). This evidence shows that MDD is perhaps a connectivity-
based disorder and may not be localised to a specific brain region or tract. As such, 
stratification of genetic risk factors may be needed to uncover, for instance, risk 
conferred by variants localised to a specific genomic region, and whether these are 
associated with more specific white matter tracts based on their functionality, which is 
discussed below. 
 
4.2 Biological pathway specific PRS 
 PRS may be further stratified in terms of biological functionality of loci and 
genes, clustered in biological pathways. Biological pathways are defined as a series of 
actions and reactions among molecules inside a cell which lead to a change in the cell 
(e.g. turning genes on and off, producing molecules such as proteins). Numerous 
databases have been created that aggregate and describe biological processes and 
structures in which genes and proteins are involved; this has been helpful in identifying 
gene-sets which take part in the same biological process and pathway (Khatri et al., 
2012).  




information about the combined effect and behaviour of multiple risk variants in 
relation to a trait or disease, allowing researchers to gain mechanistic insight into 
disrupted molecular and biological mechanisms in relation to disorders (Herold et al., 
2012), as well as identify possible pharmacological targets (Sullivan & Posthuma, 
2015). Sullivan and Posthuma (2015) conducted a review of 42 studies investigating 
biological pathways in five major psychiatric disorders, finding that biological 
pathways converge in schizophrenia and bipolar disorder, but not in other psychiatric 
disorders. In MDD, larger samples were needed at the time, reflecting the scarce 
GWAS results driven by a low sample size. 
Methods to conduct pathway analysis, as well as ever-increasing sample sizes, 
have since provided more success in identifying biological pathways in relation to 
MDD. Howard et al. (2019) conducted pathway analysis on the MDD GWAS results 
using MAGMA (Multi-marker Analysis of GenoMic Annotation), a tool that identified 
genes in biological pathways, and investigated the significance of association between 
each pathway and depression utilizing p-values for each gene. Using pathway 
information from the Gene Ontology Consortium, they found 14 biological pathways 
enriched for depression, of which 8 were cellular components in the nervous system, 
and 6 were biological processes implicated in behaviour. This information aided in 
uncovering several biological pathways involved in depression, including enrichment 
in synaptic structure and activity, and response and behaviour to external stimuli 
(Howard et al., 2019).  
Zeng et al. (2016) integrated regional heritability analysis and pathway analysis 
in order to identify MDD-specific biological pathways in two independent samples 
(Generation ScotlandN = 6,455; Psychiatric Genomics Consortium MDDN = 18,759). 
Regional heritability analysis is generally applied in order to identify specific genomic 
regions which contribute a significant amount of heritability to a trait, more so than 
other regions. Pathway analysis is applied to identify related proteins within biological 
pathways in relation to traits of interest (Zeng et al., 2016). The authors found that of 
1,035 biological pathways across numerous databases investigated, one pathway, the 
NETRIN1 Signaling Pathway, was significant in both datasets. In addition, Zeng et al. 
calculated pathway-specific PRS tailored to the NETRIN1 Signaling Pathway and 




prediction of MDD. They found that NETRIN1-specific PRS explained 0.216% of the 
variance in MDD, while whole-genome PRS explained 0.198%, indicating that this 
region alone explained more variance than PRS derived from the rest of the genome. 
Their study provided evidence that biological pathway-tailored PRS may 
provide novel avenues for research in MDD and showed that there is rationale to 
investigate the relationship between brain phenotypes and the NETRIN1 Signaling 
Pathway, which is known to be implicated in thalamo-cortical axon guidance (Bonnin 
et al., 2007). As such, in Chapter 3, I investigate the association between MDD PRS 
calculated for SNPs within the NETRIN1 Signalling Pathway, as well as PRS 
calculated for SNPs outside the pathway, and global, regional, and individual white 
matter tracts. The study provides evidence of novel associations implicating 
functionally similar risk variants for MDD in white matter microstructure.  
As sample sizes increase in cohorts combining neuroimaging and genetic data, 
it is necessary to examine novel links between specific genetic variants, biological 
pathways, and neurobiological factors in MDD. Despite its inherent heterogeneity, 
localised effects may be uncovered in relation to MDD. Investigating both genome-
wide and pathway-specific PRS in white matter microstructure is therefore important 
for refining the genetic and biological mechanisms underlying MDD, and their effects 
on neurobiological phenotypes. 
 
5. DNA methylation in MDD   
In the context of traits and disease phenotypes, equally important to the human 
genome is a mechanism used by cells to determine at what point in space and time a 
gene is expressed. This mechanism is known as an epigenetic process, and is known 
to induce changes during cell division, such as altered patterns of gene expression 
within a specific cell type, thereby influencing the genome without changing its 
sequence (Tost, 2009).  
DNA methylation (DNAm), one of many epigenetic processes, alters gene 
expression through the addition of methyl groups at cytosine-phosphate-guanine 
(CpG) sites, chemically changing DNA, and is situated at the intersection between 
genetic and environmental factors (Robertson, 2005). This process is led by DNA 




methyl groups to DNA (Jaenisch & Bird, 2003). Approximately 75% of CpG 
dinucleotides are methylated at varying levels throughout the genome of mammals, 
marking DNAm as a promising biomarker in the context of differentially methylated 
CpG sites in association with phenotypes, at least partially (Tost, 2009). Fraga et al. 
(2005) found that twins’ epigenomes are indistinguishable during early life, but as 
monozygotic twins advance in life, their DNAm signatures are different. Their results 
indicate that epigenetic mechanisms may provide an insight into how different 
phenotypes may arise even with the same genome as a starting point (Fraga et al., 
2005). 
Patterns in DNAm are particularly susceptible to change as a result of 
environmental stimuli, such as lifestyle factors. Joehanes  et al. (2016) conducted a 
meta-analysis of previous studies investigating DNAm in relation to cigarette smoking 
behaviour in 15,907 individuals across 16 cohorts. They found a remarkable 
epigenome-wide influence on smoking, consisting of 18,760 CpG sites annotated to 
more than 7,000 genes. Mendelson et al. (2017) conducted an epigenome-wide 
association study (EWAS), the epigenome equivalent of a GWAS, of body mass index 
(BMI) in more than 3,700 individuals and led a replication analysis in a further 4,000 
individuals. They found that BMI was associated with 83 differentially methylated 
CpG sites. Lastly, Liu et al. (2018) conducted an EWAS of alcohol consumption in 
13,317 participants across 13 cohorts and identified 144 CpG sites highly predictive 
in the discrimination between heavy alcohol drinkers and non-drinkers. As the results 
of the above study indicate, differentially methylated CpG sites associated with various 
environmental factors may in future act as biomarkers to advance our understanding 
of molecular mechanisms implicated in the phenotypes. 
Alterations in DNAm also exist in the manifestations of disease phenotypes 
(Robertson, 2005; Bergman & Cedar, 2013). Cancer is one of the most studied diseases 
in its relationship with epigenetic modifications. One acting mechanism is both 
hypomethylation (decrease of methylation) across the entire genome within tumours, 
and hypermethylation (increase of methylation) in specific regions and genes which 
act as tumour suppressors. This increase in promoter regions of tumour suppressor 
genes has been associated with transcriptional silencing, thus giving rise to tumour 




Epigenetic modifications and their impact on complex psychiatric disorders 
have also been investigated. Gene-specific hypo- and hypermethylation has been 
found in schizophrenia, bipolar disorder, and autism spectrum disorder (Grayson & 
Guidotti, 2013; Klengel et al., 2014). DNAm alterations in relation to pathological 
states may act as the link between genotype and phenotype. Therefore, investigating 
the epigenetic impact on disease susceptibility loci may in future be of clinical and 
therapeutic relevance. 
In recent years, DNAm has also been investigated in relation to MDD, and has 
been posited to play a role in the susceptibility of the disorder via dysregulation of 
gene expression catalysed by both environmental and genetic risk factors (Dalton et 
al., 2014). For instance, early life stress has been posited to act as a mechanism of 
lifelong changes in gene expression. Franklin et al. (2010) showed, in mice, that 
chronic and unpredictable situations where the mother is separated during the early 
post-natal timeframe leads to depressive-like symptoms and modifies the offspring’s 
behavioural responses to novel environments as well as altered DNAm at several genes 
in the germline (Franklin et al., 2010). Their results indicate that early-life stress 
modifies behaviours and alters the epigenetic profile across generations through hypo- 
and hyper-methylation. 
Studies investigating specific genetic loci have indicated several genes that 
may be of interest to depression from a DNAm standpoint. These include BDNF, 
which is known to regulate neuronal plasticity and neurotransmitter signalling (Roth 
et al., 2009); SLC6A4, which transmits serotonin from synaptic spaces to pre-synaptic 
neurons (Kang et al., 2013); and the glucocorticoid receptor gene NR3C1, which is 
important within the stress response system (Watkeys et al., 2018). Differential DNAm 
at these specific sites may elucidate specific links to MDD (Li et al., 2019). 
 Reviews examining the relationship between DNAm alterations and 
depression show that EWAS findings have not generally been replicated across 
studies, but this might be due to a number of factors, such as small sample sizes or 
heterogeneity of analyses (Dalton et al., 2014; Januar et al., 2015). Recently, Jovanova 
et al. (2018) ran an EWAS of depressive symptoms in a middle-aged and elderly 
sample of 7,948 individuals across 9 cohorts and attempted replication in an 




to be associated with depressive symptoms. These included sites at CDC42BPB, which 
plays a role in the regulation of cytoskeleton organisation, cell migration, and 
regulation of neurite outgrowth; ARHGEF3, which plays a role in axon guidance 
through co-expression with other gene families; and a third site situated in an 
intergenic region and is associated with SEMA4B, which in turn interacts with PSD-
52 to promote synapse maturation (Jovanova et al., 2018). All three CpG sites seem to 
be implicated in axon guidance, leading to conclude that this pathway may be disrupted 
in MDD. 
 Furthermore, Aberg et al. (2018) ran an EWAS of CpG-SNPs, defined as CpG 
sites which are created or destroyed by SNPs, to investigate whether they contribute 
to risk of MDD in 1,132 individuals (320 controls; 812 cases) and found 27 CpG sites 
that were suggestively associated with MDD. Among the key genes at these sites are 
ASIC2, which plays a role in neurotransmission; DCC, which is implicated in axon 
guidance and neurite outgrowth in developing neurons; and ROBO2, which also 
participates in axon guidance and cell migration (Aberg et al., 2018). Their findings 
complement those of Jovanova et al. (2018) and further confirm that the axon guidance 
pathway may be a putative disrupted pathway in MDD. 
 The findings from the studies described above indicate that DNAm plays an 
important role in MDD. However, research studies have been hindered by the 
complexity of DNAm, small sample sizes, and heterogeneity of analysis and 
phenotype, as well as hundreds of thousands of individual CpG sites across the 
epigenome. Therefore, investigation of DNAm through EWASs often poses the same 
issues as a GWAS study. As such, a DNAm risk score may be created, which acts in 
the same manner as a PRS. Such risk scores have shown to be successful in the 
investigation of other traits in the past.  
For instance, Shah et al. (2015) investigated whether the contribution of 
DNAm profiles are associated with body mass index (BMI) and height independently 
of genotypic information (Shah et al., 2015). The authors first conducted an EWAS 
for both BMI and height in two independent cohorts (NDiscovery = 1,366; NValidation = 
750). They also calculated DNAm profile scores, a weighted sum of methylation level 
at associated CpG sites, in the validation dataset based on observed associations in the 




with the two traits in addition to PRS (Shah et al., 2015). They found that the DNAm 
score, PRS, and the two combined accounted for 7%, 8%, and 14% of the variance in 
BMI, respectively, in one of the cohorts, and 5%, 9%, and 13%, respectively, in the 
second cohort. The DNAm score did not account for much variation in height, which 
is consistent with previous literature indicating a larger genetic influence for height 
(Shah et al., 2015). 
McCartney et al. (2018) used penalised regression models to train DNAm 
predictors for ten health and lifestyle factors, including BMI, total cholesterol, HDL 
cholesterol, LDL with remnant cholesterol, total:HDL cholesterol ratio, waist-to-hip 
ratio, percentage body fat, and self-reported alcohol consumption and smoking status  
(N = 5,087). They then developed DNAm scores and PRS for the ten traits in an 
independent sample (N = 895). They found that DNAm predictors explained a high 
proportion of variance in smoking (60.9%), medium proportion of variance in BMI, 
alcohol consumption, and HDL cholesterol (12.5 – 15.6%) and a small proportion of 
variance for the rest of the traits (0.6 – 4.5%). The DNAm scores and PRS additively 
explained the most variance in each trait (McCartney et al., 2018). The study showed 
that DNAm predictors are able to predict various traits as well as add to variance 
explained when combined with a genetic predictor, indicating a strong rationale to 
study DNAm scores in relation to other traits and disease phenotypes. 
A DNAm score for MDD has recently been developed to investigate whether 
DNAm explains variance in both prevalent (N = 1,780) and incident (N = 1,607) MDD 
in an additive manner to PRS (Barbu et al., 2019). It was found that the DNAm score 
explained 1.75% and 0.52% of the variance in prevalent and incident MDD, 
respectively. In prevalent MDD, the combined DNAm score and PRS explained 3.99% 
of the variance. Furthermore, when accounting for lifestyle factors, including BMI, 
smoking status, pack years, and alcohol consumption, the DNAm score explained 
0.68% of the variance, as opposed to 1.75% on its own. This indicates that the DNAm 
score effect is attenuated by lifestyle factors, however the score is still independent in 
its prediction of MDD. The study showed that there is rationale for investigating a 
DNAm score in relation to MDD, and provides a basis for relating DNAm scores for 
MDD in relation to other traits which might in turn be associated with the disorder. 




alterations at specific sites across the epigenome. A review detailing imaging genetic 
studies in MDD indicated previous studies which found altered DNAm at specific 
genes associated with structural changes in the brain. The genes included SLC6A4, 
where methylation was associated with hippocampal grey matter; OXTR methylation 
level, which was associated with amygdala responsiveness; DNAm at NR3C1 and 
hippocampal volume; and BDNF methylation level, which was associated with 
anterior corona radiata structure alterations (Won & Ham, 2016).  
This indicates that part of the effect of DNAm at specific loci and genes on 
MDD may be exerted through brain phenotypes. What is more, one of the key 
disrupted pathways uncovered in DNAm investigations of MDD is the axon guidance 
pathway. Two of the genes found by Aberg et al. (2018) participate in the NETRIN1 
Signalling Pathway, which guides axons from the thalamus to other parts of the brain 
in neurodevelopment (Tang & Kalil, 2005), and which is investigated in the current 
thesis in terms of aggregated MDD genetic risk in relation to white matter 
microstructure. These findings combined indicate that an MDD DNAm risk score 
could have predictive ability in relation to white matter microstructure; a significant 
risk score-white matter association would aid in developing and determining 
neurobiological markers on which DNAm acts. This would have both clinical and 
therapeutic relevance, and could lead to advancements in the treatment and diagnosis 
of MDD. As such, in chapter 4, I investigate the association between a DNAm risk 
score and whole-genome PRS and global and individual white matter tracts, as 
measured by FA and MD. The study aids in advancing research relating to DNAm 
associated with both MDD and white matter microstructure.  
 
6. Neuroimaging and genetic & epigenetic research – past studies and current 
thesis 
 Following the sequencing of the first human genome, the genetics field has led 
to important advances in the understanding of heritable traits. Most importantly, when 
investigating disease, genetic loci and genes offer a mechanistic insight of the disease 
and allow for the identification of high-risk individuals. Moreover, genetic variants aid 
in uncovering molecular and cellular processes acting within diseases. Similarly, 




structural and functional processes within the brain, and complement the genetic 
approach by aiding in the identification of neural systems and brain circuitry (Hariri et 
al., 2006). Therefore, imaging genetics provide a unique opportunity to gain an 
understanding of biological, chemical, and molecular mechanisms, as well as specific 
pathways modulating variation in traits and disorders.  
 Neuroimaging genetics provide an avenue to investigate the structural and 
functional impact of polymorphisms on brain traits, ultimately leading to an 
understanding of aberrant or neurotypical behavioural manifestations. Due to the fact 
that genes give rise to both brain function and structure, responsible for the 
development of cognitive and behavioural processes, genetic variation may indirectly 
impact behavioural traits through neural systems. In this way, neuroimaging traits may 
act as endophenotypes, or the path from genotype to phenotype. Furthermore, mapping 
genetic variants in association with specific neural phenotypes also allows for the 
identification of candidate genes and their neural impact in vivo (Scharinger et al., 
2010; Bigos & Weinberger, 2010).  
 GWAS have led to important discoveries in relation to numerous traits and 
diseases along the years. Although the method’s clinical utility is still in its infancy, 
genetic variants identified through GWAS may serve as biomarkers for imaging 
phenotypes. For instance, Elliott et al. (2018) carried out GWAS for 3,144 imaging-
derived phenotypes (IDP), covering the entire brain, including white matter 
connectivity, in more than 8,428 individuals. Of the total 3,144 phenotypes, 1,578 
showed significant SNP heritability, indicating that brain traits are generally heritable. 
Within diffusion MRI, tractography-based IDPs generally showed lower heritability 
than tract-skeleton-based IDPs, indicating that different modalities and pre-processing 
pipelines may vary in their genetic underpinnings (Elliott et al., 2018).  
 For polygenic traits such as MDD, the amount of phenotypic variance 
explained by single SNPs is small, while a large number of SNPs is thought to underlie 
risk for complex disorders. PRS aggregate the contribution of a large number of SNPs, 
and can be used to test the genetic overlap between MDD and brain traits. In this way, 
novel associations between PRS and disorders may be uncovered by specific brain 




allow for the use of pathway-based approaches to investigate functionally related SNPs 
aggregated within a single biological pathway in relation to brain phenotypes. Inkster 
et al. (2010) investigated a pathway contributing to risk of MDD, the Wnt signalling 
pathway, in relation to grey matter volume, in 1,022 MDD patients and 1,000 healthy 
individuals. They found that numerous polymorphisms within the genes showed 
genotype-by-MDD interactions with regional grey matter volume (Inkster et al., 2010). 
These findings lend support to the use of candidate pathway approaches in the 
investigation of neuroimaging phenotypes.  
 Lastly, epigenetic modifications are ideal candidates in the investigation of 
brain-related phenotypes, as they reflect the direct influence of environmental factors 
(Lancaster et al., 2018). As such, using neuroimaging traits to examine the relationship 
between DNAm, for instance, and aberrant and neurotypical traits and behaviours has 
become popular in the past years. However, unique challenges accompany this 
research approach, not dissimilar to GWAS approaches. For instance, there are 
approximately 28 million CpG sites along the human haploid genome, leading to 
difficulty in investigating each site (Lancaster et al., 2018). The use of a DNAm score 
has proved to be useful in the past, in terms of aggregating sites into a single, 
continuous measure. 
 In addition to challenges mentioned above, past studies have encountered a 
number of difficulties in analysing and interpreting findings. One of the most common 
issues is sample size; when investigating neuroimaging genetics within a complex 
disorder, such as MDD, this issue is threefold. Firstly, sample sizes used within studies 
may not reflect the general population, due to phenotypic heterogeneity of MDD; 
patients may have different symptom manifestations, making specific associations 
difficult to assess and interpret. Moreover, in the investigation of both genetic and 
neuroimaging data in MDD, very large samples are needed in order to account for 
genetic heterogeneity and number of neuroimaging phenotypes. Until recently, a 
combination of both types of data within the same individuals had not been achieved.  
 A further issue in the investigation of neuroimaging genetics in MDD is 
accuracy of inferences and assumptions when looking at GWAS downstream analyses. 




biologically informative findings stemming from combined neuroimaging and genetic 
data are. However, the accuracy of these inferences is limited by previous information 
used to identify the pathway and its relationship to the function it carries out.  
 Finally, DNAm and gene expression analyses pose unique challenges, as they 
are both dynamic, tissue- and cell-specific, and variable (Fazzari & Greally, 2004; 
McKenzie et al., 2014). Therefore, both data types can only be assessed and 
investigated within the physical brain post-mortem, which in turn introduces its own 
challenges, such as differential gene expression post- as opposed to ante-mortem, and 
a possible heterogeneous sample limited in size. Neuroimaging phenotypes therefore 
provide a novel, non-invasive method of investigating genetic and epigenetic impact 
on the brain in vivo. 
Therefore, in the current thesis, I address some of the issues mentioned above 
by aiming to uncover links between white matter microstructure and differential gene 
expression, as well as to identify its role in relation to (1) genetic risk stratified by 
biological function and (2) whole-genome epigenetic risk of MDD. The overall aim of 
the thesis was to stratify genetic and epigenetic risk for MDD and identify novel 
genetic links to structural brain connectivity. 
I utilise neuroimaging genetics approaches in two large projects, UK Biobank 
and Generation Scotland: Scottish Family Mental Health (GS:SFHS). UK Biobank is 
a large, population-based health resource aiming to prevent, diagnose, and treat 
numerous disorders by investigating genetic and environmental risk factors in middle 
and old age (Sudlow et al., 2015). The prospective study comprises 502,617 
individuals aged 40-69 years whose genetic and environmental (e.g. lifestyle factors, 
medication intake) data were collected between 2006 and 2010 
(http://www.ukbiobank.ac.uk/). A total of 488,363 individuals were genotyped using 
two arrays, the UK BiLEVE and the UK Biobank Axiom arrays (Bycroft et al., 2018). 
At the time of the current thesis, approximately 20,000 individuals have neuroimaging 
data across a number of modalities, including structural, diffusion, and functional. This 
number will in time increase to 100,000 participants, making UK Biobank a unique 
resource for investigating neurobiological markers of disease in association with 




 GS:SFHS is a family-based population study investigating the genetics of 
health and disease in approximately 24,000 individuals across Scotland aged 18 – 98 
years, with baseline data collected between 2006 and 2011 (Smith et al., 2006; Smith 
et al., 2011). Data include environmental factors (e.g. lifestyle, medication intake) as 
well as genetic. Genome-wide DNAm data was also profiled from blood samples, 
marking GS:SFHS as one of the largest cohorts with available DNAm data. A subset 
of individuals, as part of Stratifying Resilience and Depression Longitudinally 
(STRADL), were followed-up, with the project aiming to further assess mental health, 
especially depression. Neuroimaging data was also collected for over 1,000 
individuals within the STRADL subset (Navrady et al., 2017). The data make it 
possible for researchers to investigate neuroimaging phenotypes in relation to a vast 
amount of data, including DNAm, in a large number of individuals. 
In the current thesis, I first start by investigating eQTL in relation to white 
matter microstructure in order to explore its genetic underpinnings. I applied a PRS 
derived from eQTL GWAS, with each score acting as a genetic proxy for the 
expression of a single gene. I found that expression scores of 8 genes were significantly 
associated with white matter microstructure after correction for multiple comparisons 
across scores and DTI metrics. More specifically, genes whose expression was linked 
to better white matter microstructural integrity were previously associated with 
developmental neural processes, such as neurite outgrowth; genes whose expression 
was linked to worse white matter microstructural integrity were previously associated 
with neuropsychiatric and neurological disorders (Chapter 2).  
Having lent support to white matter microstructure being genetically linked to 
differential expression patterns, I next investigated genetic risk for MDD aggregated 
within a biological pathway, the NETRIN1 Signalling Pathway, which had previously 
been associated with MDD, and its relationship to white matter microstructure. I 
calculated PRS for SNPs within and outside the pathway, and compared the two PRS 
lists in their association with white matter tracts. Findings indicated that the PRS 
aggregated within the NETRIN1 pathway was associated with large tracts connecting 
frontal-to-occipital areas of the brain, such as the superior and inferior longitudinal 




regionally and individually, as the biological pathway itself guides axons from the 
thalamus to the rest of the cortex in neurodevelopment (Chapter 3). 
Finally, to investigate increased epigenetic risk for MDD, I calculated an 
epigenome-wide DNAm risk score as well as a genome-wide PRS and associated both 
with white matter microstructure. While both risk scores were associated with MDD, 
supporting previous findings of an epigenetic signature of MDD, neither was 
associated with white matter tracts, globally or individually (Chapter 4). The results 
indicated the need for larger sample sizes in neuroimaging epigenetic studies, 
reflecting a similar pattern to genetic fields, which may in future prove to be more 
successful. Finally, the thesis ends with a summary of the main findings, strengths and 

















Chapter 2: Expression quantitative trait loci-derived scores and white matter 
microstructure in UK Biobank: a novel approach to integrating genetics and 
neuroimaging 
 
1. Chapter Introduction  
Previous GWAS of white matter microstructure reported it to be moderately 
heritable, indicating a genetic component contributing to white matter formation 
(Elliot et al., 2018). However, gene expression-based data has not previously been 
investigated in relation to white matter tracts in large sample sizes. Novel insight into 
expression changes in relation to brain connectivity may be gained and downstream 
analyses investigating brain-related traits and disorders (e.g. cognition, psychiatric 
disorders) may be interrogated as a result of this exploration. Therefore, the aim of the 
current study was to utilise a novel approach to identify genetic underpinnings of white 
matter microstructure, globally at whole-brain level, and with increasing regional 
specificity, in order to form a basis for future MDD genetic risk-associated studies in 
relation to brain connectivity. This chapter investigates the association between 
genetic proxies of gene expression for specific genes and white matter microstructure. 
In total, 6,457 eQTL scores, each representing the genetic profile of a single gene’s 
expression, were calculated for N = 14,518 individuals with FA data and N = 14,485 
individuals with MD data in UK Biobank. The study has been summarised in a 
manuscript entitled, “Expression quantitative trait loci-derived scores and white matter 
microstructure in UK Biobank: a novel approach to integrating genetics and 
neuroimaging”, and is under review at Translational Psychiatry 
(https://doi.org/10.1101/646646). As the first author, I designed the experiment, 




Expression quantitative trait loci (eQTL) are genetic variants associated with 
gene expression. Using genome-wide genotype data, it is now possible to impute gene 




previously unexplored relationships between gene expression and heritable in-vivo 
measures of human brain structural connectivity.  
Using large-scale eQTL mapping studies, 6,457 gene expression scores (eQTL 
scores) were computed using genome-wide genotype data in UK Biobank, where each 
score represents a genetic proxy measure of gene expression. These scores were then 
tested for associations with two diffusion tensor imaging measures, fractional 
anisotropy (NFA=14,518) and mean diffusivity (NMD=14,485), representing white 
matter microstructural integrity. 
FDR-corrected significant associations were found between 8 eQTL scores and 
structural connectivity phenotypes, including global and regional measures (βabsolute 
FA=0.0339-0.0453; MD=0.0308-0.0381) and individual tracts (βabsolute FA=0.0320-
0.0561; MD=0.0295-0.0480). The loci within these eQTL scores have been reported 
to regulate expression of genes involved in various brain-related processes and 
disorders, such as neurite outgrowth and Parkinson’s disease (DCAKD, SLC35A4, 
SEC14L4, SRA1, NMT1, CPNE1, PLEKHM1, UBE3C).  
Our findings indicate that eQTL scores are associated with measures of in-vivo 
brain connectivity and provide novel information, not previously found by 
conventional genome-wide association studies. Although the role of expression of 
these genes regarding white matter microstructural integrity is not yet clear, these 
findings suggest it may be possible, in future, to map potential trait- and disease-
associated eQTL to in-vivo brain connectivity and better understand the mechanisms 
of psychiatric disorders and brain traits, and their associated imaging findings. 
 
2.2 Introduction 
Expression quantitative trait loci (eQTL) are genetic variants which are 
proximally (cis) or distally (trans) associated with variation in the expression of genes 
(Nica & Dermitzakis, 2013). Previous animal and human studies have found that 
changes in gene expression lead to phenotypic variation, including adaptive 
phenotypic changes and evolutionary developments. In humans, for instance, cis-




lactase persistence in adulthood (Wray, 2007). With respect to psychiatric disorders, 
major depressive disorder (MDD) and bipolar disorder have been associated with 
decreased expression of prodynorphin messenger RNA (mRNA), which is involved in 
regulation of mood and expressed in limbic-related areas within the brain (e.g. 
amygdala, hippocampus) (Hurd, 1996; Hurd, 2002; Gandal et al., 2018). These 
findings indicate the importance of cis-regulatory mutations and variations in trait 
evolution. 
Variation in gene regulation leads to differences in individual phenotypes, 
indicating that eQTL may play a role in susceptibility to disease (De Jong et al., 2012; 
Luo et al., 2015). To test this hypothesis, methods which combine gene expression 
data with genome-wide association studies (GWAS) summary statistics have been 
developed. These approaches may provide further insight into the potential causal 
pathways and genes involved in specific disorders, or predict the regulatory roles of 
single nucleotide polymorphisms (SNPs) in linkage disequilibrium (LD) with 
previously associated variants (Gilad et al., 2008). Previous studies have found that 
genetic variation may explain some of the variance in levels of gene expression in 
human tissues, including post-mortem brain tissue (Stranger et al., 2005; Hernandez 
et al., 2012; Ramasamy et al., 2014; Zhu et al., 2016). In one such study, Zou et al. 
(2012) conducted an expression genome-wide association study (eGWAS) on post-
mortem brains of individuals with Alzheimer’s disease (AD) and other brain 
pathologies (non-AD; including progressive supranuclear palsy). They found 2,980 
cisSNPs associated with both AD and non-AD conditions. By investigating brain 
eQTL in post-mortem tissue therefore, researchers have been able to discover 
associations between gene expression and disease states in the brain.  
Using brain tissue in order to investigate gene expression levels is however 
problematic, due to limitations such as small sample sizes and possible expression 
level differences in post-mortem versus ante-mortem brains (McKenzie et al., 2014). 
As such, alternative approaches have therefore been investigated. One such approach 
is using eQTL measured from whole blood gene expression as a proxy for brain gene 
expression; an approach supported by important benefits such as greater sample size 
and easier accessibility (Qi et al., 2018). Although it is recommended that wherever 




considerable overlap has been demonstrated between blood and brain eQTL, 
indicating the validity of the approach (McKenzie et al., 2014). 
Neuroimaging measures provide a novel opportunity to investigate whether 
eQTL are significantly associated with in vivo brain phenotypes, and thereby 
increasing our knowledge of the role of eQTL in the wider context of psychiatric 
disorders. White matter microstructure, as measured by diffusion tensor imaging 
(DTI), is consistently heritable across tracts (Kochunov et al., 2015; Vuoksimaa et al., 
2017; Sprooten et al., 2014) and is compromised in several psychiatric disorders. 
Generally, decreased microstructural integrity of white matter is characterised by 
lower directionality of water molecule diffusion (reduced fractional anisotropy, FA) 
and less constrained water molecule diffusion (increased mean diffusivity, MD). 
Consistent findings across studies have indicated higher MD and lower FA in 
individuals suffering from MDD, for example (Whalley et al., 2013; Shen et al., 2017). 
Investigating the regulatory loci associated with white matter microstructure in health 
and disease may aid in the detection of molecular mechanisms influencing disease 
through aberrant structural brain connectivity.  
Within the current study, eQTL scores were derived based on two well-
powered whole-blood eQTL studies (Westra et al., 2013; Gusev et al., 2016). 
GENOSCORES, a database of filtered summary statistics of publicly-available 
GWAS covering multiple phenotypes, including gene expression, was used to 
calculate eQTL scores  (https://pm2.phs.ed.ac.uk/genoscores/).  
The resultant eQTL-based genetic scores can be considered proxies for the 
expression of particular genes, which can then be tested for association with traits of 
interest. Here, their association with white matter microstructure as measured by FA 
and MD was analysed in UK Biobank using participants from the October 2018 UK 
Biobank neuroimaging release (NFA = 14,518; NMD = 14,485). The purpose of the 
study was to utilise a novel approach to investigate associations between regulatory 
SNPs and white matter microstructure. This approach could lead to further specialised 
investigation into psychiatric and neurological disorders, as well as other brain-related 





2.3 Methods and materials 
2.3.1 UK Biobank (UKB) 
UK Biobank is a health resource aiming to prevent, diagnose and treat 
numerous disorders. It is comprised of 502,617 individuals whose genetic and 
environmental data (e.g. lifestyle, medications) were collected between 2006 and 2010 
in the United Kingdom (http://www.ukbiobank.ac.uk/). UKB received ethical 
approval from the Research Ethics Committee (reference: 11/NW/0382). This study 
has been approved by the UKB Access Committee (Project #4844). Written informed 
consent was obtained from all participants. 
 
2.3.2 Study population – neuroimaging measures 
In the current study, individuals were excluded if they participated in studies 
such as the Psychiatric Genomics Consortium (PGC) MDD GWAS or Generation 
Scotland (Scottish Family Health Study) to remove overlap of genetic samples.  
From the total of 502,617 individuals participating in UK Biobank, a subset 
was invited to attend neuroimaging assessments following the initial appointment. A 
total of 14,506 individuals who were part of the latest UK Biobank neuroimaging 
release (May 2018) were used in the current chapter. The age at the imaging 
assessment here ranged from 44.58-80.25 (mean: 62.69 +/- 7.48), of which 47.91% 
were men.  
The current study used two DTI scalars, FA and MD. DTI data pre-processing 
and quality checking included correction for eddy currents and head motion in the 
scanner, outlier-slices correction, as well as grand distortion correction. FA maps were 
used to generate tract masks, using probabilistic tractography analysis as part of the 
AutoPtx package in FSL (Mori et al., 2002). A total of 27 tracts were generated, of 
which 12 were bilateral and 3 unilateral; weighted mean FA and MD were then 
calculated for each tract and these were used as variables in the current chapter. 
Images were acquired, pre-processed, and quality controlled by UK Biobank 
using FMRIB Software Library (FSL) packages through a standard protocol 




scanner settings and that did not pass initial quality control were excluded from current 
analyses (Alfaro-Almagro et al., 2018). Moreover, individuals whose global measures 
for FA and MD lay more than three standard deviations from the sample mean were 
excluded (Shen et al., 2017; Barbu et al., 2019). This resulted in 14,518 individuals 
with FA values (Nfemale = 7,561 (52%); Nmale = 6,957 (48%); mean age: 63.14 +/- 7.4; 
age range: 45.92 – 80.67) and 14,485 individuals with MD values (Nfemale = 7,552 
(52%); Nmale = 6,933 (48%); mean age: 63.12 +/- 7.39; age range: 45.92 – 80.67).  
Tables 1 and 2 below detail general mental health for all individuals with FA 
and MD values, as taken from the mental health questionnaire administered to all UK 
Biobank participants (http://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=137). 
 Ever sought/received professional help for mental distress 
Ever suffered mental distress 
preventing usual activities 





Prefer not to 
answer 
4,180 (M=1,490) 3,603 (M=1,313) 
6,481 (M=3,481) 6,957 (M=3,596) 
18 (M=10) 121 (M=71) 
13 (M=6) 11 (M=7) 
MD   
Yes 
No 
Do not  
know 
Prefer not to 
answer 
4,175 (M=1,486) 3,598 (M=1,308) 
6,462 (M=3,469) 6,939 (M=3,586) 
18 (M=10) 120 (M=70) 
13 (M=6) 11 (M=7) 
Table 1. Mental distress reported with the on-line mental health questionnaire; 
M=male; column headers indicate questions asked in the questionnaire; mental health 
data is not available for all participants with FA and MD measures. 
 Mental health problems ever diagnosed by a professional 








Psychological over-eating or binge-eating (N=1) 
Anxiety, nerves or generalized anxiety disorder (N=1) 
Agoraphobia (N=1) 
ADD/ADHD (N=1) 
Anxiety, nerves or generalized anxiety disorder (N=2) 
Table 2. Mental health conditions present within both FA and MD samples; 7 
individuals with FA (N=14,518) and MD (N=14,485) have previously been diagnosed 




2.3.3 Genotyping and eQTL score calculation 
A total of 488,363 UKB blood samples (N female = 264,857; N male = 
223,506; http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=22001) were genotyped 
using the UK BiLEVE array (N = 49,949; 
http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=149600) and the UK Biobank Axiom 
array (N = 438,417; http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=149601). Details 
of genotyping and quality control are described in more detail by Hagenaars et al. 
(2016) and Bycroft et al. (2017). 
From GENOSCORES, eQTL analysis summary statistics from two studies of 
whole-blood eQTL were used (Westra et al., 2013; Gusev et al., 2016). Briefly, Gusev 
et al. (2016) developed a novel approach aimed at identifying associations between 
gene expression and complex traits in cases where gene expression level is not directly 
measured. These authors reported eQTL based on a sample of 1,414 individuals with 
whole-blood expression measured using the Illumina HumanHT-12 version 4 
Expression BeadChip. Westra et al. (2013) performed a large eQTL meta-analysis in 
5,311 samples across 7 studies from peripheral blood, with gene expression measured 
using Illumina whole-genome Expression BeadChips (HT12v3, HT12v4 or H8v2 
arrays). Their aim was to investigate the magnitude of the effect of cis and trans SNPs 
on gene expression, as well as to observe whether mapping eQTL in peripheral blood 
could uncover biological pathways associated with complex traits and disease. Further 
details of data acquisition and protocols are described in more detail in the two studies 
(Westra et al., 2013; Gusev et al., 2016). 
Before being imported into the GENOSCORES database, summary statistics 
were filtered at a liberal p-value < 1E-4 (0.0001). A total of 10,884 eQTL scores (N 
Gusev study = 3,801; N Westra study = 7,083) were computed for individuals included 
in the imaging sample (NFA: 14,518; NMD: 14,485) from the SNPs found in 
GENOSCORES, using a p-value threshold of 1E-5 (0.00001). Overlapping eQTL 
scores between the two studies (i.e. scores for which SNPs affect expression of the 
same gene in both studies) were then excluded by only including the score where a 
SNP had the lowest p-value, i.e. most significant association. The final eQTL score 




used as input variables in subsequent statistical analyses (Appendix 1: Figure S4 
provides a summary of the score derivation process).  
Briefly, eQTL scores were computed as a sum of the genotypes for an 
individual (g, scored as 0, 1, 2 copies of the reference allele) weighted by the effect 
size estimate (βt) for the trait of interest t. In order to adjust for LD, vector βt was pre-
multiplied by the generalized inverse of the SNP-SNP correlation matrix R estimated 
from the 1000 Genomes reference panel, limited to the individuals with European 
ancestry. 
The formula to compute the eQTL score for trait t for an individual (i) is 
therefore: 
score(i,t) = gi βt R-1 
 
2.3.4 Magnetic resonance imaging (MRI) acquisition 
In the current study, imaging-derived phenotypes (IDPs) produced by UKB 
were used. MRI acquisition and pre-processing procedures for white matter tracts were 
performed by UKB using standardised protocols 
(https://biobank.ctsu.ox.ac.uk/crystal/docs/brain_mri.pdf). Briefly, images were 
acquired in Manchester (NFA = 12,248; NMD = 12,221) and Newcastle (NFA = 2,270; 
NMD = 2,264) on a standard Siemens Skyra 3T scanner with a 32-channel radio-
frequency (RF) receive head coil and later pre-processed using the FMRIB Software 
Library (FSL), and parcellation of white matter tracts was conducted using AutoPtx 
(Alfaro-Almagro et al., 2018). Individual white matter tracts belonging to each tract 
category can be observed in Appendix 1, Table S13. 
Owing to the fact that head position and RF coil in the scanner may affect data 
quality and subsequent pre-processing, three scanner brain position variables were also 
generated by UKB, with the aim of being used as confounding variables in subsequent 
analyses. These are lateral brain position – X 
(http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=25756), transverse brain position – 




position – Z (http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=25758). The three 
variables were included as covariates in the statistical analysis described below. 
 
2.3.5 Statistical methods 
All analyses were conducted using R (version 3.2.3) in a Linux environment. 
Generalised linear mixed models (function “lme” in package “nlme”) were used for 
bilateral brain regions, which were included as dependent variables. The eQTL scores 
were included as independent variables separately in each model, with additional 
covariates: age, age2, sex, fifteen genetic principal components to control for 
population stratification, three MRI head position coordinates, MRI site and genotype 
array, while hemisphere was included as a within-subject variable. For unilateral tracts, 
as well as global measures and white matter tract categories of FA and MD, also 
included in the models as dependent variables, a general linear model (function “lm”) 
was used, using the same covariates as above, without hemisphere included as a 
separate term, and again including the eQTL scores as independent variables 
separately in each model. 
For global measures and white matter tract categories of FA and MD, principal 
component analysis (PCA) was applied on the white matter tracts of interest (all 27 for 
global measures; 12 for association fibres; 6 for thalamic radiations; 9 for projection 
fibres) in order to extract a latent measure. Scores of the first unrotated component 
were extracted and set as dependent variables in general linear models. False discovery 
rate (FDR) correction using the “p.adjust” function in R (q < 0.05) was applied across 
the eQTL scores and the individual white matter tracts (Ntests = 98,855), and separately 
across eQTL scores and global and tract categories (Ntests = 25,828). 
 
2.4 Results 
There were several eQTL scores that showed significant associations with a 
number of global measures, tract categories, and white matter tracts post FDR 
correction (Table 3; Figure 1a & 1b and Figure 2a & 2b; Appendix 1: Tables S5 – 




0.0561) and 24 scores with MD values (βabsolute = 0.0295-0.0480) in several tracts 
(these are fully detailed in Appendix 1: Tables S1, S2, S3 and S4; Figure S1 and S2). 
Among these scores, 8 were associated with white matter tracts measured by both FA 
and MD. The primary findings reported in this thesis section focus on these 8 
overlapping scores (consistent with the submitted paper), as these were considered to 
provide the most consistent information with regards to gene expression within white 
matter tracts as measured by two different DTI scalars (see tables 4 and 5).  










DCAKD_eQTL_cis 8 DCAKD Gusev et al. 
Expressed in glioma; 
ubiquitous expression in brain; 
implicated in a number of 
psychiatric and neurological 
disorders (Latourelle et al., 
2012; Gonzalez-Lozano et al., 
2016; Schizophrenia Working 
Group, 2018; Butler et al., 
2015) 
SLC35A4_eQTL_cis 12 SLC35A4 Gusev et al. Expressed in brain (Sosicka et al., 2017) 
SEC14L4_eQTL_cis 1 SEC14L4 Westra et al. 
Specific function not yet 
determined; may be 
implicated in 
neurodegeneration (Curwin et 
al., 2008) 
SRA1_eQTL_cis 15 SRA1 Westra et al. 
Involved in regulation of 
many NR (nuclear receptor) 
and non-NR activities (e.g. 
chromatin organisation); may 
be associated with idiopathic 
hypogonadotropic 
hypogonadism (Kotan et al., 
2016; Bianco et al., 2009) 
 
NMT1_eQTL_cis 7 NMT1 Westra et al. 
Ubiquitous expression in 
brain; may be implicated in 
brain tumours (Deng et al., 
2018; Lu et al., 2005; Ducker 
et al., 2005) 
CPNE1_eQTL_cis 1 CPNE1 Westra et al. 
May regulate molecular events 
at the interface of the cell 
membrane and cytoplasm; 
expressed during brain 
development and implicated in 
neurite outgrowth in rats (Kim 
et al., 2018; Park et al., 2012; 
Park et al., 2014)  
PLEKHM1_eQTL_cis 5 PLEKHM1 Gusev et al. 
Protein encoded by this gene 
is important for bone 




role in vesicular transport in 
the osteoclast (Fujiwara et al., 
2016; McEwan et al., 2015) 
UBE3C_eQTL_cis 4 UBE3C Westra et al. 
Expressed in brain; may be 
implicated in Parkinson’s 
disease (Garriock et al., 2010; 
Filatova et al., 2014) 
Table 3. Information regarding eQTL scores with significant associations for both FA and MD-
measured tracts.  
 
 
The effect of the 8 scores on FA measures of white matter microstructure 




DCAKD eQTL score      
Global FA 
Thalamic radiations 
Superior longitudinal fasciculus (SLF) 

































Inferior longitudinal fasciculus (ILF) 
















































Posterior thalamic radiation 
Superior longitudinal fasciculus (SLF) 































































NMT1 eQTL score      

























PLEKHM1 eQTL score      
Forceps minor -0.0347 0.0078 -4.4321 9.40E-06 0.0337 
UBE3C eQTL score      
Forceps minor -0.0382 0.0078 -4.8721 1.12E-06 0.0077 
Table 4. Significant associations between eQTL scores and global measures, category, and individual 
white matter tracts (FA); the first column indicates standardised effect size (β); FDR = false discovery 
rate; for each score, tracts are arranged from global to individual tracts. 
 
The effect of the 8 scores on MD measures of white matter microstructure 











Inferior longitudinal fasciculus (ILF) 
Anterior thalamic radiations (ATR) 
Inferior fronto-occipital fasciculus 
(IFOF) 


























































SLC35A4 eQTL score      
Global MD 










































SRA1 eQTL score      




NMT1 eQTL score      
Global MD 
Inferior longitudinal fasciculus (ILF) 
Inferior fronto-occipital fasciculus 
(IFOF) 
Anterior thalamic radiations (ATR) 

































CPNE1 eQTL score      
Global MD 
Association fibres 
Inferior longitudinal fasciculus (ILF) 



























Superior longitudinal fasciculus (SLF) 































UBE3C eQTL score      
Forceps minor 












Table 5. Significant associations between eQTL scores and individual white matter tracts (MD); the 
first column indicates standardised effect size (β); FDR = false discovery rate; for each score, tracts are 












Figure 1 (A and B). Indicates nominal p-values between each of the 8 scores (shown in legend entitled 
“eQTL score”) and global and tract category measures (noted on the x-axis; FA = fractional anisotropy 
(figure 1A, top); MD = mean diffusivity (figure 1B, bottom), note for 1B there were no significant 
relationships with projection fibres). All values in the figure met FDR correction. Two of the scores 
with the circular black border around the points (CPNE1 and NMT1) had an effect size in the opposite 
direction to all other scores (also indicated by -β for MD in figure legend). The colours of the plot points 
indicate the score to which they belong. Magnitude of standardised effect is shown in the legend entitled 











Figure 2 (A and B). Indicates nominal p-values between each of the 8 scores (shown in legend entitled 
“eQTL score”) and individual white matter tracts (noted on the x-axis; FA = fractional anisotropy (figure 
2A, top); MD = mean diffusivity (figure 2B, bottom)). SLF = superior longitudinal fasciculus; 
ILF = inferior longitudinal fasciculus; IFOF = inferior fronto-occipital fasciculus; ATR = anterior 
thalamic radiations; PTR = posterior thalamic radiations). All values in the figure met FDR correction. 
Two of the scores with the circular black border around the points (CPNE1 and NMT1) had an effect 
size in the opposite direction to all other scores (+β and -β for FA and MD, respectively in figure legend). 
The colours of the plot points indicate the score to which they belong. Magnitude of standardised effect 











Allen Brain Atlas gene expression pattern 
 The Allen Brain Atlas is a multi-modal atlas of gene expression across brain 
regions, integrating structure, function, and gene expression data to aid in the 
investigation of the human brain in health and disease (Shen et al., 2012). For the 
current chapter, the atlas was used to investigate the 8 significantly-associated eQTL 
scores in terms of gene expression patterns across brain regions in 6 donors (Table 6; 
Figures 3 and 4). 
Allen Brain Atlas Donor Demographic characteristics 
H0351.2001 24 years, Male, African American 
H0351.2002 39 years, Male, African American 
H0351.1009 57 years, Male, Caucasian 
H0351.1012 31 years, Male, Caucasian 
H0351.1015 49 years, Female, Hispanic 
H0351.1016 55 years, Male, Caucasian 
Table 6. Descriptive statistics of the 6 donors included in the Allen Brain Atlas 







Figure 3. Average gene expression patterns across brain regions in N = 6 donors for 
2 neurodevelopment-linked genes. Points on the plot indicate participants’ own gene 
expression level, while the bars indicate the mean gene expression value across all 
donors. The y-axis indicates gene expression values (normalized z-scores). Brain 




Figure 4. Average gene expression patterns across brain regions in N = 6 donors for 6 
disease-linked genes. Points on the plot indicate participants’ own gene expression 
level, while the bars indicate the mean gene expression value across all donors. The y-
axis indicates gene expression values (normalized z-scores). Brain structures are 







Genome-wide associations between score SNPs and white matter tracts  
Using a previously published GWAS of imaging traits (Elliott et al., 2018), the 
association between the SNPs comprising each of the 8 scores (Ntotal = 53; SNP list can 
be found in Appendix 1: Table S14) with those found previously for the white matter 
tracts of interest (i.e. the tracts which showed post-FDR significant associations) were 
investigated. This SNP look-up was performed in order to observe whether our 
analysis of eQTL scores, comprising SNPs which together regulate the expression of 
a single gene, yielded any novel associations with white matter tracts which were not 
previously found in conventional GWAS.  
The Brain Imaging Genetics (BIG) database (http://big.stats.ox.ac.uk/) was 
used to extract the effect size and p-value of each SNP of interest as associated with 
the white matter tracts of interest, as provided in Elliott et al. (2018). As GWAS for 
global and tract category measures were not performed in the original study, these 
GWAS were performed as part of the current project (i.e. GWAS for global measures, 
association fibres, thalamic radiations and projection fibres). Our GWAS parameters 
and quality check procedures are described in more detail in Appendix 1. P-values and 
effect size of each SNP for each individual white matter tract of interest (left and right 
hemispheres separately from Elliott et al., 2018), as well as for global and tract 
categories (run locally), are also contained in Appendix 1: Figure S3. Briefly, only one 
SNP across two eQTL scores (SLC35A4; SRA1) was previously found to reach 
genome-wide significance with forceps minor (FA), projection fibres (FA) and global 
FA (GWAS run locally): rs2237077. 
 
2.5 Discussion 
The current study utilised a novel approach to investigate whether eQTL 
scores, corresponding to the expression of specific genes in whole blood, were 
significantly and specifically associated with white matter tracts in N > 14,000 
individuals. Significant associations were found in white matter microstructure as 
measured by both FA and MD for a number of scores (FAN scores = 25; MDN scores = 24). 
Of these, 8 scores were found to be significantly associated with various white matter 




the association between forceps minor (FA) and the eQTL score for SLC35A4, and 
across several tracts measured by MD for the eQTL score for DCAKD. Although these 
eQTL were derived from whole blood, there is evidence of expression in the brain for 
some of the genes, outlined in further detail below. These findings also provided novel 
information not previously found by conventional genome-wide association studies.  
All 8 scores were associated with white matter microstructural integrity of the 
forceps minor as measured by FA (7 of which were also associated with MD values). 
The forceps minor forms the anterior part of the corpus callosum, connecting 
homologous regions of the prefrontal cortex between hemispheres. It is postulated to 
be involved in numerous cognitive and behavioural skills, such as decision making, 
social behaviour, and language (Miller et al., 2001). This connection therefore 
implicates forceps minor in a wide range of cognitive skills, and damage to the tract 
has been associated with neuropsychiatric and neurological disorders, such as multiple 
sclerosis and depression (Gobbi et al., 2014; Mamiya et al., 2018). 
2.5.1 Global and individual tract findings – largest associations  
The two genes with the largest associations were DCAKD, globally and across 
numerous tracts as measured by higher MD, and SCL35A4 across tracts measured by 
lower FA, with a peak in projection fibres, localised to forceps minor. DCAKD is a 
protein coding gene which is ubiquitously expressed in brain, among other tissues 
(Latourelle et al., 2012). Previous evidence using mouse models indicates expression 
of this gene has a putative role in neurodevelopment (Gonzalez-Lozano et al., 2016), 
and is associated with a number of psychiatric and neurological disorders, including 
schizophrenia, autism spectrum disorder, and Parkinson’s disease (Latourelle et al., 
2012; Schizophrenia Working Group, 2018; Butler et al., 2015). Evidence for 
involvement in autism spectrum disorder comes from Butler et al. (2015), who 
compiled a list of clinically relevant genes for the disorder, with DCAKD among the 
participating susceptibility genes. Expression of DCAKD was also found to be 
implicated in Parkinson’s disease (Latourelle et al., 2012), a disorder previously 
associated, along with other characteristic neurobiological features, with lower white 
matter integrity in tracts within the temporal, parietal and occipital lobes (Auning et 




SLC35A4 belongs to the SLC35 family, members of which act as transporters 
of nucleotide sugars, and is known to be expressed in brain (Sosicka et al., 2017). 
There is limited knowledge about its specific function, although a recent review 
investigating the subcellular localization and topology of SLC35A4 demonstrated that 
it localizes mainly to the Golgi apparatus (Sosicka et al., 2017). 
2.5.2 Disease-linked genes - lower FA & higher MD (decreased white matter 
integrity) 
Four genes identified through eQTL methods (SRA1, UBE3C, SEC14L4, 
PLEKHM1) were associated with lower FA within several individual tracts pertaining 
to projection and association fibres, as well as with higher global MD. SRA1 encodes 
both non-coding and protein-coding RNAs, is implicated in the regulation of numerous 
nuclear receptor activities, such as metabolism and chromatin organization, and is 
known to be expressed in the brain. Kotan et al. (2016) posited that SRA1 plays a role 
in the initiation of puberty in humans by finding that inactivating SRA1 variants were 
associated with idiopathic hypogonadotropic hypogonadism (IHH) in three 
independent families. IHH is a rare genetic disorder caused by the inability of the 
hypothalamus to secrete gonadotropin-releasing hormones (GnRH) or by the inability 
of GnRH to act on pituitary gonadotropes (Bianco et al., 2009). These previous results 
might link the association of SRA1 with projection fibres, which connect the cerebral 
cortex to the spinal cord and brainstem, as well as to other centres of the brain (e.g. 
thalamus). 
UBE3C contains ubiquitin-protein ligase (E3), an enzyme which accepts 
ubiquitin from E2 before transferring it to the target lysine; ubiquitin targets proteins 
for degradation via the proteasome. UBE3C is expressed in numerous tissues, 
including the brain, and has been previously associated with some neuropsychiatric-
related phenotypes. For instance, Garriock et al. (2010) performed a GWAS to 
determine the association between genetic variation and Citalopram response. 
Although not genome-wide significant, their top finding was a SNP in proximity to 
UBE3C and was found to be associated with antidepressant response and MDD 
remission (rs6966038, p = 4.65e-07 and p = 3.63E-07, respectively) (Garriock et al., 
2010). Moreover, Filatova et al. (2014) studied the expression of genes within the 




disease, in mice with MPTP-induced pre-symptomatic and early symptomatic stages 
of Parkinson’s disease. They found decreased expression in the striatum and the 
substantia nigra of mice, which may lead to a decrease in performance of the system. 
This may in turn lead to accumulation of abnormal and toxic proteins which guide 
neuronal cell death (Filatova et al., 2014).  
The specific function of SEC14L4 has not yet been determined, although the 
protein encoded by it is similar to a protein encoded by the SEC14 gene in 
saccharomyces cerevisiae, which is essential to the biogenesis of Golgi-derived 
transport vesicles. Curwin and McMaster (2008) found that mutations in several 
SEC14 domain-containing proteins in humans may be implicated in 
neurodegeneration, although it is not clear what the role of SEC14L4 is within this 
context. Lastly, PLEKHM1 is important in bone resorption, may be involved in 
vesicular transport in the osteoclast, and is weakly expressed in the brain. Although 
mutations in this gene have been associated with numerous phenotypes (Fujiwara et 
al., 2016; McEwan et al., 2015), none were neuropsychiatric-related. 
2.5.3 Development-linked genes - higher FA & lower MD (increased white matter 
integrity) 
Two of the eight genes (CPNE1, NMT1) were associated with higher FA and 
lower MD, indicating increased white matter integrity, associated with increased 
expression level as quantified by the corresponding eQTL.  
CPNE1, which is thought to regulate molecular events at the cell membrane 
and cytoplasm, has previously been found to mediate several neuronal differentiation 
processes by interacting with intracellular signalling molecules. CPNE1 has also been 
found to be highly expressed during brain development, indicating that it might be 
implicated in earlier developmental stages of neuronal function (Kim et al., 2018). 
Furthermore, C2 domains of CPNE1, calcium-dependent phospholipid-binding 
motives, have been shown to be implicated in neurite outgrowth of hippocampal 
progenitor HiB5 cells, which are hippocampal cell lines derived from the hippocampal 
analgen of E16 rat (Park et al., 2012; Park et al., 2014). CPNE1 expression was 
associated here with two tracts within projection fibres (FA) and with regional 




human models, these findings may be of use when investigating neurite outgrowth 
from the hippocampus, which is part of the limbic system, an area located beneath the 
cortex. 
NMT1 (N-myristoyltransferase) catalyzes the transfer of myristate (a rare 14-
carbon saturated fatty acid) from CoA to proteins, and is expressed in numerous 
tissues, including ubiquitously in the brain. It has been found that NMT1 is required 
for early mouse development, mainly due to its role in early embryogenesis (Deng et 
al., 2018). Expression of this gene has also been implicated in human brain tumours 
(Lu et al., 2005) and tumour cell proliferation (Ducker et al., 2005). In our study, NMT1 
was associated with tracts within thalamic radiations and projection fibres (FA) and 
global MD.  
2.5.4 General Discussion 
The current study employed a novel strategy of investigating a direct 
association between eQTL scores and white matter tracts to uncover a relationship 
between specific regulatory variants and brain connectivity. Together, our findings 
indicate that increases in expression of these genes may be implicated in several 
processes which may directly or indirectly alter white matter microstructure, each with 
localised, pronounced effects in specific tracts. Further, while some of the significant 
associations had connections with other brain-related traits, such as neurite outgrowth 
or psychiatric and neurological disorders, others did not. Interestingly, decreased white 
matter microstructure integrity, as marked by lower FA and higher MD, was associated 
with eQTL scores which regulate expression of genes implicated in neuropsychiatric 
and neurological disorders. Conversely, increased white matter integrity, as marked by 
higher FA and lower MD, was associated with CPNE1 and NMT1, which are important 
in developmental processes such as neurite outgrowth. In addition, encouragingly, 
regions of the corpus callosum (i.e. the forceps minor), the largest and arguably most 
reliably measured white matter tract in the brain, was demonstrated to be associated 
with all 8 scores for FA, and 7 for MD. These findings together suggest that utilising 
this approach to associate eQTL scores with white matter microstructure may add to 
previous research which found associations between genes and these brain-related 
traits and disorders. These genes or eQTL for them might indirectly implicate brain 




The current study has several strengths and some potential limitations. First, to 
our knowledge, this study is the first one to compute eQTL scores for specific gene 
transcripts and attempt to associate them with white matter tract integrity in vivo. 
Moreover, our analysis consisted of a population-based sample of N > 14,000 
individuals recruited to the UKB, large enough to make our findings robust and 
generalizable to other samples within the same age range, background and ethnicity. 
Lastly, our findings revealed novel associations which were not previously found in 
GWAS (Elliott et al., 2018; GWAS of g measures run locally), indicating a potential 
to use such scores for further discovery analyses. 
However, a potential limitation in this study is calculation of scores for data 
taken from whole blood, although there is previous evidence indicating that whole 
blood can be used as a proxy for brain eQTL, important for study of in vivo brain traits 
(McKenzie et al., 2014).  
In summary, our results suggest that expression of the genes discussed above 
alter white matter microstructure and could facilitate the manifestation of numerous 
brain-related traits. Uncovering specific markers leading to the formation, 
maintenance and pathology of white matter could enable downstream analyses to 
elucidate links between genetics and neuroimaging in neurological and psychiatric 
disorders, as well as other brain-related traits. 
 
3. Chapter conclusion 
This study provided novel associations between gene expression-based eQTL 
scores and white matter microstructure, not previously identified by conventional 
genome-wide association studies. The finding that gene expression of previously 
disease linked-genes is associated with decreased white matter integrity, and 
previously development-linked genes are associated with increased white matter 
integrity, across two DTI scalars, indicates that the brain phenotype may in future be 
utilised to link genotype to disease phenotype. This chapter laid the foundation for the 
next two chapters, in which attempts were made to elucidate the link between stratified 






























Chapter 3:  Association of whole-genome and NETRIN1 signaling pathway-
derived polygenic risk scores for Major Depressive Disorder and white matter 
microstructure in UK Biobank 
 
1. Chapter introduction 
As indicated in chapter 2, white matter microstructure phenotypes are linked 
to differential gene expression patterns, either in disease- or health-related traits. PRS 
have previously shown their utility in predicting psychiatric disorders in analyses 
including white matter microstructure (Whalley et al., 2013; Shen et al., 2017). 
However, while providing information relating to variance explained by additive 
genetic variants, a whole-genome PRS is limited in its ability to provide specific 
mechanistic insight into disease phenotypes (Dudbridge, 2013).  
In this chapter, I attempt to look beyond whole-genome PRS and exploratory 
candidate gene pathways. I explore the relationship between PRS derived for a 
biological pathway, previously identified by large-scale data-driven genetic analyses 
and which participates both in neurodevelopment and manifestation of MDD (Zeng et 
al., 2016), and white matter microstructure. Chapter 3 therefore aims to investigate, 
using PRS, the association between white matter microstructure and genetic risk of 
MDD localised to one pathway, and uses a whole-genome PRS (excluding variants 
within the identified pathway) as a control risk score. PRS were calculated for 6,401 
individuals with FA data and 6,390 individuals with MD data in UK Biobank. The 
study has been summarised in a manuscript entitled, “Association of whole-genome 
and NETRIN1 signaling pathway-derived polygenic risk scores for Major Depressive 
Disorder and white matter microstructure in UK Biobank” and has been published in 
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. I am the first 








Background: Major Depressive Disorder (MDD) is a clinically heterogeneous 
psychiatric disorder with a polygenic architecture. Genome-wide association studies 
have identified a number of risk-associated variants across the genome, and growing 
evidence of NETRIN1 pathway involvement. Stratifying disease risk by genetic 
variation within the NETRIN1 pathway may provide important routes for 
identification of disease mechanisms by focusing on a specific process excluding 
heterogeneous risk-associated variation in other pathways. Here, associations between 
MDD polygenic risk scores derived from the NETRIN1 signalling pathway 
(NETRIN1-PRS) and the whole genome excluding NETRIN1 pathway genes 
(genomic-PRS) with white matter microstructure were tested. 
Methods: Two diffusion tensor imaging measures were used, fractional 
anisotropy (FA) and mean diffusivity (MD), in the most up-to-date UK Biobank 
neuroimaging data release (FA: N = 6,401; MD: N = 6,390). 
Results: Findings included significantly lower FA in the superior longitudinal 
fasciculus (β = -0.035, pcorrected = 0.029) and significantly higher MD in a global 
measure of thalamic radiations (β = 0.029, pcorrected = 0.021), as well as higher MD 
in the superior (β = 0.034, pcorrected = 0.039) and inferior (β = 0.029, pcorrected = 
0.043) longitudinal fasciculus and in the anterior (β = 0.025, pcorrected = 0.046) and 
superior (β = 0.027, pcorrected = 0.043) thalamic radiation associated with NETRIN1-
PRS. Genomic-PRS was also associated with lower FA and higher MD in several 
tracts. 
Conclusions: Our findings indicate that variation in the NETRIN1 signaling 








Major Depressive Disorder (MDD) is a common and frequently disabling 
psychiatric disorder and a leading cause of disability worldwide (Otte et al., 2016). 
MDD is known to result from a complex combination of environmental and genetic 
factors (Bromet et al., 2011; Zeng et al., 2016), with a moderate heritability of 
approximately 37% (Sullivan et al., 2000; Belmaker & Agam, 2008; Ripke et al., 
2013). 
Genome-wide association studies (GWAS) suggest that at least part of MDD’s 
heritability is due to the cumulative effect of alleles of small effect size (Hek et al., 
2013; Lubke et al., 2012) and have identified a number of risk-associated genetic 
variants across the genome (Ripke et al., 2013; Hek et al., 2013; Converge Consortium, 
2015; Hyde et al., 2016; Mullins & Lewis, 2017). Significant findings for GWAS 
analyses can also be annotated to specific biological pathways, revealing underlying 
cellular and molecular mechanisms. 
Following several GWAS, the Psychiatric Genomics Consortium (PGC) have 
identified an aggregation of variants in several specific biological pathways (Network 
T, 2015; Jia et al., 2012). In MDD, Zeng et al. (2017) combined pathway and regional 
heritability analysis in two independent samples and reported that the NETRIN1 
signalling pathway was involved in the genetic aetiology of MDD. Moreover, 
polygenic risk scores (PRS) calculated for this pathway alone more accurately 
predicted MDD in one of the cohorts compared to PRS calculated for the whole 
genome. Genetic variation within the NETRIN1 signalling pathway may therefore 
capture more aetiologically circumscribed liability for MDD that is less susceptible to 
heterogeneous influences from other biological pathways. 
Animal studies have previously indicated that NETRIN1, by binding to and 
activating NETRIN1 receptors such as ‘Deleted in Colorectal Cancer’ (DCC), plays 
an important role in commissural and cortical axon guidance (Serafini et al., 1996). 
More recently, DCC was identified as playing a crucial role in thalamic axonal growth, 
confirming that interaction of NETRIN1 with DCC leads to successful axon growth 




other traits related to MDD have also shown an aggregation of variants in the 
NETRIN1 pathway (Manitt et al., 2013; Ward et al., 2017). 
Previous studies have attempted to investigate psychiatric disorders by 
examining relevant quantitative traits such as brain structure or function (Reus et al., 
2017). Differences in white matter (WM) integrity as measured by diffusion tensor 
imaging (DTI) have been found between MDD patients and healthy participants in 
numerous studies, although findings have been widely inconsistent (Shen et al., 2017; 
Klimes-Dougan et al., 2010; Korgaonkar et al., 2011). For example, Shen et al. (2017) 
found significantly lower global white matter integrity in association fibres and 
thalamic radiations, as measured by fractional anisotropy (FA), in MDD patients 
compared to healthy individuals. More specifically, they also found lower FA in the 
left superior longitudinal fasciculus, superior thalamic radiations and forceps major 
tracts in MDD patients. Lower WM integrity as measured by FA has also been found 
in adolescents with MDD as compared to age-matched healthy individuals (Klimes-
Dougan et al., 2010; Korgaonkar et al., 2011). 
It has previously been shown that the NETRIN1 signaling pathway is 
associated with MDD and white matter microstructure (Zeng et al., 2017). Therefore, 
the current study sought to investigate the association between MDD risk-associated 
variants in the NETRIN1 signaling pathway and white matter integrity. Polygenic risk 
scores for pathway SNPs (NETRIN1-PRS) and SNPs excluded from the pathway 
(genomic-PRS) were created and their association with WM integrity as measured by 
FA and mean diffusivity (MD) was tested using the most up-to-date genetic and 
imaging data available (N after exclusion steps: FA = 6,401; MD = 6,390) from UK 
Biobank (UKB). It was hypothesized that NETRIN1-PRS would be significantly 
associated with WM integrity, after adjustment for genomic-PRS, indicating a 






2.3 Methods and Materials  
2.3.1 UK Biobank 
The UKB study consists of 502,617 community-dwelling individuals who 
were recruited between 2006 and 2010 in the United Kingdom 
(http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=200). UKB received ethical approval 
from the Research Ethics Committee (reference: 11/NW/0382). This study has been 
approved by the UKB Access Committee (Project #4844). Written informed consent 
was obtained from all participants. 
 
2.3.2 Study population 
In the most recent UKB imaging data release, 8,839 individuals (N female = 
4,639; N male = 4,200; mean age: 62.54 +/- 7.42 years; age range: 45.17 – 79.33) 
completed DTI assessment, and a quality check by UKB. In addition to this, for the 
current study, individuals were excluded if they participated in studies from the PGC 
MDD GWAS (Wray & Sullivan, 2017) or Generation Scotland (Scottish Family 
Health Study), or if they happened to be related, as the PGC MDD GWAS dataset was 
used in order to calculate PRS. Moreover, individuals whose FA and MD values were 
greater than three standard deviations above/below the mean were not included in the 
study (Appendix 2: Tables S4 and S5). This resulted in 6,401 individuals with FA 
values (N female = 3,334; N male = 3,067; mean age: 62.60 +/- 7.37; age range: 45.92 
– 78.42; N control: 3,736; N case: 2,512) and 6,390 individuals with MD values (N 
female = 3,327; N male = 3,063; mean age: 62.58 +/- 7.36; age range: 45.92 – 78.42; 
N control: 3,729; N case: 2,508), excluding 19 and 30 individuals with FA and MD 
values from a total of 6,420, respectively. Details of data exclusion as well as 
participant information for the full dataset (N = 6,420) are shown in Appendix 2: 
Tables S1 and S2. 
 
2.3.3 The NETRIN1 signalling pathway and SNP annotation 
 The NETRIN1 pathway is implicated in axon guidance, by binding to and 




guided by extracellular axon guidance cues (Braisted et al., 2000). Figure 1 below 
indicates the NETRIN1-dependent axon guidance pathway process.  
 
Figure 1. Model of signalling pathways and interactions downstream of DCC in the 
NETRIN1-dependent axon guidance pathway, as shown in Boyer and Gupton (2018). 
As shown in the figure, DCC interacts with enzymes and adaptor proteins in the 
absence of NETRIN1, which can initiate responses to ligand binding. Valency is 
increased by NETRIN1 through multimerization of DCC homodimers. Intracellular 
domains of the receptors are thus brought into close apposition, which forms a 
scaffolding for recruitment and activation of proteins. In the figure, solid green arrows 
indicate direct activation steps, and dashed green arrows represent known connections. 
The pathways modify the intracellular environment together to promote directional 






Genic SNPs found in the NETRIN1 signaling pathway as taken from Zeng et 
al.’s (2017) study (N genes = 43; gene list is presented in Appendix 2: Table S3) and 
genic SNPs excluded from the pathway were annotated using the program 
ANNOVAR. ANNOVAR is a biostatistical tool used to annotate genetic variants to 
functional genomic regions (Yang & Wang, 2015). In the current study, a gene-based 
annotation was performed for SNPs used in the largest available GWAS of MDD 
(N=461,134, of which 130,664 were MDD cases), carried out by the Psychiatric 
Genomics Consortium (Wray & Sullivan, 2017), which includes summary statistics 
from the personal genetics company 23andMe, Inc. (Hyde et al., 2016). Gene 
boundaries were defined as an extended region of 20 kb from transcription start sites 
and transcription end sites. After SNPs were annotated to genes, they were further 
mapped to the NETRIN1 signalling pathway. All protein-coding genes within this file 
were annotated in reference to hg 19. Intergenic SNPs were not included in the 
annotated files. The resulting output file included: function of each SNP, gene name, 
chromosome number, start position, end position, reference and alternative alleles, 
odds ratio, standard error and p-value for each variant. 
Following functional annotation, a file containing the 43 gene names included 
in the NETRIN1 signaling pathway was used as an input in order to extract gene-based 
SNPs located in the pathway. For the genomic-PRS, all gene-based SNPs excluding 
those implicated in the NETRIN1 signaling pathway were extracted. The two files 
were then used as input for creation of PRS. 
 
2.3.4 Genotyping and PRS profiling 
A total of 488,363 UKB blood samples (N female = 264,857; N male = 
223,506; http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=22001), were genotyped 
using two different arrays: UK BiLEVE array (N = 49,949) 
(http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=149600) and UK Biobank Axiom 
array (N = 438,417) (http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=149601). 
Details of genotyping and quality control are described in more detail by Hagenaars et 




Using the largest available GWAS of MDD, PRS for each individual were 
computed using PRSice (Euesden et al., 2014), at five p-value thresholds (0.01, 0.05, 
0.1, 0.5, 1) by adding the number of risk alleles and weighting them by the strength of 
association with MDD. PRS were created both from SNPs annotated to the NETRIN1 
signalling pathway and from SNPs from the rest of the genome, thus resulting in 
separate PRS lists. PRS were created both with and without clump-based pruning of 
SNPs in linkage disequilibrium (r2 = 0.25, 250km window). The primary analysis 
reported in this manuscript concerns unpruned SNPs, owing to the potential of causal 
variants within the NETRIN1 pathway to be in LD with other variants, and uses SNPs 
which met a significance level of p = 0.5, in line with previous studies (Purcell et al., 
2009; Whalley et al., 2016). Secondary analyses with other PRS p-value thresholds, as 
well as with LD pruned SNPs, are presented in Appendix 2, Tables S6 – S21. 
 
2.3.5 MRI acquisition 
In the present study, imaging-derived phenotypes (IDPs) produced by UKB 
were used. MRI acquisition and pre-processing procedures for FA and MD values of 
white matter tracts were performed by UKB using standardised protocols 
(https://biobank.ctsu.ox.ac.uk/crystal/docs/brain_mri.pdf). Briefly, images were 
collected on a single Siemens Skyra 3.0 T scanner with a standard Siemens 32-channel 
head coil and were pre-processed using FSL packages; parcellation of white matter 
tracts was conducted using AutoPtx (Alfaro-Almagro et al., 2017). 
Summary data were composed of tract-averaged FA and MD values for 15 
major white matter tracts, of which 12 are bilateral and three are unilateral. The white 
matter tracts were also categorised into three separate subsets, as follows: association 
fibres: inferior fronto-occipital fasciculus, uncinate fasciculus, cingulum bundle (gyrus 
and parahippocampal), superior and inferior longitudinal fasciculus; thalamic radiation 
fibres: anterior, superior and posterior thalamic radiations; projection fibres: forceps 
major and minor, corticospinal tract, acoustic radiation, medial lemniscus and middle 
cerebellar peduncle. Global measures of FA and MD are referred to as general factors 




Exclusion criteria comprised removal of scans with severe normalisation 
problems by UKB. Moreover, individuals whose FA and MD values were higher than 
three standard deviations from the sample mean were also excluded. Descriptive 
statistics for the full dataset with outliers included and excluded are also presented in 
Appendix 1: Tables S1 and S2. Lastly, due to the fact that the position of the head and 
radio-frequency coil in the scanner may affect data quality as well as IDPs, three 
scanner brain position variables which may be used as confounding variables in 
subsequent analyses were generated by UKB: lateral brain position – X 
(http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=25756), transverse brain position –Y 
(http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=25757) and longitudinal brain 
position – Z (http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=25758). The three 
variables were included as covariates in the statistical analysis described below. 
 
2.3.6 Statistical methods 
All analyses were conducted using R (version 3.2.3) in a Linux environment. 
In order to test the association between the NETRIN1 signaling pathway- and genomic 
pathway-derived unpruned PRS lists, repeated measures linear mixed-effects models 
(function “lme” in package “nlme”) were used for 12 bilateral brain regions, correcting 
for hemisphere, with age, age2, sex, fifteen genetic principal components, three MRI 
head position coordinates and genotype   array set as covariates. For unilateral tracts, 
global measures of FA and MD, and tract categories, a general linear model (function 
“lm”) was used, using the same covariates as above, and without hemisphere included 
as a separate term in the model. All models included both the genomic-PRS and the 
NETRIN1-PRS as predictor variables. 
First, the association between unpruned PRS (both NETRIN1-PRS and 
genomic-PRS) and global white matter integrity was tested. Principal component 
analysis (PCA) was then applied on the 27 white matter tracts (12 tracts in both the 
right and left hemisphere and three unilateral tracts) in order to extract a latent measure. 
Scores of the first unrotated component of FA and MD (variance explained = 37.52% 




general linear model in order to test association with both NETRIN1-PRS and 
genomic-PRS. 
The three categories of white matter tracts were examined by applying PCA on 
the regions involved in each, as a substantial proportion of white matter 
microstructural properties shows substantial commonality across these pathways (Cox 
et al., 2016). Scores of the first unrotated component of FA and MD were similarly 
extracted and set as dependent variables in general linear modelling, as above. 
Variance explained for each white matter tract subset was as follows: association 
fibres: 45.36% (FA), 50.76% (MD); thalamic radiations: 60.85% (FA), 73.40% (MD); 
projection fibres: 35.54% (FA), 29.28% (MD). 
Lastly, the association between PRS (both NETRIN1-PRS and genomic-PRS) 
and each individual white matter tract (N = 15) was tested, using a repeated-effect 
linear model for the 12 bilateral tracts and a random-effect general linear model for the 
three unilateral tracts. 
False discovery rate correction was applied separately for the 15 individual 
tracts and for global and tract category values. 
 
2.3.7 Permutation analysis 
In order to establish that the effect of the NETRIN1 pathway-derived PRS on 
WM integrity as measured by FA and MD was not due to chance, a circular genomic 
permutation method developed by Cabrera et al. (2012) was applied to the pathway 
SNP genotypes. The permutation approach uses GWAS SNP association results to 
identify the significance of pathway associations while accounting for the linkage 
disequilibrium structure of SNPs. As such, for a given GWAS, all SNPs are placed in 
what is called a “circular genome” based on their location. The complete set of p-
values derived from the GWAS SNP associations are then permuted in a rotational 
fashion with respect to the genomic locations of the SNPs. This allows SNPs to retain 
the same position within the genome and with respect to each other, but gain new 
random association p-values. Once simulated p-values are assigned, a Fisher’s 




to increase understanding of gene-sets and pathways implicated in traits without 
generating pathway associations that are false-positive (Cabrera et al., 2012).  
In this study, this was done by placing all SNPs in the whole genome 
(excluding those in the NETRIN1 pathway) in a circular genome, according to their 
location. One thousand SNP lists with the same set size as the NETRIN1 pathway were 
permuted using the method described above and 1000 PRS lists were created, which 
were then fitted in linear mixed-effects and general linear models, depending on the 
white matter tract tested, and their association with five white matter tracts and one 
tract category, found to be significantly associated with NETRIN1, was tested. 
 
2.4 Results 
Results presented below are significant specifically to each pathway. White 
matter tracts showing a significant association with both the NETRIN1-PRS and the 
genomic-PRS pathways are described in Appendix 2. Results for all individual white 
matter tracts, tract categories and global measures can be found in tables 1-4 and 
figures 2-5. 
2.4.1 The effect of unpruned NETRIN1-PRS & genomic-PRS on measures of 

























CGC -0.025 0.011 0.020 0.152 0.062 -0.019 0.011 0.069 0.115 0.038 
PHC -0.008 0.011 0.435 0.544 0.007 -0.020 0.011 0.061 0.115 0.040 
IFOF -0.023 0.011 0.046 0.172 0.053 -0.028 0.012 0.016 0.060 0.076 
ILF -0.023 0.011 0.043 0.172 0.054 -0.024 0.012 0.040 0.115 0.056 
SLF -0.036 0.012 0.002 0.030 0.128 -0.023 0.012 0.047 0.115 0.053 
UF -0.019 0.011 0.081 0.202 0.102 -0.032 0.011 0.003 0.043 0.102 
TR
 ATR -0.022 0.011 0.057 0.172 0.048 -0.015 0.011 0.190 0.238 0.023 
PTR -0.014 0.011 0.205 0.308 0.020 -0.022 0.011 0.054 0.115 0.047 
STR -0.006 0.012 0.622 0.718 0.003 -0.015 0.012 0.213 0.244 0.022 
PF
 
AR 0.003 0.011 0.759 0.814 0.001 -0.013 0.011 0.228 0.244 0.016 
CST 0.002 0.011 0.863 0.863 0.000 -0.018 0.011 0.103 0.154 0.034 
ML -0.009 0.010 0.400 0.544 0.008 -0.003 0.010 0.803 0.803 0.001 
Fmaj -0.016 0.012 0.193 0.308 0.024 -0.032 0.012 0.009 0.043 0.100 
Fmin -0.018 0.012 0.135 0.262 0.032 -0.032 0.012 0.009 0.043 0.099 





Table 1. The effect of NETRIN1-PRS & genomic-PRS at PRS threshold 0.5 on 
individual white matter tracts (FA values). The first column for each PRS indicates 
standardised effect size (β). Statistically significant p-values after false discovery rate 
correction for each pathway individually are shown in bold. R2 = estimate of variance 




Figure 2. The effect of NETRIN1-PRS & genomic-PRS on FA values of white matter 
tracts. The x-axis indicates the standardised effect size of each pathway's PRS; the y-
axis indicates the white matter tracts. The legend indicates the tract category belonging 
to each white matter tract. The error bar represents standard deviation of mean. 
Effect of NETRIN1-PRS (left) and Genomic-PRS (right) on tract categories (FA values) 
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gFA -0.026 0.012 0.028 0.056 0.068 -0.033 0.012 0.006 0.011 0.109 
AF -0.033 0.012 0.006 0.023 0.107 -0.034 0.012 0.005 0.011 0.113 
TR -0.018 0.012 0.138 0.185 0.032 -0.022 0.012 0.064 0.064 0.050 
PF -0.011 0.012 0.366 0.366 0.012 -0.029 0.012 0.016 0.021 0.083 
Table 2. The effect of NETRIN1-PRS & genomic-PRS at PRS threshold 0.5 on global 
FA and 3 white matter tract categories. The first column for each PRS indicates 
standardised effect size (β). Statistically significant p-values after false discovery rate 
correction for each pathway individually are shown in bold. R2 = estimate of variance 






Figure 3. The effect of NETRIN1-PRS & genomic-PRS on FA values of tract 
categories and global FA. The x-axis indicates the standardised effect size of each 
pathway's PRS; the y-axis indicates the tract categories. The error bar represents 
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Lower global FA (gFA) was significantly associated with higher genomic-PRS 
(β = -0.033, pcorrected = 0.011) only. 
Tract categories 
The association between NETRIN1-PRS and Genomic-PRS and three subsets 
of white matter tracts (association fibres, thalamic radiations and projection fibres) was 
then tested. Significantly lower FA values in projection fibres were found for genomic-
PRS (β = -0.028, pcorrected = 0.020) only. 
Individual white matter tracts 
Lastly, the effect of NETRIN1-PRS and genomic-PRS on WM integrity in 15 
individual white matter tracts was investigated. NETRIN1-PRS, but not genomic-PRS, 
was associated with significantly lower FA in the superior longitudinal fasciculus (β = 
-0.035, pcorrected = 0.029).  
In the genomic-PRS, there was significantly lower FA in the forceps major (β 
= -0.031, pcorrected = 0.043), forceps minor (β = -0.031, pcorrected = 0.043) and 
uncinate fasciculus (β = - 0.031, pcorrected = 0.043). None of these tracts showed 












2.4.2 The effect of unpruned NETRIN1-PRS & genomic-PRS on measures 
of white matter integrity – MD (N = 6,390) 
Figure 4. The effect of NETRIN1-PRS & genomic-PRS on MD values of white matter 
tracts. The x-axis indicates the standardised effect size of each pathway's PRS; the y-
axis indicates the white matter tracts. The legend indicates the tract category belonging 























CGC 0.020 0.011 0.061 0.130 0.040 0.035 0.011 0.001 0.014 0.124 
PHC -0.002 0.011 0.861 0.861 0.000 0.033 0.011 0.002 0.014 0.107 
IFOF 0.027 0.011 0.014 0.047 0.075 0.031 0.011 0.005 0.019 0.098 
ILF 0.029 0.011 0.009 0.043 0.086 0.025 0.011 0.027 0.067 0.061 
SLF 0.034 0.011 0.003 0.039 0.116 0.024 0.011 0.033 0.071 0.058 
UF 0.018 0.010 0.090 0.168 0.085 0.029 0.010 0.005 0.019 0.084 
TR
 ATR 0.025 0.011 0.016 0.047 0.065 0.021 0.011 0.043 0.080 0.046 
PTR 0.025 0.011 0.020 0.050 0.062 0.002 0.011 0.876 0.876 0.000 
STR 0.027 0.010 0.006 0.043 0.074 0.018 0.010 0.077 0.096 0.031 
PF
 
AR 0.004 0.010 0.708 0.772 0.002 0.019 0.011 0.064 0.087 0.038 
CST 0.016 0.011 0.162 0.221 0.025 0.022 0.011 0.055 0.082 0.047 
ML 0.004 0.011 0.721 0.772 0.001 0.004 0.011 0.692 0.741 0.002 
Fmaj 0.018 0.012 0.135 0.203 
-
0.026 0.028 0.012 0.018 0.055 0.019 
Fmin 0.019 0.012 0.101 0.168 
-
0.063 0.023 0.012 0.050 0.082 -0.051 
MCP 0.013 0.012 0.290 0.363 0.016 0.010 0.012 0.394 0.455 0.010 
Table 3. The effect of NETRIN1-PRS & genomic-PRS at PRS threshold 0.5 on 
individual white matter tracts (MD values).  The first column for each PRS indicates 
standardised effect size (β). Statistically significant p-values after false discovery 
rate correction for each pathway individually are shown in bold. R2 = estimate of 
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MD values for association fibres (β = 0.041, pcorrected = 0.001) and projection 
fibres (β = 0.028, pcorrected = 0.023) were found to be significantly higher for 
genomic-PRS, but not NETRIN1-PRS. MD values for thalamic radiations were found 
to be significantly higher in the NETRIN1-PRS (β = 0.029, pcorrected = 0.021), 











size(β) SD p value 
p corrected 
(FDR) R2 
gMD 0.028 0.011 0.016 0.031 0.076 0.034 0.011 0.003 0.007 0.111 
AF 0.022 0.012 0.058 0.077 0.048 0.042 0.012 0.000 0.001 0.172 
TR 0.030 0.011 0.005 0.021 0.089 0.013 0.011 0.218 0.218 0.017 
PF 0.021 0.012 0.077 0.077 0.045 0.029 0.012 0.017 0.023 0.081 
Table 4. The effect of NETRIN1-PRS & genomic-PRS at PRS threshold 0.5 on global 
MD and 3 white matter tract subsets.  The first column for each PRS indicates standardised 
effect size (β). Statistically significant p-values after false discovery rate correction for 
each pathway individually are shown in bold. R2 = estimate of variance explained by each 





Figure 5. The effect of NETRIN1-PRS & genomic-PRS on MD values of tract categories 
and global MD. The x-axis indicates the standardised effect size of each pathway's PRS; 




















































Individual white matter tracts 
Within the 15 individual white matter tracts, numerous areas were significantly 
associated with both the NETRIN1-PRS and genomic-PRS. With regards to 
NETRIN1-PRS, MD values were significantly higher in the inferior longitudinal 
fasciculus (β = 0.029, pcorrected = 0.043), superior longitudinal fasciculus (β = 0.034, 
pcorrected = 0.039), and in the anterior (β = 0.025, pcorrected = 0.046) and superior 
(β = 0.027, pcorrected = 0.043) thalamic radiations. All of these significant 
associations were specific for NETRIN1-PRS. 
In the genomic-PRS, there were significantly higher MD values in the cingulate 
gyrus (β = 0.035, pcorrected = 0.013) and parahippocampal (β = 0.032, pcorrected = 
0.014) part of cingulum and in the uncinate fasciculus (β = 0.029, pcorrected = 0.018). 
 
2.4.3 Permutation analysis 
NETRIN1-PRS, but not genomic-PRS, were found to be individually 
significantly associated with white matter microstructure in the following white matter 
tracts: superior longitudinal fasciculus as measured by lower FA; superior and inferior 
longitudinal fasciculus and anterior and superior thalamic radiations, as well as 
thalamic radiations tract category, as measured by higher MD. Therefore, an additional 
circular genomic permutation analysis was performed and it was found that the 
variance explained by NETRIN1-PRS in these tracts was significantly higher than 
expected by chance (table 5). 
White matter tract 











Superior longitudinal fasciculus 
(FA) -0.035 -3.093 0.004 
Superior longitudinal fasciculus 
(MD) 0.034 3.008 0.004 
Inferior longitudinal fasciculus 
(MD) 0.029 2.624 0.014 
Anterior thalamic radiations (MD) 0.025 2.419 0.023 
Superior thalamic radiations (MD) 0.027 2.757 0.007 
Thalamic radiations (MD) 0.029 2.785 0.008 
Table 5. Permutation results for NETRIN1-PRS at PRS threshold 0.5 on 5 significant white 
matter tracts and one significant tract category. The first column indicates standardised 







The present study aimed to investigate whether PRS calculated from the 
NETRIN1 signalling pathway are significantly and specifically associated with WM 
integrity while simultaneously modelling genomic-PRS in more than 6,000 
individuals. Significant differences were found in white matter integrity in both 
NETRIN1-PRS and genomic-PRS, for both FA and MD values. Regarding FA values, 
for NETRIN1-PRS, but not for genomic-PRS, a significant association was observed 
in the superior longitudinal fasciculus. NETRIN1-PRS alone were significantly 
associated with higher generalised thalamic radiations as measured by MD, as well as 
higher MD in the superior and inferior longitudinal fasciculus, and the anterior and 
superior thalamic radiations. Genomic-PRS were also significantly associated with FA 
and MD values in several tracts. 
One of the main findings in our paper was both a reduction of FA and an 
increase of MD in the SLF in relation to NETRIN1-PRS. The SLF, a tract in 
association fibres, connects the frontal, temporal, parietal and occipital lobes, and has 
been shown to be highly involved in MDD (Wu et al., 2011; Cole et al., 2012). FA 
reductions in the SLF have also been found in previous studies combining genetic and 
neuroimaging techniques (Whalley et al., 2013), further indicating that the tract might 
be an important biomarker of MDD. In addition to this finding, there was also an 
increase in MD values in the ILF, a tract connecting the temporal and occipital lobes. 
Key areas in these two lobes include the amygdala and hippocampus, which are known 
to be implicated in emotion processing, a process which is disrupted in MDD (Ritchey 
et al., 2011). Previous studies have found disrupted white matter integrity in this tract 
in association with MDD using FA, indicating that it may play an important role in the 
pathophysiology of MDD (Whalley et al., 2013). 
An  MD  increase  in  the  thalamic  radiations  tract  category was also found.  
Thalamic radiations connect the thalamus with numerous cortical areas (Cabrera et al., 
2012; Braisted et al., 2000), and are connected to various cognitive processes, such as 
attention and wakefulness (Bonnin et al., 2007). Thalamocortical axons play an 
important role during development, as their projection from the dorsal thalamus (DT) 
transmit sensory information to the neocortex (Braisted et al., 2000). Thalamic 




decrease in FA was found in the TR subset in a large UKB sample comparing 335 
MDD patients with 754 healthy individuals (Shen et al., 2017). This tract subset was 
also found to be significantly associated with higher PRS, indicating that there is a link 
between the sets of tracts and a potential genetic predisposition to MDD (Whalley et 
al., 2013). 
NETRIN1, and its receptor DCC, one of the genes in the NETRIN1-pathway, 
have been previously implicated in thalamic axonal growth. NETRIN1 promotes 
growth of thalamocortical axons by binding to and activating DCC, which is expressed 
in the DT. Moreover, NETRIN1 has been shown to enhance axonal growth in explants 
of the DT, as well as providing guidance from the DT to the cortex (Braisted et al., 
2000). It has also been found that serotonin, which is highly implicated in MDD, 
modulates the effect of NETRIN1 on embryonic thalamocortical axons (Braisted et 
al., 2000; Bonnin et al., 2007; Clasca et al., 2016). The active involvement of 
NETRIN1 in thalamocortical axonal growth, therefore, may explain our findings, and 
further confirms that there is a potential link between a biological pathway and specific 
neurobiological markers in MDD. 
Several other tracts also showed a significant association of FA (individually 
in forceps major and minor and uncinate fasciculus, and in global measures of FA and 
projection fibres) and MD (individually in cingulate part of the cingulum, 
parahippocampal part of cingulum and uncinate fasciculus, and in global measures of 
association and projection fibres) with genomic-PRS, most of which have also been 
previously associated with MDD (Shen et al., 2017; Whalley et al., 2013). This 
evidence further confirms that there is an association between genetic predisposition 
to MDD and disruptions in white matter integrity, also for variants that lie outside the 
NETRIN1-DCC pathway. As such, these findings suggest that both PRS lists affect 
integrity across the white matter tracts, each with localized, pronounced effect in 
specific tracts. 
The current study has several strengths and a few potential limitations. First of 
all, it is the largest combined genetic and neuroimaging study investigating the effect 
of PRS derived from a specific biological pathway on white matter integrity, to our 




ambulant individuals recruited to UKB. Our findings might therefore be robust and 
generalizable to other samples within a certain age range, although studies such as 
UKB are not immune to biases associated with study participation, such as collider 
bias (Day et al., 2016). 
In addition to the large sample, the fact that NETRIN1-PRS are derived from 
only 43 genes, comprising approximately 0.215% of the genes in the whole genome 
(N = ~ 20,000) suggests that MDD risk associated variation exerts a disproportionate 
influence on white matter microstructure. Our findings are also further supported by 
permutation analysis. The association between the NETRIN1 pathway and white 
matter integrity is therefore likely to reflect the importance of a specific pathway in 
the pathophysiology of MDD. 
The NETRIN1 signaling pathway has previously been found to be implicated 
in MDD (Zeng et al., 2017). The current study found specific neurobiological 
structural connectivity markers associated with this biological pathway. To our 
knowledge, the current study is the first one to note an association between PRS 
derived specifically from the NETRIN1 signaling pathway and several white matter 
tracts in a large genetic and neuroimaging dataset. This indicates that these brain 
structures may be involved in the manifestation of genetic risk of MDD and ultimately 
the aetiology of the disorder. 
 
3. Chapter conclusion 
In this study, a PRS calculated from SNPs within a single biological pathway 
was significantly associated with global, regional, and individual white matter 
microstructure across two DTI scalars, FA and MD. Most interesting is the association 
between PRS and regional and individual thalamic radiations, which lends support to 
the hypothesis that focusing on biological pathways with specific functions may 
elucidate the mechanistic genetic underpinnings of MDD. Finding such connections 
may in future aid in conducting more focused analyses to detect gene-sets which are 
defined by biologically functional mechanisms in an effort to identify treatment targets 




Chapter 4: Genetic and epigenetic prediction of Major Depressive Disorder and 
associations with white matter microstructure in Generation Scotland 
 
1. Chapter introduction 
In chapter 3, an MDD PRS calculated using multiple variants with a similar 
biological function, as well as cumulative genome-wide variants (whole-genome 
PRS), were associated with white matter microstructure. In complex, multifactorial 
disorders, equally important to the investigation of genetic risk are environmental 
factors and their impact on biology. One way to measure the effect of multiple 
environmental risk factors objectively is by looking at the epigenome (McCartney et 
al., 2018). Investigating the relationship between MDD and DNAm, which is 
environmentally modifiable, is especially important as MDD is in part the result of 
environmental risk factors. 
Previously, both MDD and a higher genetic risk for MDD have been associated 
with disruptions in white matter microstructure (Shen et al., 2017; Shen et al., 2019), 
indicating that these disruptions are present throughout the manifestation of the 
disorder. Recently, a higher MDD DNAm risk score (hereafter named MRS) was 
associated with MDD, as well as with an archive of lifestyle factors known to impact 
MDD, such as smoking, BMI, and alcohol consumption (Barbu et al., 2019). Given 
that white matter microstructural disruptions are generally present in MDD, the aim of 
chapter 4 is to explore whether a higher MRS for MDD also plays a role in the above-
mentioned structural deficits, as well as to identify whether this role is additive to 
MDD PRS. This was investigated in 621 individuals with FA data and 623 individuals 
with MD data in Generation Scotland (GS). Due to the fact that the current sample is 
smaller than in Barbu et al. (2019) (N = 625 versus N = 1,780), the ability of the MRS 
to predict MDD diagnosis here was also tested. The study is presented as a paper 
entitled, “Genetic and epigenetic prediction of Major Depressive Disorder and 
associations with white matter microstructure in Generation Scotland”, and is now 
ready for submission. As the first author, I designed the experiment, ran analyses, and 







Background: Major Depressive Disorder (MDD) is among the most prevalent 
psychiatric disorders, resulting from a combination of genetic and environmental 
factors. Higher MDD genetic risk has been associated with white matter 
microstructural disruptions in association fibres and thalamic radiations. DNA 
methylation (DNAm), an environmentally modifiable epigenetic process, has recently 
been associated with MDD and lifestyle factors that play a role in MDD. It is therefore 
important to identify whether DNAm also plays a role in white matter microstructural 
disruptions in MDD, and whether this role is additive to MDD genetic risk. The current 
study aims to explore this relationship by using a DNAm risk score (MRS) in 
conjunction with a polygenic risk score (PRS). 
Methods: First, penalised regression was used to train an MRS for MDD based 
on epigenome-wide methylation at CpG sites in N = 4,211 individuals. Next, in an 
independent test sample, MDD MRS and PRS were used to investigate associations 
with white matter microstructure as measured by FA (N = 621) and MD (N = 623) and 
MDD diagnosis (N = 625) and to explore whether the two risk scores acted additively. 
Results: MRS (β = 0.143, p = 0.0002) and PRS (β = 0.084, p = 0.039) separately 
explained 2.11% and 0.69% of the variance in MDD, respectively and together 
explained  2.13% of the variance in the disorder (MRS: β = 0.144, p = 0.0002; PRS: β 
= 0.084, p = 0.033). The AUC for the MRS and PRS were 0.63 and 0.56, respectively. 
Neither score however was significantly associated with white matter microstructure, 
globally or regionally (MRS: FAβ range: 0.002 – -0.039; MDβ range: -0.002 – -0.075; PRS: 
FAβ range: -0.0006 – -0.078; MDβ range: -0.0006 – 0.041). The greatest effect sizes were 
for MRS and MD in the anterior corona radiata (β = -0.075) and PRS and FA in the 
superior fronto-occipital fasciculus (β = -0.078).  
Conclusion: Both MRS and PRS for MDD were significantly associated with 
MDD, together explaining 2.13% of the variance in the disorder. However, neither 
score was significantly associated with white matter microstructure at corrected 








Major Depressive Disorder (MDD) is the leading cause of global disability 
worldwide, currently affecting around 300 million individuals (WHO, 2017). 
Although the exact cause is unknown, it is thought to result from a complex 
combination of genetic and environmental risk factors (Otte et al., 2016).  
Twin-based heritability studies indicate estimates of around 37% (Sullivan et 
al., 2000), and a proportion of this heritability is explained by the cumulative effect of 
common alleles of small effect size, as shown by genome-wide association studies 
(GWAS; Ripke et al., 2013; Wray et al., 2017). A recent meta-analysis investigated 
three large GWAS of depression (N = 807,553) and found 102 independent variants 
associated with depression, enriching our understanding of risk-associated variants 
across the genome (Howard et al., 2019). 
A useful method of investigating this additive effect of common risk-
associated variants is through the creation of polygenic risk scores (PRS). These are 
computed by adding risk alleles for a certain trait at an optimised p-value threshold, 
and weighing them by the strength of their association with the trait of interest. This 
method is especially useful in aiding downstream analyses, by associating a single 
score, which depicts an individual's overall risk at a given p-value threshold, with other 
factors known to relate to a specific trait. Although useful, the amount of variance PRS 
explain, particularly for MDD, is small. For instance, polygenic risk for MDD explains 
1.5 – 3.2% of the phenotypic variance in MDD (Howard et al., 2019).  
As shown in chapter 3, PRS for MDD may be used to explore associations with 
neuroimaging traits that may be implicated in MDD, such as white matter 
microstructure. Chapter 3 showed that MDD PRS comprising SNPs that form a 
specific biological pathway are associated with thalamic radiations when compared 
with a PRS comprising SNPs in the rest of the genome. Other studies have shown 




microstructural integrity, with some indications of regional specificity, including in 
thalamic radiations and association fibres (Shen et al., 2017; Shen et al., 2019). These 
findings suggest that disruptions in white matter microstructure are present in MDD.  
There is evidence that along with risk ascribed to specific genetic variants, 
effects of gene expression and regulation are also important in the manifestation of 
disorders and associated traits (Peedicayil et al., 2007). DNA methylation (DNAm) is 
one such epigenetic mechanism affecting gene expression whereby chemical changes 
to DNA occur, through the addition of methyl groups at cytosine-phosphate-guanine 
(CpG) nucleotide base pairings (Robertson, 2005). DNAm is essential for normal 
development, is tissue- and cell-specific, is involved in gene expression and regulation 
without altering DNA sequence, and can be influenced by both genetic and 
environmental factors (Jaenisch & Bird, 2003).  
There is indeed strong evidence that such differential DNAm changes occur in 
complex disorders and traits (Cordova-Palomera et al., 2018). In MDD, a recent meta-
analysis of multi-ethnic epigenome-wide association studies (EWAS) in multiple 
cohorts (N = 11,256) found three CpGs significantly associated with depressive 
symptoms. These sites included CDC42BPB, which plays a role in the regulation of 
cytoskeleton organisation, cell migration, and regulation of neurite outgrowth; 
ARHGEF3, which plays a role in axon guidance through co-expression with other gene 
families; and a third site situated in an intergenic region and associated with SEMA4B, 
which in turn interacts with PSD-52 to promote synapse maturation (Jovanova et al., 
2018). Interestingly, all three CpG sites seem to be implicated in axon guidance, 
suggesting a role played by DNAm in brain connectivity in the presence of depressive 
symptoms. These results, together with findings in chapter 3 where disruptions in 
white matter microstructural thalamic radiations were linked to a polygenic risk score 
comprising SNPs that form an axonal guidance pathway, further indicate that this 
pathway may be disrupted in MDD.  
Recently, studies have derived DNAm predictors to predict MDD in 
independent testing samples. For instance, Clark et al. (2019) found a significant 
association between blood DNAm from 581 MDD patients at baseline with MDD 
status 6 years later. Using machine learning methods, they trained a DNAm risk score 




discriminate between MDD cases and controls with an area under the curve (AUC) of 
0.74 (Clark et al., 2019). Barbu et al. (2019) trained an MRS on 1,223 MDD cases and 
1,824 healthy individuals which was then tested in 1,780 independent individuals (363 
cases and 1,417 controls). The MRS was significantly associated with MDD status, 
explaining 1.75% of the variance in the disorder, and was independent of PRS, which 
explained 2.40% of the variance in MDD. Together, the two risk scores explained 
3.99% of the variance in MDD. Moreover, the MRS was significantly associated with 
a number of lifestyle factors implicated in MDD, such as smoking status, pack years, 
and alcohol consumption (Barbu et al., 2019). 
Examining quantitative traits relevant to psychiatric disorders, such as brain 
structure and function, may elucidate mechanisms through which genetic risk and 
DNAm may act. Previous evidence indicates an association between MDD PRS and 
disrupted white matter integrity (Shen et al., 2019) as well as associations between 
MDD MRS and MDD-associated lifestyle factors (Barbu et al., 2019). Given these 
associations connecting MDD MRS to MDD-related traits, the current chapter firstly 
aims to explore whether a higher MRS for MDD is also associated with disrupted white 
matter microstructure, as well as to investigate whether the MDD MRS acts additively 
in relation to the PRS. The ability of the MRS to predict MDD status was also tested. 
To achieve this, MDD PRS were trained on N = 807,579 from the most recent 
MDD GWAS (Howard et al., 2018) and MDD MRS were trained on N = 4,211 in 
Generation Scotland (GS) (McCartney et al., 2018), both the largest samples of genetic 
and DNAm currently available for MDD. The two scores were tested for associations 
with MDD status (N = 625), as well as white matter microstructure as measured by 
fractional anisotropy (FA; N = 621) and mean diffusivity (MD; N = 623), two white 
matter measures derived from diffusion tensor imaging (DTI) as discussed elsewhere 
in this thesis, in independent samples from the Stratifying Resilience and Depression 
Longitudinally (STRADL) cohort, a subsample of GS (Navrady et al., 2017; Habota 
et al., 2019). The purpose of the current study was to determine the proportion of 
individual and additive variance explained by an MDD PRS and MDD MRS in MDD 





2.3 Methods and Materials 
2.3.1 Study populations 
Training sample - GS 
GS is a large, family-based epidemiological study and a health resource aiming 
to investigate the genetics of health and disease in approximately N = 24,000 
individuals across Scotland, aged 19-98 years. Data was collected between 2006 and 
2011, with 98.1% of the study population having available genetic data. At the time of 
the current study, N = 5,087 individuals had DNAm measures derived (McCartney et 
al., 2018). Environmental data (e.g. lifestyle, demographics) was also present in a high 
proportion of the study participants (Smith et al., 2006; Smith et al., 2013). GS 
received ethical approval from NHS Tayside Research Ethics Committee (REC 
reference number 05/S1401/89). Written consent was obtained from all participants.  
Testing sample - STRADL 
STRADL is a project aimed at studying the aetiology and stratification of depression, 
and was achieved through re-contacting individuals who previously participated in GS 
and further obtaining data on mental health, specifically depression. A total of N = 
9,618 individuals responded at the re-contact recruitment stage and were assessed on 
numerous mental health and lifestyle measures; 1,095 were contacted for scanning, 
and 625 provided usable DTI data at the time of the current study. Details of 
recruitment and study information have been reported previously (Navrady et al., 
2017). STRADL is supported by the Wellcome Trust through a Strategic Award 
(reference 104036/Z/14/Z). Written consent at each stage of the study was obtained 
from all participants.  





Figure 1. Flowchart detailing the number of participants with MDD PRS, MDD MRS 
and imaging data available. MDD PRS training sample has been taken from the most 
recent MDD GWAS (N = 807,579) (Howard et al., 2018) and is therefore not shown 
in the flowchart. 
 
2.3.2 MDD diagnosis 
The axis-I Structured Clinical Interview of the Diagnostic and Statistical 
Manual, version IV (SCID) was administered to participants who answered “yes” to 
either of two screening questions for MDD diagnosis at baseline. MDD status was 
measured prospectively by remote paper questionnaire between 4 and 10 years after 
baseline assessment (2015-2016) using the Composite International Diagnostic 
Interview - Short Form (CIDI-SF). 
Healthy individuals used in the control group were defined as those who 
answered “no” to the two screening questions and did not fulfil criteria for a diagnosis 
of current or previous MDD following the SCID interview and CIDI-SF remote 
follow-up assessment. Individuals fulfilling criteria for schizophrenia or bipolar 
disorder, or who self-reported these diagnoses, were excluded from both case and 
control groups. 
Generation Scotland
N = 24,000 genetic and environmental data
N DNAmCurrent study = 5,087











2.3.3 Genotyping and PRS profiling 
A total of N = 20,195 individuals in GS were genotyped using the Illumina 
OmniExpress BeadChip. Individuals with a call rate < 98%, SNPs with a genotype rate 
< 98%, minor allele frequency < 1%, and p-value < 10−6 Hardy-Weinberg equilibrium 
were removed from the initial dataset. Following this, imputation was performed using 
the Sanger Imputation Service with the Haplotype Reference Consortium panel v1, 
resulting in 19,997 individuals with genome-wide data (Nagy et al., 2017; Howard et 
al., 2019). 
Briefly, using the largest available depression GWAS (Howard et al., 2019), 
MDD PRS for N = 18,977 individuals were computed using Plink v1.90b4 (Chang et 
al., 2015) using SNPs that met a significance level of p ≤ 0.05, in line with previous 
studies which have shown that this threshold explained the most variance in MDD 
status. Clumping was applied using a linkage disequilibrium r2 < 0.1 and a 500-kb 
window. 
 
2.3.4 Methylation preparation and DNAm prediction 
At the time of the current study, a total of 5,087 individuals in GS had genome-
wide DNAm data profiled from blood samples using the Illumina Human-
MethylationEPIC BeadChip. These individuals were part of a single batch. 
ShinyMethyl (Fortin et al., 2014) was used to exclude samples where predicted sex 
mismatched recorded sex, as well as to plot the log median intensity of methylated and 
unmethylated signals per array; where outlying values were subsequently excluded. 
WaterRmelon (Pidsley et al., 2013) was then used to remove samples in which > 1% 
of cytosine-guanine dinucleotides had a detection p-value > 0.05; probes with a 
beadcount of < 3 in more than 5% samples; and probes in which > 0.5% of samples 
had a detection p-value > 0.05 (McCartney et al., 2018). These steps left N = 5,087 
participants for analysis. 
Training dataset 
The final number of individuals with DNAm data used in the training dataset, 




data, was N = 4,211. CpG sites measured in these individuals were input as 
independent variables in a LASSO penalised regression model using the “glmnet” 
function in R.  Depression status was regressed on age, sex, and ten genetic principal 
components, and the extracted residuals from this model were input as the dependent 
variable in the LASSO regression model. Tenfold cross-validation was applied, and 
the mixing parameter was set to 1 for our LASSO penalty (Friedman et al., 2010). 
Testing dataset 
Using the set of CpG sites selected from the penalised regression, MRS were 
calculated in the testing dataset (a subset of STRADL participants who had complete 
PRS, DTI and DNAm data, N = 625) by summing the weights estimated in the training 
set. This resulted in a single continuous variable for each participant, with a higher 
score corresponding to a higher MRS of MDD. 
 
2.3.5 Magnetic Resonance Imaging (MRI) acquisition and pre-processing 
In the current study, DTI imaging-derived phenotypes (IDPs) pre-processed 
and produced locally were used. MRI acquisition was performed in two sites in 
Scotland, Aberdeen and Dundee.  
Aberdeen 
Data was acquired using a Philips Achieva 3T TX-series scanner (Philips 
Healthcare, Best, Netherlands) at the University of Aberdeen, with a 32-channel 
phased-array head coil with a back-facing mirror (software version 5.1.7; gradients 
with maximum amplitude 80 mT/m and maximum slew rate 100 T/m/s) (Romaniuk et 
al., 2019).  
Dundee 
Data was acquired using a Siemens 3T Prisma-FIT (Siemens Healthineers, 
Erlangen, Germany) at the University of Dundee, with 20 channel head and neck coil 
and a back-facing mirror (software version VE11, gradient with max amplitude 80 





Pre-processing – quality check and tract-based spatial statistics (TBSS) 
Standard tools available from FSL (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki) were 
used to quality check and exclude abnormal scans from downstream analyses. All 
quality checking steps were performed separately for the two scanning centres, as the 
acquired number of volumes differed between them (Nvolume Aberdeen: 73; Nvolume Dundee: 
72). These included (1) correcting for eddy current-induced distortions and subject 
movement in the scanner; (2) skull stripping using BET at a threshold of 0.2; (3) using 
DTIFIT in order to compute diffusion tensor characteristics (i.e. principal eigenvectors 
or V1, V2, V3; eigenvalues or L1, L2, L3; fractional anisotropy (FA), mean diffusivity 
(MD), and others); and (4) visually checking the quality of FA images at this stage in 
order to exclude distorted images. 
TBSS was carried out according to the ENIGMA DTI protocol 
(http://enigma.ini.usc.edu/protocols/dti-protocols/) for both scanning centres. Briefly, 
images were first slightly eroded in order to remove brain-edge artefacts as well as 
other outlying measures. All images were then nonlinearly registered to the ENIGMA 
template and all subjects were taken into 1x1x1mm standard space. A mean of all 
registered FA images was then calculated, in order to create a white matter skeleton. 
At this step, images were visually inspected in order to exclude badly registered 
images. Finally, a recommended threshold of FA > -0.049 was used in order to project 
the aligned FA data for each participant onto the skeleton created earlier. This final 
step created an individual FA skeleton image per subject. ROI extraction analyses 
using protocols provided by ENIGMA (http://enigma.ini.usc.edu/protocols/dti-
protocols/) were then performed, in order to extract IDPs, including FA and MD.. This 
resulted in 5 unilateral tracts and 19 bilateral tracts, as well as an average measure, for 
all 4 DTI scalars noted above (for a list of all white matter tracts, see table 1 below). 
The tracts are based on the Johns-Hopkins University (JHU) DTI-based white matter 
atlas (Mori et al., 2005). The final number of participants before merging with PRS 
and MRS, following quality check and exclusion criteria, was N = 968 (details of the 






White matter tract Abbreviation 
Average FA/MD* aMD 
Global FA/MD* gMD 
Cingulum (hippocampus) CGH 
Cingulum (cingulate gyrus) CGC 
Fornix* FX 
Fornix (cres) / Stria terminalis FX / ST 
Inferior fronto-occipital fasciculus IFO 
Superior fronto-occipital fasciculus SFO 
External capsule EC 
Superior longitudinal fasciculus SLF 
Sagittal striatum SS 
Uncinate fasciculus UNC 
Body of corpus callosum* BCC 
Genu of corpus callosum* GCC 
Splenium of corpus callosum* SCC 
Corpus callosum* CC 
Corona radiata CR 
Internal capsule IC 
Anterior corona radiata ACR 
Posterior corona radiata PCR 
Superior corona radiata SCR 
Corticospinal tract CST 
Anterior limb of internal capsule ALIC 
Posterior limb of internal capsule PLIC 
Posterior thalamic radiation PTR 
Retrolenticular limb of internal capsule RLIC 
Table 1. White matter tracts used as dependent variables in statistical analyses outlined 
below. * = unilateral tracts. 
 
2.3.6 Statistical methods 
All analyses were conducted using R (version 3.2.3) in a Linux environment. 
As GS is a family-based study, with at least one family member participating in the 
study (McCartney et al., 2018), ASReml-R was used in order to account for relatedness 
within the sample, by including pedigree information as a random effect in each model. 
Association of MRS and PRS with MDD 
MDD was regressed on PRS; MRS; and PRS and MRS in three separate 
ASReml-R models. Covariates for these models included age, sex, ten genetic 
principal components to control for population stratification, and smoking status and 
smoking pack years, as it has been shown that cigarette smoking is a strong modifier 




addition, using the “ROCR” R package, the predictive ability of PRS and MRS in 
MDD was plotted using a Receiver Operating Characteristic (ROC) curve, 
representing the sensitivity and specificity of the scores in relation to MDD. 
Association of MRS and PRS with IDPs (FA and MD) 
Firstly, for global measures of FA and MD, principal component analysis 
(PCA) was applied on the white matter tracts of interest (Ntracts = 38; for a list of the 
tracts included in the PCA, see Appendix 3: Table S1) in order to extract a latent 
measure. Scores of the first unrotated component were extracted and set as dependent 
variables in ASReml-R. MRS and PRS were included as independent variables, with 
additional covariates: sex, age, age2, ten genetic principal components, smoking status, 
smoking pack years, and MRI site. 
Each white matter tract (N = 24; 5 unilateral and 19 bilateral) was then included 
as dependent variables in separate ASReml-R models. MRS and PRS were included 
















2.3.7 Descriptive statistics 
Table 2 provides descriptive statistics relating to the training sample. Tables 3 
and 4 below provide descriptive statistics relating to the testing sample. 
Descriptive statistics – training sample (N = 4,211) 
 
Table 2. Descriptive statistics of individuals included in training dataset; SD = 






Variables Descriptive statistics 
Depression status  
Cases (%) 1,036 (25%) 
Controls (%) 3,175 (75%) 
Sex  
Female (%) 2,619 (62%) 
Male (%) 1,592 (38%) 
Age  
Mean +/- SD, range 47.83 +/- 14.42, 18 - 95 
Smoking status  
Current smoker 
Pack years (mean +/- SD, range) 
835 
19.98 +/- 18, 0.03 – 120 
Former smokers who quit under a year ago 
Pack years (mean +/- SD, range) 
117 
17.31 +/- 18.36, 0.004 – 88.80 
Former smokers who quit over a year ago 
Pack years (mean +/- SD, range) 
1,082 
14.31 +/- 16.60, 0.01 – 116 
Never smoked tobacco 
Pack years (mean +/- SD, range) 
2,177 
-  
Unsure of smoking status 







Descriptive statistics – testing sample (MDD; N = 625) 
Variables Descriptive statistics 
Depression status  
Cases (%) 122 (20%) 
Controls (%) 503 (80%) 
Sex  
Female (%) 378 (60%) 
Male (%) 247 (40%) 
Age  
Mean +/- SD, range 52.81 +/- 9.12, 20 - 72 
Smoking status  
Current smoker 
Pack years (mean +/- SD, range) 
78 
25.37 +/- 18.52, 0.36 – 79.55 
Former smokers who quit under a year 
ago 
Pack years (mean +/- SD, range) 
12 
23.54 +/- 12.68, 3.33 – 46.20 
Former smokers who quit over a year 
ago 
Pack years (mean +/- SD, range) 
195 
16.28 +/- 18.78, 0.004 – 107.60 
Never smoked tobacco 
Pack years (mean +/- SD, range) 
333 
- 
Unsure of smoking status 




Table 3. Descriptive statistics of individuals included in testing dataset (MDD); SD = 

















Descriptive statistics – testing sample (FA; N = 621 and MD; N = 623) 
 
 
Variables Fractional anisotropy 
(FA)  
Mean diffusivity (MD)  
Depression status   
Cases (%) 122 (20%) 121 (19%) 
Controls (%) 499 (80%) 502 (81%) 
Sex   
Female (%) 376 (60%) 377 (60%) 
Male (%) 245 (40%) 246 (40%) 
Age   
Mean +/- SD, range 52.77 +/- 9.13, 20 - 72 52.78 +/- 9.10, 20 - 72 
Smoking status   
Current smoker 
Pack years (mean +/- SD, 
range) 
78 
25.37 +/- 18.52, 0.36 – 
79.55 
78 
25.37 +/- 18.52, 0.26 – 
79.55 
Former smokers who quit 
under a year ago 








23.54 +/- 12.68, 3.33 – 
46.20 
Former smokers who quit 
over a year ago 








16.31 +/- 18.82, 0.004 – 
107.60 
Never smoked tobacco 






Unsure of smoking status 






Total 621 623 
Table 4. Descriptive statistics of individuals included in testing dataset (FA and MD); 
individuals whose global measures for FA and MD lay more than three standard 
deviations (SD) from the sample mean were excluded; number of pack-years = (packs 






In the LASSO penalised regression model, 256 CpG sites with the lambda 
value corresponding to the minimum mean cross-validated error were extracted and 
applied to CpG sites in the independent testing sample (Friedman et al., 2010) (see 
Appendix 3: Table S2 for a list of CpG sites and their regression weights). 
 
2.4.1 Association of MRS and PRS with MDD 
ASReml-R models showed that both MRS (β = 0.1433, p = 0.0002, R2 = 
2.11%) and PRS (β = 0.0839, p = 0.0387, R2 = 0.69%) explained a small proportion of 
variance in MDD. The model including both MRS (β = 0.144, p = 0.0002) and PRS (β 
= 0.084, p = 0.033) explained the most variance (R2 = 2.13%), though this was not 
significantly greater than MRS alone. Information relating to this can be viewed in 






Figure 2. PRS and MRS prediction of MDD in neuroimaging sample (N = 625); 
variance explained (R2) is shown as follows: PRS (blue), MRS (salmon), and additive 
PRS and MRS (violet) in the bar graphs above. 
Figure 3. Receiver Operating Characteristic (ROC) curve indicating the sensitivity 
and specificity of MRS and PRS for MDD. The legend shows the AUC estimates for 

















2.4.2 Association of MRS and PRS with FA and MD 
Fractional anisotropy 
One white matter tract was found to be nominally significantly associated with 
PRS (FA; superior fronto-occipital fasciculus: β = -0.077, p = 0.022). Table 5 contains 
standardised effect size (β), standard error, nominal p-value, and R2 for the association 

















ACR 0.015 0.038 0.693 0.023 -0.014 0.034 0.673 0.021 
ALIC -0.004 0.039 0.901 0.003 -0.04 0.035 0.255 0.167 
CGC  0.01 0.038 0.776 0.012 -0.058 0.034 0.093 0.341 
CGH 0.023 0.033 0.488 0.054 -0.011 0.029 0.7 0.013 
CR 0.004 0.038 0.914 0.002 -0.025 0.034 0.469 0.065 
CST 0.007 0.04 0.856 0.005 0.018 0.035 0.612 0.033 
EC -0.027 0.038 0.469 0.08 -0.037 0.034 0.281 0.14 
FX / ST -0.015 0.032 0.64 0.024 -0.052 0.029 0.077 0.272 
IC -0.011 0.035 0.736 0.015 -0.032 0.031 0.302 0.108 
IFO -0.032 0.037 0.383 0.108 0.005 0.033 0.874 0.003 
PCR 0.024 0.039 0.534 0.061 -0.012 0.034 0.713 0.017 
PLIC -0.014 0.034 0.676 0.021 -0.026 0.03 0.388 0.07 
PTR 0.024 0.037 0.514 0.061 0.005 0.033 0.869 0.003 
RLIC -0.007 0.034 0.818 0.006 -0.013 0.03 0.667 0.018 
SCR -0.022 0.04 0.58 0.052 -0.031 0.036 0.387 0.101 
SFO 0.003 0.037 0.925 0.001 -0.077 0.033 0.022 0.598 
SLF -0.021 0.039 0.577 0.05 0.004 0.035 0.901 0.002 
SS 0.019 0.037 0.597 0.041 -0.042 0.033 0.207 0.186 
UF 0.012 0.039 0.759 0.015 -0.0004 0.035 0.987 0 
CC -0.026 0.039 0.503 0.071 -0.029 0.035 0.406 0.086 




GCC -0.019 0.039 0.612 0.041 -0.016 0.035 0.64 0.027 
SCC -0.002 0.033 0.949 0 -0.006 0.03 0.821 0.005 
FX -0.009 0.037 0.802 0.009 -0.056 0.033 0.094 0.324 
Global 
FA 0.001 0.036 0.96 0 -0.038 0.032 0.242 0.153 
Average 
FA -0.014 0.038 0.712 0.02 -0.033 0.034 0.328 0.113 
Table 5. The association between MRS and PRS with white matter tracts (FA). 
Nominally significant p-values are shown in bold. The first column for MRS and PRS 
indicates standardised effect size (β). R2 = estimate of variance explained by each 
pathway in %. 
 
 
Figure 4.  The effects of MRS (above) and PRS (below) on fractional anisotropy (FA) 
values of white matter tracts. The x-axis indicates the standardized effect size of each 
score association, and the y-axis indicates the white matter tracts. The error bar 






Table 6 contains standardised effect size (β), standard error, nominal p-value, 
and R2 for the association of both MRS and PRS with global measures and individual 




MRS PRS  
 Effect 











ACR -0.074 0.041 0.068 0.578 0.002 0.036 0.945 0.001 
ALIC -0.061 0.038 0.113 0.39 0.04 0.034 0.24 0.166 
CGC  -0.054 0.034 0.115 0.31 0.026 0.03 0.391 0.071 
CGH -0.013 0.028 0.641 0.018 0.024 0.025 0.345 0.059 
CR -0.064 0.039 0.107 0.428 0.018 0.035 0.61 0.033 
CST 0.024 0.04 0.544 0.059 0.002 0.035 0.933 0.001 
EC -0.035 0.037 0.346 0.129 -0.005 0.033 0.874 0.003 
FX / ST -0.01 0.03 0.738 0.011 0.008 0.027 0.741 0.008 
IC -0.044 0.029 0.138 0.208 0.014 0.026 0.594 0.021 
IFO -0.008 0.035 0.816 0.007 0.04 0.031 0.194 0.167 
PCR -0.055 0.036 0.13 0.31 0.027 0.032 0.388 0.078 
PLIC -0.022 0.028 0.441 0.05 -0.004 0.025 0.874 0.002 
PTR -0.049 0.035 0.168 0.248 0 0.031 0.985 0 
RLIC -0.034 0.028 0.23 0.122 0.006 0.025 0.796 0.004 
SCR -0.037 0.038 0.329 0.147 0.026 0.034 0.437 0.072 
SFO -0.002 0.039 0.951 0.001 -0.008 0.035 0.802 0.008 
SLF -0.011 0.036 0.763 0.013 0.023 0.032 0.475 0.055 
SS -0.05 0.035 0.154 0.268 0.005 0.031 0.856 0.003 
UF -0.052 0.039 0.188 0.276 0.015 0.035 0.661 0.024 
CC -0.016 0.037 0.663 0.027 0.029 0.033 0.377 0.088 
BCC 0.007 0.04 0.853 0.006 0.038 0.035 0.281 0.149 
GCC -0.048 0.038 0.205 0.241 0.019 0.034 0.574 0.037 




FX -0.011 0.04 0.78 0.013 0.013 0.036 0.703 0.019 
Global 
MD -0.032 0.039 0.411 0.106 0.019 0.035 0.578 0.038 
Average 
MD -0.017 0.037 0.646 0.03 0.022 0.032 0.502 0.05 
Table 6. The association between MRS and PRS with white matter tracts (MD). The 
first column for MRS and PRS indicates standardised effect size (β). R2 = estimate of 
variance explained by each pathway in %. 
 
 
Figure 5. The effects of MRS (above) and PRS (below) on mean diffusivity (MD) 
values of white matter tracts. The x-axis indicates the standardized effect size of each 
score association, and the y-axis indicates the white matter tracts. The error bar 







The aim of the current study was to investigate whether MDD poly-epigenetic 
risk scores were significantly associated with MDD and changes in white matter 
microstructure as measured by FA and MD in > 600 individuals and to observe 
whether these associations are independent from MDD polygenic risk scores. 
DNAm predictors for MDD were identified in a training dataset of 4,211 
individuals and were significantly associated with MDD in an independent testing 
dataset. The study showed that the MRS explained 2.11% of the phenotypic variance 
in MDD, as compared with MDD PRS, which only explained 0.69%. Together, the 
two risk scores explained 2.13% of the variance in MDD.  
PRS derived from GWAS have offered insight into how cumulative risk from 
a large number of common genetic variants of small effect relate to MDD (Howard et 
al., 2019). On the other hand, studies of differential DNAm in MDD have only recently 
become possible at sufficient scale with the availability of large datasets including 
epigenomic and diagnostic data. For instance, Jovanova et al. (2018) found 3 CpG sites 
associated with depressive symptoms at epigenome-wide significance in N = 11,256 
individuals.  
Moreover, MRS based on DNAm in large datasets have also recently shown 
interesting results implicating environmental and lifestyle factors in the relationship 
between DNAm and MDD. Clark et al. (2019) showed that an MDD MRS, in 
combination with 27 lifestyle characteristics, including smoking status, alcohol 
consumption, body mass index (BMI), and physical activity, could discriminate 
between MDD cases and controls with an area under the curve (AUC) of 0.742. 
Moreover, Barbu et al. (2019) showed associations between MDD MRS and MDD 
status as well as numerous lifestyle factors, including smoking status, pack years, 
alcohol consumption, and BMI, which are known to play a role in MDD (Paperwalla 
et al., 2004; De Wit et al., 2010; Briere et al., 2014; Opel et al., 2015). They concluded 
that MRS may reflect lifestyle factors, indicating that some of the variation in MDD 
may be explained by environmental factors through DNAm. Results here show that 
both MRS and PRS are significantly associated with MDD, although their contribution 




PRS do have an additive nature in MDD prediction, perhaps due to an increased 
sample size and statistical power. 
The findings here and in the studies above aid in elucidating a role played by 
DNAm in MDD. However, unlike fixed genetic factors, DNAm changes throughout 
life, which may either be a cause or a consequence of altered environmental and 
lifestyle factors. Due to the temporal variation of DNAm, reverse causality may arise 
in cross-sectional studies where DNAm samples are collected at the same time as a 
diagnosis is made (Walton et al., 2019). In other words, it may be that individuals with 
MDD have differentially methylated CpG sites as a result of disorder manifestation, 
leading to changes in their environment and lifestyle, or that  their altered lifestyle may 
lead to differential DNAm. It may be possible, in future, to investigate direction of 
causality using methods such as mendelian randomisation, which measures variation 
in genes with a known function to examine causality (Lawlor et al., 2008). However, 
this approach would need to be repeated longitudinally, due to the dynamic nature of 
DNAm across life. Future studies could also measure DNAm before a diagnosis is 
made, as this may reduce confounding by reverse causation, although this approach 
does not completely reverse the risk of confounding (Juvinao-Quintero et al., 2019). 
In the current study, MRS and PRS were not associated with white matter tracts 
as measured by FA or MD. To the author’s knowledge, this is the first study attempting 
to investigate the association between a DNAm-based risk score for MDD and white 
matter tracts. A previous study has shown that elevated levels of DNA methylation in 
SLC6A4, a gene previously associated with both depression and white matter 
microstructure, was associated with decreased FA in the body of corpus callosum in 
MDD patients, although this analysis was based on five focussed CpG sites within the 
gene (Won et al., 2016). Choi et al. (2015) also found that differential DNA 
methylation at four CpG sites in the BDNF promoter region, previously associated 
with both white matter microstructure and depression, was associated with decreased 
integrity in the right anterior corona radiata of MDD patients. Importantly, these 
previous studies used a priori hypotheses linking specific genes and methylation 





PRS have previously shown associations with a wide range of neuropsychiatric 
traits and white matter microstructure measures, as indexed by FA and MD (Shen et 
al., 2019). Shen et al. (2019) conducted a phenome-wide association study in 21,888 
individuals to explore how PRS at different p-value thresholds associate with 
behavioural and neuroimaging traits. They showed that MDD PRS p ≤ 0.01 showed 
the largest effect sizes in neuroimaging phenotypes (Shen et al., 2019). This indicates 
that the PRS p-value threshold used here (p ≤ 0.05) may not be optimal in detecting 
meaningful associations, although the threshold was selected based on its ability to 
explain the most variance in MDD status (Howard et al., 2019). Moreover, in addition 
to significant associations between individual white matter tracts and MDD PRS, Shen 
et al. (2019) also found evidence of global and regional associations, for which effect 
sizes were larger. This may indicate that the effect of the two risk scores may be global 
rather than tract-specific, although this is not reflected in the global and average FA 
and MD associations with either score in the current study. 
Moreover, Barbu et al. (2019) investigated whether MRS and PRS for MDD 
capture different exposures to behavioural and environmental phenotypes. They found 
that the MDD MRS was more significantly associated with sociodemographic and 
lifestyle measures, while the MDD PRS was more significantly associated with disease 
and mental health variables (Barbu et al., 2019). In the current study, both risk scores 
were associated with MDD, but none with white matter microstructure. Given previous 
evidence relating MDD PRS to decreased white matter integrity and more robust 
associations with mental health variables, it may be that the genetic risk score is more 
well-suited to identify disruptions in white matter in relation to MDD, while epigenetic 
risk may exert its effect on MDD through environmental modifications, rather than 
through changes in white matter microstructure. 
Although associations are non-significant, this is also reflected in the direction 
of effect from each risk score; the PRS seem to relate to decreased FA and increased 
MD in most tracts, an indication of white matter microstructural disruptions. This 
reflects previous findings associating higher MDD PRS with decreased white matter 
microstructural integrity (Shen et al., 2019; Barbu et al., 2019). On the other hand, the 
MRS seem to indicate increased FA and decreased MD in a large number of tracts, 




proportion of the variance in multiple white matter tracts in FA (FA R2 = 0 – 0.6%; 
MD R2 = 0 – 0.17%), while the MRS explained a greater proportion of the variance in 
MD-measured tracts (FA R2 = 0 – 0.15%; MD R2 = 0.001 – 0.58%) (Tables 5 and 6). 
Previous studies investigating PRS and white matter microstructure 
associations have used sample sizes larger than 5,000 (Shen et al., 2019; Barbu et al., 
2019). In addition, lack of significant associations may be due to the current sample, 
which is a relatively healthy community-based sample that may not reflect severe 
depression or depressive symptoms. These results together indicate that a larger 
sample size might be needed to detect an association between increased risk of 
depression, both polygenic and poly-epigenetic, and white matter microstructure.  
A strength of the current study is the analysis between a novel MDD MRS and 
white matter microstructure as measured by FA and MD. Moreover, findings revealed 
an association between DNAm risk and MDD, indicating a potential to use such a 
score for further analyses, as well as for other traits which are implicated in MDD. 
In summary, results show that MDD MRS and PRS are associated with MDD. 
Results suggest that a larger sample may be needed to uncover robust associations 
between white matter microstructure and both MDD risk scores. Moreover, based on 
previous findings, DNAm may contribute to MDD via environmental and lifestyle 
factors, rather than through disruptions in white matter microstructure. Further testing 
and validation in clinically ascertained samples is needed, however the findings here 
may justify future efforts to collect DNAm in larger samples and investigate 
associations between DNAm risk and emotional, cognitive and other brain imaging 
traits related to depression. 
 
3. Chapter conclusion 
The study found an association between both MRS and PRS with MDD status, 
although no associations were found between the two risk scores and white matter 
microstructure post-FDR correction. A small-sized sample comprised of community-
based, generally healthy individuals, may reflect the non-significant findings here, as 




more robust than individual tracts, as reflected by previous studies. Moreover, as 
DNAm is environmentally modifiable, it may be that changes in lifestyle and 
environment, rather than disruptions in white matter microstructure, may connect 
DNAm to MDD prevalence. In conclusion, larger studies comprising genetic, 
epigenetic, and neuroimaging data will be needed in future to examine the role of an 
MRS in white matter microstructure and investigate whether this score is independent 






















Chapter 5: Discussion 
 
1. Introduction 
 The current thesis aimed to investigate the genetic relationship between white 
matter microstructure and gene expression, as well as to identify its association with 
stratified genetic and epigenetic risk for MDD. The thesis included two large-scale 
cohorts, UKB and GS (and sub-sample STRADL), which combine neuroimaging and 
genetic data, with samples ranging from 620 to 14,500. 
 In the past, white matter microstructure has been reported to be moderately 
heritable and associated with MDD, both globally and regionally. As white matter 
represents the brain’s connectivity network, having a far-reaching structural and 
temporal effect, there is rationale to study its relationship to psychiatric and 
neurological disorders. The aims of this thesis were therefore to (1) investigate the 
genetic basis of gene expression changes in relation to white matter microstructure, in 
order to form a basis for in-depth downstream analyses of disease- and trait-linked 
genes; (2) stratify genetic risk for MDD by a validated biological pathway and 
investigate its association with white matter microstructure; and (3) objectively 
investigate the effect of potential environmental insults by analysing epigenetic risk of 
MDD in relation to the disorder and white matter microstructure. To do this, 
increasingly specific genetic analysis approaches were used, all of which included 
computing scores that aggregate the cumulative effect of multiple genetic variants and 
CpG sites for (i) gene expression; (ii) genetic risk for MDD; and (iii) epigenetic risk 
for MDD.  
The three research chapters each include a discussion section which is 
specifically tailored to the analysis and findings presented there. Therefore, the aim of 
this chapter is to provide a broader discussion of the findings and how they 
interconnect in the investigation of MDD. The chapter then concludes with strengths 






2. Summary of main findings 
 
2.1 Genetic underpinnings of gene expression in white matter microstructure – 
specific and global findings 
To investigate the relationship between white matter microstructure and 
genetic risk of complex disorders, the genetic underpinnings of white matter were first 
explored. Although heritability of white matter microstructure has been previously 
established, the role of the genetic variants involved is unknown (Sprooten et al., 
2014). In the current thesis, to gain understanding of the functional effects of 
regulatory variants, the genetic basis of gene expression was investigated in relation 
to white matter tracts, globally and with increasing regional specificity.  
One of the main findings was the association between higher white matter 
microstructural integrity and genetic variants regulating neural development-linked 
genes, and lower white matter microstructural integrity and genetic variants regulating 
disease-linked genes. The genes found here are different in functionality, and findings 
from this chapter allow for in-depth insight into expression-based effects of regulatory 
loci on white matter microstructure. As a result, future studies may investigate 
differential genotypes at regulatory loci and differential gene expression between 
patients and healthy control participants in downstream analyses combining 
neuroimaging and genetic data. 
Furthermore, while all other white matter tracts were found to be associated 
with genetic variants regulating gene expression of either disease- or development-
linked genes, the forceps minor was found to be associated with both. Interestingly, 
the forceps minor forms the anterior part of the corpus callosum, and connects 
homologous prefrontal cortex regions between hemispheres, thus enabling 
communication between the two (Wakana et al., 2007). It is reported to be involved in 
numerous cognitive and behavioural skills, as well as neuropsychiatric and 
neurological disorders (Mamiya et al., 2018). This finding is therefore unsurprising, as 
the corpus callosum is less prone to errors during the imaging process and is arguably 




regions to each other (Hofer & Frahm, 2006). Undoubtedly, a large number of genes 
may be expressed in the formation, maintenance, and pathology of this tract. 
In addition to these specific findings, differences were also found globally for 
some of the genes investigated, suggesting that the expression of some genes has a 
more widespread effect on white matter microstructure than others. In addition to 
analysis of disease states and traits, these findings may be leveraged in downstream 
analyses to investigate loci implicated in the formation, development, and plasticity of 
white matter microstructure globally. 
As discussed in chapters 1 and 2, neuroimaging phenotypes provide a novel 
and sound opportunity to investigate the genetics of gene expression in relation to in 
vivo brain phenotypes. This method accounts for the increasing number of limitations 
in analysing gene expression in the brain directly, such as cause of death and post-
mortem expression level differences (McKenzie et al., 2014). For a comprehensive 
understanding, the findings discussed here involve changes in both FA and MD across 
tracts in relation to regulatory loci. However, these loci may implicate FA and MD 
measures of white matter microstructure across different tracts, regionally or 
specifically, as the two scalars capture different characteristics of white matter 
microstructural integrity (Jones et al., 2013).  
Lastly, the findings in chapter 2 uncovered novel associations which were not 
previously reported by GWAS (Elliott et al., 2018), suggesting that genetic loci 
important in white matter maintenance and pathology are regulatory. This is 
additionally important as future studies may leverage these regulatory loci to 
investigate their direct effects on both traits and disease states through the alteration of 
white matter microstructure.  
 
2.2 Thalamic radiations are key neurobiological markers in stratified genetic risk 
for MDD 
Polygenic risk of MDD has continuously been associated with white matter 
microstructure in the past (Whalley et al., 2017; Shen et al., 2017). However, findings 




increased risk of MDD. This has made it difficult to uncover genetic risk factors and 
their effect on brain connectivity in the context of MDD. Here, findings concerning 
thalamic radiations as both white matter tracts and stratified biological pathway 
process are discussed. 
As discussed previously, MDD is a highly heterogeneous disorder, both 
clinically and biologically. Methods to stratify MDD have been considered in order to 
gain an understanding in the aetiology and manifestation of the disorder. Here, genetic 
risk for MDD was stratified based on genetic variants aggregated within a biological 
pathway. The third chapter found higher general MD in thalamic radiations and 
superior and inferior longitudinal fasciculi, as well as lower FA in superior 
longitudinal fasciculus associated with PRS computed using variants aggregated 
within the NETRIN1 Signalling Pathway. While several white matter tracts including 
tracts pertaining to association and projection regional fibres were associated with PRS 
computed from variants outside the pathway, interestingly, they were not associated 
with thalamic radiations.  
This result is fitting as the NETRIN1 Signalling Pathway is responsible for 
neuronal migration and guiding axons branching from the thalamus to the rest of the 
cortex during neuronal development (Braisted et al., 2000). The thalamus is a 
subcortical structure located above the brain stem with widespread connections to both 
cortex & subcortical areas (Sherman, 2016). The thalamus is often referred to as the 
hub of the brain, as it is linked to cortical areas globally as well as to various subcortical 
structures, such as the hippocampus and amygdala, and uses these global connections 
to relay information between cortical and subcortical structures (Sherman, 2016). 
Therefore, the hub is implicated in negative emotional processing, cognitive 
functions such as memory, executive functions, attention, and information processing, 
and is known to regulate states of sleep and wakefulness (Herrero, Barcia & Navarro, 
2002; Saalmann & Kastner, 2011; Yousaf et al., 2018). These are all factors 
contributing to the MDD symptom profile (e.g. inability to concentrate, insomnia and 
hypersomnia, enhanced negative emotional states), so it is unsurprising that a 
heterogeneous disorder such as MDD is associated with a structure that is so 




Moreover, PRS confined to the NETRIN1 Signalling Pathway also showed 
associations with disrupted microstructural integrity in large association fibres, such 
as the superior and inferior longitudinal fasciculi, which connect different cortical 
areas across the four lobes to each other (Schmahmann et al., 2007). This finding fits 
well with the thalamocortical connections, indicating that stratified risk of MDD in 
this particular biological pathway is related to lower white matter microstructural 
integrity in tracts connecting cortical and subcortical regions throughout the brain.  
The findings in chapter 3 indeed show a strong connection between genetic 
risk for MDD aggregated in a biological process and brain connectivity, both 
implicating the thalamus. The results indicate that stratifying MDD by biology may 
uncover novel insights into specific connectivity deficits related to the disorder. In 
downstream analyses, stratification of both symptom profiles and genetic risk may 
lead to specific genetic variants linked to particular symptoms. In addition, future 
studies may attempt to investigate functional connectivity in relation to stratified MDD 
genetic risk. 
 
2.3 Whole-epigenome DNAm identified as a novel risk factor for MDD 
 Genetic studies have only recently garnered success in uncovering part of the 
genetic basis of psychiatric disorders (Howard et al., 2019). As MDD is a 
multifactorial, complex disorder, with both genetics and the environment playing a 
pivotal role in its development, it is safe to assume that research investigating the 
disorder would benefit from an integrated approach including both genetic and 
epigenetic risk factors. Moreover, MDD is reported to have a heritability of 37% based 
on family studies, however GWAS indicate that common genetic variants explain only 
part of this total heritability (Howard et al., 2019). Therefore, a proportion of variance 
in MDD may be explained by changes in gene expression induced by epigenetic 
factors. Support to this is lent in chapter 4, where both whole-genome and whole-
epigenome risk explained a small proportion of variance in MDD (additive R2 = 
2.13%), indicating that epigenetic mechanisms may be important in the formation and 




 Research has so far focused on DNAm alterations of specific genes posited to 
be associated with MDD, such as BDNF, SLC6A4, and NR3C1, although it is now 
widely believed that candidate genes may not be an optimal way to investigate MDD, 
due to its polygenicity and complex nature (Border et al., 2019). The findings in 
chapter 4 are one of the first to indicate that a whole-epigenome approach may be more 
indicative in uncovering novel risk factors for MDD. As it is one of the first studies to 
investigate epigenetic risk for MDD aggregated in a single variable, the research 
presented here provides a basis for future epigenetic-based analyses for MDD. For 
instance, future studies may investigate associations between environmental and 
lifestyle factors implicated in MDD, such as childhood trauma, smoking status, alcohol 
consumption, and body mass index (BMI) in relation to DNAm risk for MDD. 
Furthermore, DNAm signatures of antidepressants, one of the most widely-used 
treatments for MDD acting on biological pathways, may be investigated in future to 
observe whether differential DNAm exists between those who take and do not take 
antidepressants. 
 Moreover, it is perhaps unsurprising that epigenetic alterations, situated at the 
intersection between genetic and environmental factors, play a role in MDD. A number 
of lifestyle and environmental insults, such as childhood adversity, work-related stress, 
smoking, and alcohol, are associated with MDD, many of which may silence or 
activate specific genes through hyper- or hypo-methylation at promoter sites to give 
rise to the disorder. As this study is relatively novel due to the rarity of studies 
containing large DNAm data, it is presently unclear in what way epigenetic 
modifications influence MDD. Epigenetic alterations may well be one of the 
mechanisms integrating both environmental and genetic risk factors in MDD, and 
combined analyses that include a wide variety of environmental, genetic, and 
epigenetic risk factors, should be carried out. 
 
2.4 No association revealed between MRS for MDD and white matter 
microstructure 
 The study additionally set out to investigate links between whole-epigenome 




diagnosis, the association between DNAm alterations at specific sites across the 
genome posited to be related to MDD and disrupted white matter microstructure has 
been previously established, providing a rationale to investigate links between the two 
(Won & Ham, 2016). However, in the current study, there was no association between 
a genetic or an epigenetic risk score for MDD and white matter microstructure, despite 
previous evidence associating whole-genome PRS for MDD with the brain 
connectivity network (Whalley et al., 2013; Shen et al., 2017).  
The null findings here may be due to a number of factors. Firstly, the sample 
size comprising non-clinically ascertained individuals used in the study (NFA = 621; 
NMD = 623) is small compared to usual neuroimaging genetics studies. Previous studies 
showing an association between genetic risk for MDD and white matter microstructure 
contained sample sizes of over 1,000 individuals (Shen et al., 2017; Shen et al., 2019). 
Reus et al. (2017) computed PRS for MDD, schizophrenia, and bipolar disorder, and 
associated them with subcortical brain volumes (N = 978) and white matter 
microstructure (N = 816). The authors found no link between subcortical volumes or 
white matter microstructure and PRS for either disorder, although their findings may 
be due to formerly underpowered GWAS which led to scarce common genetic variants 
for use in the calculation of PRS. In addition, the study used the first release of UK 
Biobank imaging data (Reus et al., 2017); later releases adding participants to this 
original number and the more successful findings indicated that the lack of findings 
may have been due to small sample size. 
 Secondly, previous studies investigating a whole-epigenome MRS in 
association with various traits used sample sizes of approximately 900 individuals, 
indicating the need for a larger sample size here (Shah et al., 2015; McCartney et al., 
2018). Moreover, it would be reasonable that genetic risk for MDD would be 
associated with white matter microstructure, which is also moderately heritable (Elliott 
et al., 2018), and epigenetic risk for MDD would be associated with lifestyle and 
environmental factors, which partly influence the epigenome. Barbu et al. (2019) 
found that an MDD MRS was more significantly associated with sociodemographic 
and lifestyle measures, while an MDD PRS was more significantly associated with 
disease and mental health variables (Barbu et al., 2019). The association between an 




consumption, and self-reported antidepressant use, was also shown in Barbu et al. 
(2019). It therefore remains to be seen, as sample sizes increase and analysis methods 
advance, whether whole-epigenome MDD risk is associated with brain connectivity. 
 
3. Strengths and limitations of the current thesis and suggestions for future 
research 
Two major strengths for the studies conducted in this thesis are (1) the large 
sample size within UK Biobank, which can accommodate both biological and clinical 
heterogeneity of MDD and (2) a combination of neuroimaging and genetic data in 
these large samples. Firstly, UK Biobank is an invaluable resource combining a vast 
amount of data; this includes neuroimaging data collected at only two sites, thus 
accounting for limitations and artefacts resulting from scanning individuals across 
multiple sites; and genetic data, which has now been released for approximately 
500,000 individuals, and permits investigation into a large number of phenotypes in 
relation to genotype. 
Moreover, although sample size within GS is small for genetic-neuroimaging 
associations, it is important to note that the cohort is a rich resource containing 
invaluable data, including a combination of genetic, neuroimaging, and DNAm in a 
carefully chosen sample. In addition to this, the individuals for which neuroimaging 
data is available were specifically chosen to study resilience and depression (Navrady 
et al., 2017), which adds to the value of investigating the above-mentioned data in 
relation to the disorder. 
As discussed in the introductory chapter, neurobiological markers implicated 
in psychiatric disorders may provide a mechanistic insight into the formation and 
manifestation of disease states. Integrating both neuroimaging and genetic data in the 
investigation of psychiatric disorders may therefore pave the way to further specialised 
studies and uncover therapeutic targets to be used for prevention and treatment. 
One of the limitations present in both datasets used in this thesis is the cohorts’ 
age range, which generally reflect older populations (Mean age: UKB: 56.52 +/- 8.09 




participants in both cohorts are generally healthier and wealthier than the rest of the 
population. This may induce some bias in the interpretation of the results implicating 
MDD, as the average age of onset is 25, a much younger age than those of participants 
in the studies, although MDD may appear at any age (WHO, 2017). Moreover, in a 
study presented in the introduction, Bromel et al. (2011) showed that MDD 12-month 
prevalence was similar between high- and low-income countries. While these factors 
may not have a great impact on MDD, it is still advised to carefully consider them 
when interpreting findings for further analyses.  
 Further, although the large sample sizes used here are lauded, data from a 
higher number of participants still must be collected in order to be able to conduct 
more complex and in-depth genetic and neuroimaging analyses. Stratification by 
biology or genetic factors, such as biological pathways, haplotype blocks, or genetic 
correlations, and even more general genetic analyses such as GWAS, may need 
hundreds of thousands of individuals, especially in the investigation of MDD, where 
different combinations of genes and SNPs act together to give rise to the disorder. 
Replication of findings between the already-existing large studies may strengthen the 
conclusions made so far and encourage further studies to carefully select participants 
for future investigation. These findings may also be used to generate hypotheses to test 
in smaller, but still substantial, genetic neuroimaging studies, incorporating a 
discovery and replication approach. 
 With regards to the neuroimaging data, two tractography-based methods, 
probabilistic tractography and TBSS, were used in the present thesis. As discussed in 
the introduction, the two methods are both highly validated and sound measures of 
capturing white matter microstructure. However, the two methods may well have 
different proportions of heritability (Elliott et al., 2018), and both utilise different 
methods to construct and annotate white matter tracts. Replication across both methods 
in the studies presented was considered beyond the scope of this thesis, although in 
future, studies should take into account the differences between the two and attempt to 
investigate both.  
 Moreover, findings were consistently different between the two scalars 




one scalar, but not the other. This is not a limitation in itself, however it should be 
mentioned that the two scalars may capture different characteristics of white matter 
microstructure and should be carefully considered when drawing conclusions from 
studies using such measures.  
 Finally, overall, very small effect sizes were reported in the three studies 
(Largest effect size: Chapter 2: -0.0561 (FA) and 0.0480 (MD); Chapter 3: -0.036 (FA) 
and 0.042 (MD); Chapter 4: 0.1440 (MDD MRS). While this may not necessarily be 
a limitation, it does provide a rationale for better-defined phenotypes in larger groups 
in future studies. Especially in MDD, stratification may provide an advantage in that 
more specific patient groups may show greater associations with particular 
phenotypes. 
 In addition to the suggestions for future studies made above, direct implications 
of the current thesis to be considered by further research are threefold. Firstly, more 
detailed investigation should be carried out in analysing genetic underpinnings of 
MDD. Future studies may wish to look at localised genetic effects aggregated in 
different functional and biological pathways and perhaps integrate gene expression-
based analyses of participating SNPs. For instance, the 8 eQTL scores uncovered in 
chapter 2 may further be analysed and tested in knockout animal models to investigate 
their possible role in MDD and white matter microstructure. Furthermore, in-depth 
investigation should be carried out into the NETRIN1 Signalling Pathway, and axon 
guidance pathways in general, as they seem to emerge in MDD analyses (Zeng et al., 
2016; Aberg et al., 2018).  
Moreover, novel developments in diffusion MRI measures, such as NODDI 
(neurite orientation dispersion and density imaging), which measures intra-neurite, 
extra-neurite, and cerebral spinal fluid volume fractions separately, may be employed 
by studies in the future to investigate more localised disruptions in white matter 
microstructure in relation to genetic and epigenetic risk for MDD (McCunn et al., 
2019). Lastly, white matter microstructure is the brain’s connectivity network, 
providing a complex mode of communication between brain regions. As such, it is 




networks as well as cortical or subcortical areas connected by specific white matter 
tracts in relation to MDD genetic risk.  
 
4. Conclusions 
 MDD is a highly heterogeneous disorder with an unclear aetiology. Genetic 
and neuroimaging links to MDD have so far been vague, indicating the need for further 
stratification, by biology or symptom profile, as well as development of more 
advanced analysis techniques incorporating both types of data. The present thesis 
contributes three studies that aid in the understanding of MDD at the intersection 
between genetics and neuroimaging. Results provide evidence of white matter 
microstructure associations with expression of disease- and neurodevelopment-linked 
genes and propose thalamic radiations as a key neurobiological factor in genetic risk 
aggregated to a small portion of the genome. The findings presented here also suggest 
that whole-epigenome risk is associated with the presence of MDD. Evidence 
presented here may be used to guide future studies and implement large cohorts, with 
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Appendix 1: Supplementary materials for Chapter 2: Expression quantitative 
trait loci-derived scores and white matter microstructure in UK Biobank: a novel 
approach to integrating genetics and neuroimaging 
 
Results for scores associated with FA (N = 17; table S1) and MD (N = 16; table S2) 
white matter tracts separately 
Score, white matter tract Effect size SD t value p value p value, FDR corrected 
ATG10_eQTL_cis, global FA 0.0341 0.0079 4.3106 1.64E-05 0.0273 
SF3A1_eQTL_cis, global FA -0.0327 0.0079 -4.1305 3.64E-05 0.0495 
SMARCAL1_eQTL_cis, global 
FA 0.0374 0.0079 4.7354 2.21E-06 0.0071 
SF3A1_eQTL_cis, association 
fibres -0.0334 0.0079 -4.2386 2.26E-05 0.0344 
SMARCAL1_eQTL_cis, 
association fibres 0.0326 0.0079 4.1375 3.53E-05 0.0495 
ATG10_eQTL_cis, thalamic 
radiations 0.0373 0.0080 4.6587 3.21E-06 0.0088 
PPP4R3A_eQTL_cis, thalamic 
radiations 0.0357 0.0080 4.4572 8.36E-06 0.0166 
SMARCAL1_eQTL_cis, thalamic 
radiations 0.0394 0.0080 4.9292 8.35E-07 0.0036 
CD14_eQTL_cis, projection 
fibres -0.0360 0.0079 -4.5691 4.94E-06 0.0116 
COG7_eQTL_cis, anterior 
thalamic radiation -0.0333 0.0076 -4.4005 1.09E-05 0.0337 
SMARCAL1_eQTL_cis, anterior 
thalamic radiation 0.0394 0.0076 5.2164 1.85E-07 0.0018 
LINC01605_eQTL_trans, 
cingulate gyrus -0.0337 0.0071 -4.7560 1.99E-06 0.0114 
ANXA1_eQTL_cis, corticospinal 
tract -0.0320 0.0074 -4.3218 1.56E-05 0.0416 
ZSCAN26_eQTL_cis, forceps 
major -0.0397 0.0081 -4.9048 9.45E-07 0.0070 
ATG10_eQTL_cis, forceps minor 0.0360 0.0078 4.5986 4.29E-06 0.0189 
CD14_eQTL_cis, forceps minor 0.0456 0.0078 5.8210 6E-09 0.0001 
SHTN1 / KIAA1598_eQTL_cis, 
forceps minor 0.0376 0.0078 4.8050 1.56E-06 0.0101 
ZNF282_eQTL_cis, forceps 
minor -0.0346 0.0078 -4.4224 9.83E-06 0.0337 
ENO4_eQTL_cis, forceps minor 0.0354 0.0078 4.5197 6.24E-06 0.0252 
COG7_eQTL_cis, forceps minor -0.0338 0.0078 -4.3127 1.62E-05 0.0416 
SMARCAL1_eQTL_cis, forceps 
minor 0.0361 0.0078 4.6056 4.15E-06 0.0189 
ASRGL1_eQTL_cis, inferior 
fronto-occipital fasciculus 0.0329 0.0077 4.2950 1.76E-05 0.0426 
ATG10_eQTL_cis, inferior 












Table S1. eQTL scores associated only with white matter tracts as measured 





















fronto-occipital fasciculus 0.0337 0.0077 4.3935 1.12E-05 0.0337 
SMARCAL1_eQTL_cis, inferior 
longitudinal fasciculus 0.0349 0.0076 4.5704 4.91E-06 0.0207 
ATG10_eQTL_cis, posterior 
thalamic radiation 0.0325 0.0075 4.3416 1.42E-05 0.0406 
ZBTB7B_eQTL_cis, superior 
longitudinal fasciculus -0.0329 0.0077 -4.2946 1.76E-05 0.0426 
GPT_eQTL_cis, superior 
longitudinal fasciculus 0.0339 0.0077 4.4153 1.02E-05 0.0337 
SMARCAL1_eQTL_cis, superior 
longitudinal fasciculus 0.0401 0.0077 5.2356 1.67E-07 0.0018 
GPT_eQTL_cis, superior 
thalamic radiation 0.0337 0.0079 4.2827 1.86E-05 0.0429 
AP2S1_eQTL_cis, superior 







Figure S1. eQTL scores associated only with white matter tracts as measured by FA (fractional 
anisotropy). Indicates nominal p-values between each of the scores (shown in legend entitled 
“eQTL score”) and global and tract category measures (noted on the x-axis). All values in the 
figure met FDR correction. Some of the scores with an additional line around the points had an 
effect size in the opposite direction to all other scores (also indicated by +β for FA in figure legend). 
The colours of the plot points indicate the score to which they belong. Magnitude of effect is shown 





Score, white matter tract Effect size SD t value p value 
p value, FDR 
corrected 
APOA1BP / NAXE_eQTL_cis, 
global MD 0.0311 0.0075 4.1331 3.6E-05 0.0423 
BTN3A2_eQTL_cis, global 
MD 0.0308 0.0075 4.0853 4.42E-05 0.0423 
UMPS_eQTL_cis, global MD -0.0319 0.0075 -4.2381 2.27E-05 0.0366 
CSF3R_eQTL_cis, global MD 0.0345 0.0075 4.5704 4.91E-06 0.0132 
TMEM154_eQTL_cis, global 
MD -0.0400 0.0076 -5.2970 1.19E-07 0.0015 
APOA1BP / NAXE_eQTL_cis, 
association fibres 0.0326 0.0077 4.2419 2.23E-05 0.0366 
BTN3A2_eQTL_cis, 
association fibres 0.0314 0.0077 4.0888 4.36E-05 0.0423 
SAMM50_eQTL_cis, 
association fibres -0.0311 0.0077 -4.0501 5.15E-05 0.0475 
UMPS_eQTL_cis, association 
fibres -0.0355 0.0077 -4.6219 3.84E-06 0.0124 
CSF3R_eQTL_cis, association 
fibres 0.0377 0.0077 4.9069 9.36E-07 0.0048 
TMEM154_eQTL_cis, 
association fibres -0.0402 0.0077 -5.2158 1.86E-07 0.0016 
HLA-C_eQTL_cis, association 
fibres -0.0342 0.0077 -4.4402 9.05E-06 0.0213 
MED15_eQTL_cis, thalamic 
radiations 0.0297 0.0072 4.1354 3.56E-05 0.0423 
KANSL1_eQTL_cis, thalamic 
radiations -0.0302 0.0072 -4.2041 2.64E-05 0.0401 
IL18RAP_eQTL_cis, projection 
fibres 0.0324 0.0078 4.1621 3.17E-05 0.0423 
C6orf106_eQTL_cis, projection 
fibres 0.0318 0.0078 4.0863 4.41E-05 0.0423 
RABEPK_eQTL_cis, acoustic 
radiation 0.0307 0.0069 4.4197 9.95E-06 0.0287 
CFDP1_eQTL_cis, anterior 
thalamic radiation 0.0298 0.0070 4.2749 1.92E-05 0.0447 
PTPN13_eQTL_cis, anterior 
thalamic radiation -0.0347 0.0070 -4.9756 6.58E-07 0.0044 
KANSL1_eQTL_cis, anterior 
thalamic radiation -0.0369 0.0070 -5.3005 1.17E-07 0.0016 
TMEM154_eQTL_cis, anterior 
thalamic radiation -0.0303 0.0070 -4.3269 1.52E-05 0.0372 
UMPS_eQTL_cis, cingulate 
gyrus -0.0323 0.0073 -4.3999 1.09E-05 0.0297 
PLEC_eQTL_cis, forceps minor 0.0335 0.0076 4.3887 1.15E-05 0.0297 
TMEM154_eQTL_cis, forceps 
minor -0.0384 0.0076 -5.0145 5.38E-07 0.0043 
TMEM154_eQTL_cis, inferior 
fronto-occipital fasciculus -0.0330 0.0075 -4.3971 1.1E-05 0.0297 
TMEM154_eQTL_cis, inferior 












Table S2. eQTL scores associated only with white matter tracts as measured by MD. 













parahippocampal part of 
cingulum 
-0.0303 0.0071 -4.2755 1.92E-05 0.0447 
BTN3A2_eQTL_cis, superior 
longitudinal fasciculus 0.0350 0.0076 4.6271 3.74E-06 0.0155 
UMPS_eQTL_cis, superior 
longitudinal fasciculus -0.0413 0.0076 -5.4562 4.94E-08 0.0008 
TMEM154_eQTL_cis, superior 
longitudinal fasciculus -0.0377 0.0076 -4.9633 7.01E-07 0.0044 
PTPN13_eQTL_trans, superior 
thalamic radiation -0.0336 0.0068 -4.9424 7.8E-07 0.0046 
TMEM154_eQTL_cis, superior 
thalamic radiation -0.0323 0.0068 -4.7333 2.23E-06 0.0106 
TMEM154_eQTL_cis, uncinate 






Figure S2. eQTL scores associated only with white matter tracts as measured by MD (mean 
diffusivity). Indicates nominal p-values between each of the scores (shown in legend entitled 
“eQTL score”) and global and tract category measures (noted on the x-axis). All values in the 
figure met FDR correction. Some of the scores with an additional line around the points had an 
effect size in the opposite direction to all other scores (also indicated by -β for MD in figure legend). 
The colours of the plot points indicate the score to which they belong. Magnitude of effect is shown 




Brief gene look-up for genes whose expression was associated with FA (N = 17; table 
1) and MD (N = 16; table 2) separately 
 
Score name 










_cis 7 ATG10 Gusev et al. 
E2-like enzyme involved in 2 
ubiquitin-like modifications essential 
for autophagosome formation; 
expressed in brain (1) 
SF3A1_eQTL
_cis 23 SF3A1 Westra et al. 
Expressed in brain; gene encodes a 





L1 Westra et al. 
Protein encoded by this gene is a 
member of SWI/SNP family of 
proteins; members have helicase and 
ATPase activities and are thought to 
regulate transcription of certain genes 
by altering chromatin structure around 
those genes; expressed in brain; 
associated with Schimke 
immunoosseous dysplasia (3) 
PPP4R3A_eQ
TL_cis 1 PPP4R3A Westra et al, 
Expressed in brain; may be involved in 
Alzheimer’s disease risk (4) 
CD14_eQTL_
cis 18 CD14 Gusev et al. 
Protein encoded by this gene is a 
surface antigen that is preferentially 
expressed on monocytes/macrophages; 
it cooperates with other proteins to 
mediate the innate immune response to 
bacterial lipopolysaccharide; expressed 
in brain (5) 
COG7_eQTL_
cis 1 COG7 Westra et al. 
Protein encoded by this gene resides in 
the golgi and is part of 8 subunits of the 
conserved oligomeric Golgi (COG) 
complex; expressed in brain; mutations 
in gene associated with microcephaly, 
adducted thumbs, growth retardation, 





5 Westra et al. 
RNA gene; affiliated with non-coding 
RNA class; expression of gene 
associated with bladder cancer (8) 
ANXA4_eQT
L_cis 5 ANXA4 Gusev et al. 
Little expression in brain; gene belongs 
to annexin family of calcium dependent 
phospholipid binding proteins (9) 
ZSCAN26_eQ




5 SHTN1 / KIAA1598 Gusev et al. 
Expressed in brain; involved in 
generation of internal asymmetric 
signals required for neuronal 
polarization and neurite outgrowth; 
mediated netrin-1-induced F-actin 
substrate coupling or clutch 
engagement within axon growth cone 




















Table S3. Information regarding eQTL scores with significant associations FA-measured 
tracts. 1 score (LINC01605_eQTL_trans) is trans, while all others are cis. 
 













/ NAXE Gusev et al. 
Expressed in brain; diseases 
associated with gene: 
encephalopathy; brain edema 
(16) 
BTN3A2_eQTL_cis 42 BTN3A2 Gusev et al. 
May be involved in adaptive 
immune system response; may 
be involved in risk for gastric 
cancer (17) 
UMPS_eQTL_cis 5 UMPS Westra et al. 
Encoded protein is a 
bifunctional enzyme that 
catalyzes the final 2 steps of the 
de novo pyrimidine biosynthetic 
pathway (18) 
CSF3R_eQTL_cis 5 CSF3R Westra et al. 
Mutations in this gene are a 
cause of Kostmann syndrome / 
congenital neutropenia; not 
expressed in brain (19) 
TMEM154_eQTL_cis 20 TMEM154 Westra et al. Very little expression in brain 
ZNF282_eQT
L_cis 7 ZNF282 Gusev et al. 
Expressed in brain; diseases associated 
with gene: T-cell leukemia (11) 
ENO4_eQTL_
cis 7 ENO4 Westra et al. Expressed in brain 
ASRGL1_eQ
TL_cis 5 ASRGL1 Gusev et al. 
Expressed in brain; may be involved in 
production of L-aspartate, which can 
act as an excitatory neurotransmitter in 
some brain regions; may be implicated 





B Gusev et al. 
Expressed in brain; may be implicated 
in axon degeneration (13) 
 
ZBTB7B_eQT
L_cis 8 ZBTB7B Gusev et al. 
Expressed in brain; gene encodes a 
zinc finger-containing transcription 
factor that acts as a key regulator of 
lineage commitment of immature T-
cell precursors (14) 
GPT_eQTL_ci
s 5 GPT Westra et al. Little expression in brain 
AP2S1_eQTL
_cis 5 AP2S1 Westra et al. 
One of 2 major clathrin-associated 
adaptor complexes, AP-2 is a 
heterotetramer which is associated with 
the plasma membrane; complex is 
composed of 2 large chains, 1 medium 
chain and 1 small chain, and the gene 





SAMM50_eQTL_cis 15 SAMM50 Gusev et al. 
Gene encodes a component of 
the Sorting and Assembly 
Machinery of the mitochondrial 
outer membrane (20) 
HLA-C_eQTL_cis 38 HLA-C Westra et al. Expressed in nearly all cells 
MED15_eQTL_cis 6 MED15 Westra et al. Expressed in brain 
KANSL1_eQTL_cis 3 KANSL1 Westra et al. 
Gene encodes a nuclear protein 
that is a subunit of 2 protein 
complexes involved with 
histone acetylation (21) 
IL18RAP_eQTL_cis 12 IL18RAP Gusev et al. 
Mutations in this gene have 
been associated with Crohn's 
disease; expressed in brain (22) 
C6orf106_eQTL_cis 5 C6orf106 Westra et al. Expressed in cortex  
RABEPK_eQTL_cis 9 RABEPK Gusev et al. Expressed in brain 
CFDP1_eQTL_cis 4 CFDP1 Gusev et al. 
Expressed in brain; may be 
implicated in coronary artery 
disease risk (23) 
PTPN13_eQTL_trans 1 PTPN13 Westra et al. 
Protein encoded by this gene is 
a member of the PTP family, 
which are signalling molecules 
that regulate cellular processes 
(e.g. cell growth, differentiation, 
mitotic cell cycle, oncogenic 
transformation); disease 
associated with this gene: 
tropical spastic paraparesis, a 
disease of the nervous system 
affecting people living near the 
equator; expressed in the brain 
(24) 
 
EVL_eQTL_cis 1 EVL Westra et al. 
Expressed in brain; actin-
associated proteins involved in 
processes such as axon guidance 
and lamellipodial and filopodial 
dynamics in migrating cells; 
enhances actin nucleation and 
polymerization (25) 
PLEC_eQTL_cis 3 PLEC Westra et al. 
Prominent member of a protein 
family of proteins which 
interlink different elements of 
the cytoskeleton; expressed in a 
wide range of cell types and 
tissues (including brain) (26) 
Table S4. Information regarding eQTL scores with significant associations MD-measured 













size SD t value p value 
p value, FDR 
corrected 
FA      
Global FA -0.0367 0.0079 -4.6474 3.39161E-06 0.0088 
Thalamic radiations -0.0403 0.0080 -5.0378 4.76577E-07 0.0025 
Anterior thalamic 
radiations -0.0429 0.0076 -5.6798 1.37465E-08 0.0002 




-0.0386 0.0077 -5.0327 4.89475E-07 0.0040 
MD      
Global MD 0.0404 0.0075 5.3762 7.72382E-08 0.0015 
Association fibres 0.0381 0.0077 4.9643 6.97256E-07 0.0045 
Thalamic radiations 0.0327 0.0072 4.5625 5.09715E-06 0.0132 
Acoustic radiation 0.0295 0.0069 4.2470 2.17989E-05 0.0472 
Anterior thalamic 
radiations 0.0403 0.0070 5.7964 6.91525E-09 0.0003 
Cingulate gyrus 0.0352 0.0073 4.7887 1.69554E-06 0.0085 
Forceps minor 0.0480 0.0076 6.3085 2.89925E-10 2.76005E-05 
Inferior fronto-
occipital fasciculus 0.0410 0.0075 5.4805 4.31258E-08 0.0008 
Inferior longitudinal 




0.0415 0.0076 5.4902 4.08256E-08 0.0008 
Uncinate fasciculus 0.0314 0.0068 4.6086 4.08933E-06 0.0162 
Table S5. Significant associations between DCAKD_eQTL_cis and FA and MD-measured 
white matter tracts. The first column indicates standardised effect size (β). 
White Matter Tracts Effect size SD t value p value 
p value, FDR 
corrected 
FA      
Global FA -0.0403 0.0079 -5.0996 3.44595E-07 0.0022 
Association fibres -0.0347 0.0079 -4.4036 1.07241E-05 0.0198 
Projection fibres 0.0453 0.0079 5.7612 8.51978E-09 0.0002 
Acoustic radiation -0.0326 0.0069 -4.7044 2.56987E-06 0.0133 
Corticospinal tract -0.0326 0.0074 -4.3945 1.11801E-05 0.0337 
Forceps minor -0.0561 0.0078 -7.1754 7.5595E-13 7.3217E-08 
Inferior longitudinal fasciculus -0.0335 0.0076 -4.3887 1.14829E-05 0.0337 
Superior longitudinal fasciculus -0.0367 0.0077 -4.7887 1.6956E-06 0.0103 
MD      
Global MD 0.0308 0.0075 4.0893 4.3502E-05 0.0423 
Forceps minor 0.0432 0.0076 5.6773 1.3949E-08 0.0004 
Inferior longitudinal fasciculus 0.0362 0.0073 4.9676 6.8552E-07 0.0044 
Table S6. Significant associations between SLC35A4_eQTL_cis and FA and MD-measured 







size SD t value p value 
p value, FDR 
corrected 
FA      
Global FA -0.0420 0.0079 -5.3199 1.0538E-07 0.0011 
Association fibres -0.0358 0.0079 -4.5425 5.6047E-06 0.0121 
Thalamic radiations -0.0388 0.0080 -4.8429 1.2928E-06 0.0048 
Projection fibres 0.0416 0.0079 5.2850 1.275E-07 0.0011 
Corticospinal tract -0.0320 0.0074 -4.3116 1.6311E-05 0.0416 
Forceps minor -0.0456 0.0078 -5.8270 5.763E-09 0.0001 
Inferior longitudinal 
fasciculus -0.0419 0.0076 -5.4773 4.3905E-08 0.0006 
Posterior thalamic 
radiation -0.0352 0.0075 -4.7014 2.6076E-06 0.0133 
Superior longitudinal 
fasciculus -0.0392 0.0077 -5.1143 3.1895E-07 0.0028 
MD      
Global MD 0.0326 0.0075 4.3299 1.5015E-05 0.0277 
Acoustic radiation 0.0339 0.0069 4.8778 1.0844E-06 0.0060 
Cingulate gyrus 0.0328 0.0073 4.4648 8.074E-06 0.0248 
Forceps minor 0.0348 0.0076 4.5604 5.1479E-06 0.0188 
Table S7. Significant associations between SEC14L4_eQTL_cis and FA and MD-measured 




size SD t value p value 
p value, FDR 
corrected 
FA      
Projection fibres 0.0339 0.0079 4.3032 1.6943E-05 0.0273 
Forceps minor -0.0462 0.0078 -5.8981 3.7587E-09 0.0001 
MD      
Forceps minor 0.0353 0.0076 4.6349 3.6022E-06 0.0155 
Table S8. Significant associations between SRA1_eQTL_cis and FA and MD-measured white 
matter tracts. The first column indicates standardised effect size (β). 
White Matter 
Tracts Effect size SD t value p value 
p value, FDR 
corrected 
FA      
Anterior thalamic 
radiations 0.0324 0.0076 4.2863 1.8287E-05 0.0429 
Forceps minor 0.0352 0.0078 4.4956 6.992E-06 0.0271 
MD      
Global MD -0.0328 0.0075 -4.3626 1.2941E-05 0.0257 
Anterior thalamic 
radiations -0.0339 0.0070 -4.8703 1.1263E-06 0.0060 
Forceps minor -0.0392 0.0076 -5.1537 2.5879E-07 0.0025 
Inferior fronto-
occipital fasciculus -0.0335 0.0075 -4.4845 7.3652E-06 0.0234 
Inferior longitudinal 
fasciculus -0.0311 0.0073 -4.2695 1.9718E-05 0.0447 
Superior longitudinal 
fasciculus -0.0343 0.0076 -4.5355 5.7939E-06 0.0204 
Table S9. Significant associations between NMT1_eQTL_cis and FA and MD-measured 








Tracts Effect size SD t value p value 
p value, FDR 
corrected 
FA      
Forceps major 0.0436 0.0081 5.3818 7.4908E-08 0.0009 
Forceps minor 0.0338 0.0078 4.3185 1.5817E-05 0.0416 
MD      
Global MD -0.0366 0.0075 -4.8650 1.1564E-06 0.0050 
Association fibres -0.0368 0.0077 -4.7868 1.7111E-06 0.0063 
Inferior longitudinal 
fasciculus -0.0309 0.0073 -4.2303 2.3485E-05 0.0497 
Superior longitudinal 
fasciculus -0.0356 0.0076 -4.7055 2.5555E-06 0.0116 
Table S10. Significant associations between CPNE1_eQTL_cis and FA and MD-measured 
white matter tracts. The first column indicates standardised effect size (β). 
White Matter 
Tracts Effect size SD t value p value 
p value, FDR 
corrected 
FA      
Forceps minor -0.0347 0.0078 -4.4321 9.4015E-06 0.0337 
MD      
Global MD 0.0330 0.0075 4.3859 1.1631E-05 0.0250 
Association fibres 0.0318 0.0077 4.1395 3.5002E-05 0.0423 
Thalamic radiations 0.0296 0.0072 4.1282 3.6762E-05 0.0423 
Anterior thalamic 
radiations 0.0356 0.0070 5.1101 3.2604E-07 0.0028 
Forceps minor 0.0334 0.0076 4.3876 1.154E-05 0.0297 
Superior longitudinal 
fasciculus 0.0342 0.0076 4.5223 6.1651E-06 0.0210 
Table S11. Significant associations between PLEKHM1_eQTL_cis and FA and MD-
measured white matter tracts. The first column indicates standardised effect size (β). 
White Matter 
Tracts Effect size SD t value p value 
p value, FDR 
corrected 
FA      
Forceps minor -0.0382 0.0078 -4.8721 1.1158E-06 0.0077 
MD      
Forceps minor 0.0331 0.0076 4.3465 1.3925E-05 0.0349 
Inferior fronto-
occipital fasciculus 0.0332 0.0075 4.4413 9.01E-06 0.0268 
Table S12. Significant associations between UBE3C_eQTL_cis and FA and MD-measured 











GWAS quality check and parameters 
In order to determine whether any score SNPs were previously associated with 
global and tract category measures of interest (i.e. tract categories & global measures 
found to be significantly associated with the 8 eQTL scores), 8 GWAS were run locally 
(the 3 tract categories: association fibres, thalamic radiations, and projection fibres for 
both FA and MD, and global measures for FA and MD). BGENIE (1)  was used to 
conduct the association analysis and excluded related participants (up to the third 
degree using the KING toolset (2)), as well as those who also participated in 
Generation Scotland and PGC MDD GWAS. Only variants with a minor allele 
frequency (MAF) > 0.001 (0.1%), SNP information score (quality of imputation) > 
0.1, and Hardy-Weinberg equilibrium (HWE) p-value >= 1e-6 were examined. Sex, 
age, the first 8 principal components, genotyping array, and three head position 
coordinates were fitted as covariates in the analysis.  
The output summary statistics files contain information with regards to the 
chromosome, SNP ID, p-value and effect size of association with each phenotype. The 
SNPs significantly associated with the tracts of interest were noted and the effect size 


















Individual white matter tracts and tract category to which they belong 
Fractional anisotropy and mean diffusivity 
Association fibres 




Superior longitudinal fasciculus 
Inferior longitudinal fasciculus 
Thalamic radiations 
Anterior thalamic radiation 
Posterior thalamic radiation 






Middle cerebellar peduncle* 
Corticospinal tract 
Global FA & global MD 
Table S13. White matter tracts, global white matter 
and tract categories for FA and MD.  














P-values and effect size of each SNP for each individual white matter tract results 
(Elliott et al., 2018) and global and regional results (run locally); figure produced 
locally 
 
Figure S3. GWA between SNPs, individual white matter tracts of interest (Elliott et 
al., 2018) and global and tract category measures (run locally). Each point on the plot 
corresponds to one SNP. White matter tracts of interest are noted on the x-axis (L = 
left; R = right; FA = fractional anisotropy; MD = mean diffusivity). The 8 colours of 
the plot points indicate the score to which they belong (shown in “Scores (gene name, 
eQTL type)” legend). Magnitude of effect is shown in the legend entitled “Effect size 










P-values and effect size for each SNP in association with gene expression as taken from 
GENOSCORES; these values were obtained in the two discovery datasets used in the 
current study (Gusev et al., 2016; Westra et al., 2013). 
Chromosome SNP Gene Effect size P-value 
17 rs4793119 DCAKD 0.188 3.98E-08 
17 rs17682536 DCAKD -0.114 1.20E-13 
17 rs962888 DCAKD 0.284 4.14E-19 
17 rs9898793 DCAKD 0.343 3.53E-240 
17 rs2040558 DCAKD -0.171 1.73E-52 
17 rs2239921 DCAKD 0.367 1.03E-28 
17 rs3744760 DCAKD 0.365 2.47E-184 
17 rs4986172 DCAKD 0.093 1.07E-24 
5 rs269783 SLC35A4 -0.114 6.55E-11 
5 rs13175916 SLC35A4 -0.025 1.33E-09 
5 rs2237077 SLC35A4 0.322 0 
5 rs1862176 SLC35A4 0.223 0 
5 rs6860077 SLC35A4 0.210 0 
5 rs17286676 SLC35A4 -0.041 9.04E-97 
5 rs250430 SLC35A4 0.087 4.09E-86 
5 rs250429 SLC35A4 0.208 0 
5 rs12517200 SLC35A4 0.061 7.19E-298 
5 rs1583005 SLC35A4 0.138 5.452E-06 
5 rs2286394 SLC35A4 -0.055 4.40E-39 
5 rs3733709 SLC35A4 -0.110 5.77E-24 
22 rs2267161 SEC14L4 -0.093 6.96E-06 
5 rs2237077 SRA1 -0.025 4.55E-19 
5 rs1862176 SRA1 -0.040 1.72E-39 
5 rs6860077 SRA1 -0.039 3.91E-41 
5 rs1835959 SRA1 -0.087 1.14E-20 
5 rs250430 SRA1 -0.087 1.12E-20 




5 rs2569163 SRA1 0.048 3.13E-24 
5 rs778582 SRA1 -0.016 2.08E-34 
5 rs12517200 SRA1 -0.013 6.77E-34 
5 rs1583005 SRA1 -0.005 1.10E-11 
5 rs2530241 SRA1 0.001 3.92E-14 
5 rs801186 SRA1 0.010 3.28E-18 
5 rs801171 SRA1 0.001 5.85E-15 
5 rs2531360 SRA1 0.000 6.17E-14 
5 rs2240696 SRA1 -0.007 6.31E-12 
17 rs9898793 NMT1 0.015 3.69E-08 
17 rs4793172 NMT1 0.029 1.41E-10 
17 rs2239916 NMT1 0.035 1.17E-14 
17 rs1053739 NMT1 0.032 2.77E-13 
17 rs3744760 NMT1 0.032 2.85E-10 
17 rs12946454 NMT1 0.028 8.33E-09 
17 rs4986172 NMT1 0.030 5.50E-09 
6 rs4324798 CPNE1 0.181 1.79E-06 
17 rs9898793 PLEKHM1 0.394 6.38E-78 
17 rs2239921 PLEKHM1 0.304 6.23E-13 
17 rs3744760 PLEKHM1 0.247 2.54E-79 
17 rs4986172 PLEKHM1 -0.138 3.73E-06 
17 rs1552458 PLEKHM1 0.317 2.91E-47 
7 rs17646960 UBE3C 0.342 1.49E-20 
7 rs1182398 UBE3C -0.285 1.07E-33 
7 rs1182393 UBE3C -0.298 9.37E-43 
7 rs2527866 UBE3C -0.297 2.95E-06 
Table S14. Associations between SNPs found in the 8 eQTL scores and gene 
expression (Ntotal = 53); effect size and p-values are taken from the two GWAS 








eQTL score computation process 
 











Supplementary material references 
1. Phillips, A. R., Suttangkakul, A., & Vierstra, R. D. (2008). The ATG12-
conjugating enzyme ATG10 is essential for autophagic vesicle formation in 
Arabidopsis thaliana. Genetics, 178(3), 1339-1353. 
2. Sharma, S., Wongpalee, S. P., Vashisht, A., Wohlschlegel, J. A., & Black, D. 
L. (2014). Stem–loop 4 of U1 snRNA is essential for splicing and interacts 
with the U2 snRNP-specific SF3A1 protein during spliceosome 
assembly. Genes & development, 28(22), 2518-2531. 
3. Bansbach, C. E., Bétous, R., Lovejoy, C. A., Glick, G. G., & Cortez, D. (2009). 
The annealing helicase SMARCAL1 maintains genome integrity at stalled 
replication forks. Genes & development, 23(20), 2405-2414. 
4. Christopher, L., Napolioni, V., Khan, R. R., Han, S. S., Greicius, M. D., & 
Alzheimer's Disease Neuroimaging Initiative. (2017). A variant in PPP4R3A 
protects against alzheimer-related metabolic decline. Annals of 
neurology, 82(6), 900-911. 
5. Wright, S. D., Ramos, R. A., Tobias, P. S., Ulevitch, R. J., & Mathison, J. C. 
(1990). CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS 
binding protein. Science, 249(4975), 1431-1433. 
6. Steet, R., & Kornfeld, S. (2006). COG-7-deficient human fibroblasts exhibit 
altered recycling of Golgi proteins. Molecular biology of the cell, 17(5), 2312-
2321. 
7. Morava, E., Zeevaert, R., Korsch, E., Huijben, K., Wopereis, S., Matthijs, G. 
et al. (2007). A common mutation in the COG7 gene with a consistent 
phenotype including microcephaly, adducted thumbs, growth retardation, VSD 
and episodes of hyperthermia. European Journal of Human Genetics, 15(6), 
638. 
8. Qin, Z., Wang, Y., Tang, J., Zhang, L., Li, R., Xue, J. et al. (2018). High 
LINC01605 expression predicts poor prognosis and promotes tumor 
progression via up-regulation of MMP9 in bladder cancer. Bioscience 




9. Massé, K. L., Collins, R., Bhamra, S., Seville, R. A., & Jones, E. (2007). Anxa4 
genes are expressed in distinct organ systems in xenopus laevis and tropicalis 
but are functionally conserved. Organogenesis, 3(2), 83-92. 
10. Ergin, V., Erdogan, M., & Menevse, A. (2015). Regulation of shootin1 gene 
expression involves ngf-induced alternative splicing during neuronal 
differentiation of PC12 cells. Scientific reports, 5, 17931. 
11. Yeo, S. Y., Ha, S. Y., Yu, E. J., Lee, K. W., Kim, J. H., & Kim, S. H. (2014). 
ZNF282 (Zinc finger protein 282), a novel E2F1 co-activator, promotes 
esophageal squamous cell carcinoma. Oncotarget, 5(23), 12260. 
12. Edqvist, P. H. D., Huvila, J., Forsström, B., Talve, L., Carpén, O., Salvesen, H. 
B. et al. (2015). Loss of ASRGL1 expression is an independent biomarker for 
disease-specific survival in endometrioid endometrial carcinoma. Gynecologic 
oncology, 137(3), 529-537. 
13. Bhattacharya, M. R., Geisler, S., Pittman, S. K., Doan, R. A., Weihl, C. C., 
Milbrandt, J. et al. (2016). TMEM184b promotes axon degeneration and 
neuromuscular junction maintenance. Journal of Neuroscience, 36(17), 4681-
4689. 
14. Wang, L., Wildt, K. F., Castro, E., Xiong, Y., Feigenbaum, L., Tessarollo, L. 
et al. (2008). The zinc finger transcription factor Zbtb7b represses CD8-lineage 
gene expression in peripheral CD4+ T cells. Immunity, 29(6), 876-887. 
15. Nesbit, M. A., Hannan, F. M., Howles, S. A., Reed, A. A., Cranston, T., 
Thakker, C. E. et  al. (2013). Mutations in AP2S1 cause familial hypocalciuric 
hypercalcemia type 3. Nature genetics, 45(1), 93. 
16. Spiegel, R., Shaag, A., Shalev, S., & Elpeleg, O. (2016). Homozygous 
mutation in the APOA1BP is associated with a lethal infantile 
leukoencephalopathy. Neurogenetics, 17(3), 187-190. 
17. Zhu, M., Yan, C., Ren, C., Huang, X., Zhu, X., Gu, H. et al. (2017). Exome 
array analysis identifies variants in SPOCD1 and BTN3A2 that affect risk for 
gastric cancer. Gastroenterology, 152(8), 2011-2021. 
18. Evans, D. R., & Guy, H. I. (2004). Mammalian pyrimidine biosynthesis: fresh 





19. Maxson, J. E., Gotlib, J., Pollyea, D. A., Fleischman, A. G., Agarwal, A., Eide, 
C. A. et al. (2013). Oncogenic CSF3R mutations in chronic neutrophilic 
leukemia and atypical CML. New England Journal of Medicine, 368(19), 
1781-1790. 
20. Rhee, H. W., Zou, P., Udeshi, N. D., Martell, J. D., Mootha, V. K., Carr, S. A. 
et al. (2013). Proteomic mapping of mitochondria in living cells via spatially 
restricted enzymatic tagging. Science, 339(6125), 1328-1331. 
21. Zollino, M., Orteschi, D., Murdolo, M., Lattante, S., Battaglia, D., Stefanini, 
C. et al. (2012). Mutations in KANSL1 cause the 17q21. 31 microdeletion 
syndrome phenotype. Nature genetics, 44(6), 636. 
22. Zhernakova, A., Festen, E. M., Franke, L., Trynka, G., van Diemen, C. C., 
Monsuur, A. J. et al. (2008). Genetic analysis of innate immunity in Crohn's 
disease and ulcerative colitis identifies two susceptibility loci harboring 
CARD9 and IL18RAP. The American Journal of Human Genetics, 82(5), 
1202-1210. 
23. Gertow, K., Sennblad, B., Strawbridge, R. J., Öhrvik, J., Zabaneh, D., Shah, S. 
et al. (2012). Identification of the BCAR1-CFDP1-TMEM170A locus as a 
determinant of carotid intima-media thickness and coronary artery disease 
risk. Circulation: Cardiovascular Genetics, 5(6), 656-665. 
24. Zhu, J. H., Chen, R., Yi, W., Cantin, G. T., Fearns, C., Yang, Y. et al. (2008). 
Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 
malignant signaling. Oncogene, 27(18), 2525. 
25. Wills, Z., Bateman, J., Korey, C. A., Comer, A., & Van Vactor, D. (1999). The 
tyrosine kinase Abl and its substrate enabled collaborate with the receptor 
phosphatase Dlar to control motor axon guidance. Neuron, 22(2), 301-312. 
26. Niwa, T., Saito, H., Imajoh-ohmi, S., Kaminishi, M., Seto, Y., Miki, Y. et al. 
(2009). BRCA2 interacts with the cytoskeletal linker protein plectin to form a 
complex controlling centrosome localization. Cancer science, 100(11), 2115-
2125. 
27. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K. et al. 
(2018). The UK Biobank resource with deep phenotyping and genomic data. 




28. Manichaikul, A., Mychaleckyj, J. C., Rich, S. S., Daly, K., Sale, M., & Chen, 
W. M. (2010). Robust relationship inference in genome-wide association 



























Appendix 2: Supplementary materials for Chapter 3: Association of whole-
genome and NETRIN1 signaling pathway-derived polygenic risk scores for 
Major Depressive Disorder and white matter microstructure in UK Biobank 
Supplementary notes 
• Demographic data concerning complete dataset of individuals with DTI values 
• Descriptive statistics of imaging phenotype 
• NETRIN1 signalling pathway gene list 
• Demographic data and FA descriptive statistics of individuals excluded from 
the study (N = 19) 
• Demographic data and MD descriptive statistics of individuals excluded from 
the study (N = 30) 
• Statistical analysis of FA and MD values containing: 
1. Unpruned NETRIN1- and genomic-PRS with outliers excluded (6,401 
for FA and 6,390 for MD) at all 5 thresholds (0.01, 0.05, 0.1, 0.5, 1) 
and full sample (6,420) at threshold 0.5 
2. Pruned NETRIN1- and Genomic-PRS with outliers excluded (6,401 for 
FA and 6,390 for MD) at all 5 thresholds (0.01, 0.05, 0.1, 0.5, 1) and 
full sample (6,420) at threshold 0.5 
• White matter tracts significantly associated with both NETRIN1-PRS and 
genomic-PRS. 
1. Fractional anisotropy 






Demographic data concerning complete dataset of individuals with DTI values 
Complete dataset (N = 6,420): N female = 3,345; N male = 3,075; mean age: 62.62 +/- 7.37 
years; age range: 45.92 – 78.42 
Descriptive statistics of imaging phenotype 
Fractional Anisotropy   
 Full dataset (N = 6,420) Outliers excluded dataset (N = 6,401) 
White matter tract Mean SD Mean SD 
Cingulate gyrus part of 
cingulum (left) 
0.535 0.035 0.535 0.033 
Cingulate gyrus part of 
cingulum (right) 
0.497 0.034 0.498 0.033 
Parahippocampal part 
of cingulum (left) 
0.314 0.029 0.314 0.028 
Parahippocampal part 
of cingulum (right) 
0.313 0.030 0.313 0.030 
Inferior fronto-occipital 
fasciculus (left) 
0.475 0.024 0.476 0.022 
Inferior fronto-occipital 
fasciculus (right) 
0.465 0.021 0.465 0.020 
Inferior longitudinal 
fasciculus (left) 
0.460 0.021 0.460 0.019 
Inferior longitudinal 
fasciculus (right) 
0.451 0.020 0.451 0.018 
Superior longitudinal 
fasciculus (left) 
0.440 0.022 0.440 0.020 
Superior longitudinal 
fasciculus (right) 
0.423 0.021 0.424 0.019 
Uncinate fasciculus 
(left) 
0.388 0.024 0.388 0.235 
Uncinate fasciculus 
(right) 
0.390 0.021 0.390 0.020 
Anterior thalamic 
radiation (left) 
0.399 0.019 0.399 0.017 
Anterior thalamic 
radiation (right) 
0.392 0.019 0.392 0.017 
Posterior thalamic 
radiation (left) 
0.458 0.022 0.458 0.020 
Posterior thalamic 
radiation (right) 






0.422 0.019 0.423 0.018 
Superior thalamic 
radiation (right) 
0.422 0.020 0.422 0.018 
Acoustic radiation 
(left) 
0.419 0.023 0.420 0.021 
Acoustic radiation 
(right) 
0.411 0.022 0.412 0.020 
Corticospinal tract 
(left) 
0.545 0.024 0.545 0.022 
Corticospinal tract 
(right) 
0.539 0.025 0.539 0.022 
Medial lemniscus (left) 0.419 0.024 0.419 0.023 
Medial lemniscus 
(right) 
0.422 0.025 0.422 0.024 
Forceps major 0.580 0.029 0.580 0.027 
Forceps minor 0.465 0.022 0.465 0.020 
Middle cerebellar 
peduncle 
0.481 0.031 0.481 0.029 
Table S1. Descriptive statistics of FA values (mean and standard deviation). The full dataset 
contains 6,420 individuals, while the outliers-excluded dataset contains 6,401 individuals.  
 
Mean Diffusivity   
 Full dataset (N = 6,420) Outliers excluded dataset (N = 
6,390) 
White matter tract Mean SD Mean SD 
Cingulate gyrus part of 
cingulum (left) 
0.0007 0.00003 0.0007 0.00002 
Cingulate gyrus part of 
cingulum (right) 
0.0007 0.00003 0.0007 0.00002 
Parahippocampal part 
of cingulum (left) 
0.0008 0.00006 0.0008 0.00005 
Parahippocampal part 
of cingulum (right) 
0.0008 0.00006 0.0008 0.00005 
Inferior fronto-occipital 
fasciculus (left) 
0.0008 0.00003 0.0008 0.00003 
Inferior fronto-occipital 
fasciculus (right) 
0.0008 0.00003 0.0008 0.00003 
Inferior longitudinal 
fasciculus (left) 
0.0008 0.00003 0.0008 0.00003 
Inferior longitudinal 
fasciculus (right) 
0.0008 0.00003 0.0008 0.00003 
Superior longitudinal 
fasciculus (left) 






0.0007 0.00003 0.0007 0.00003 
Uncinate fasciculus 
(left) 
0.0008 0.00004 0.0008 0.00003 
Uncinate fasciculus 
(right) 
0.0008 0.00003 0.0008 0.00003 
Anterior thalamic 
radiation (left) 
0.0007 0.00003 0.0007 0.00003 
Anterior thalamic 
radiation (right) 
0.0007 0.00003 0.0007 0.00003 
Posterior thalamic 
radiation (left) 
0.0008 0.00004 0.0008 0.00004 
Posterior thalamic 
radiation (right) 
0.0008 0.00004 0.0008 0.00004 
Superior thalamic 
radiation (left) 
0.0007 0.00003 0.0007 0.00002 
Superior thalamic 
radiation (right) 
0.0007 0.00003 0.0007 0.00002 
Acoustic radiation 
(left) 
0.0007 0.00004 0.0007 0.00003 
Acoustic radiation 
(right) 
0.0007 0.00004 0.0007 0.00003 
Corticospinal tract 
(left) 
0.0007 0.00002 0.0007 0.00002 
Corticospinal tract 
(right) 
0.0007 0.00002 0.0007 0.00002 
Medial lemniscus (left) 0.0009 0.00004 0.0009 0.00003 
Medial lemniscus 
(right) 
0.0009 0.00004 0.0009 0.00003 
Forceps major 0.0009 0.00005 0.0009 0.00005 
Forceps minor 0.0008 0.00003 0.0008 0.00003 
Middle cerebellar 
peduncle 
0.0007 0.00006 0.0007 0.00006 
Table S2. Descriptive statistics of MD values (mean and standard deviation). The full dataset 
contains 6,420 individuals, while the outliers-excluded dataset contains 6,390 individuals. 
NETRIN1 signalling pathway gene list 
Gene name Description 
UNC5D unc-5 homolog D (C. elegans) 
HFE2 hemochromatosis type 2 (juvenile) 
DCC deleted in colorectal carcinoma 
DOCK1 dedicator of cytokinesis 1 
UNC5B unc-5 homolog B (C. elegans) 
ABLIM3 actin binding LIM protein family, member 3 
FYN FYN oncogene related to SRC, FGR, YES 




ABLIM1 actin binding LIM protein 1 
MYO10 myosin X 
NCK1 NCK adaptor protein 1 
NEO1 neogenin 1 
PITPNA phosphatidylinositol transfer protein, alpha 
PLCG1 phospholipase C, gamma 1 
PRKCQ protein kinase C, theta 
RGMA RGM domain family, member A 
TRPC7 transient receptor potential cation channel 
PTK2 PTK2 protein tyrosine kinase 2 
RAC1 ras-related C3 botulinum toxin substrate 1 percursor 
NTN4 netrin 4 
ROBO1 roundabout, axon guidance receptor, homolog 1 
SIAH1 seven in absentia homolog 1 (Drosophila) 
SIAH2 seven in absentia homolog 2 (Drosophila) 
SLIT1 slit homolog 1 (Drosophila) 
SLIT3 slit homolog 3 (Drosophila) 
SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene 
TRIO triple functional domain (PTPRF interacting) 
TRPC3 transient receptor potential cation channel 
TRPC4 transient receptor potential cation channel 
TRPC5 transient receptor potential cation channel 







UNC5C unc-5 homolog C (C. elegans) 
WASL Wiskott-Aldrich syndrome-like 
UNC5A unc-5 homolog A (C. elegans) 
SLIT2 slit homolog 2 (Drosophila) 
NTN1 netrin 1 
CDC42 cell division cycle 42 (GTP binding protein) 
Table S3. Gene list and brief gene description included in the NETRIN1 signalling pathway, 
composed of 43 genes. 
Demographic data and FA descriptive statistics of individuals excluded from the study 
(N = 19) 
N female = 11; N male = 8; mean age: 69.26 +/- 4.53 years; age range: 58.92 – 77.42 
Fractional Anisotropy  
 Outlier dataset (N = 19) 
White matter tract Mean SD 
Cingulate gyrus part of cingulum (left) 0.407 0.149 
Cingulate gyrus part of cingulum (right) 0.388 0.144 
Parahippocampal part of cingulum (left) 0.246 0.091 
Parahippocampal part of cingulum (right) 0.254 0.095 
Inferior fronto-occipital fasciculus (left) 0.354 0.127 
Inferior fronto-occipital fasciculus (right) 0.354 0.127 




Inferior longitudinal fasciculus (right) 0.338 0.122 
Superior longitudinal fasciculus (left) 0.325 0.117 
Superior longitudinal fasciculus (right) 0.309 0.112 
Uncinate fasciculus (left) 0.296 0.106 
Uncinate fasciculus (right) 0.301 0.107 
Anterior thalamic radiation (left) 0.306 0.110 
Anterior thalamic radiation (right) 0.306 0.109 
Posterior thalamic radiation (left) 0.358 0.127 
Posterior thalamic radiation (right) 0.350 0.126 
Superior thalamic radiation (left) 0.335 0.119 
Superior thalamic radiation (right) 0.336 0.120 
Acoustic radiation (left) 0.324 0.116 
Acoustic radiation (right) 0.320 0.116 
Corticospinal tract (left) 0.436 0.156 
Corticospinal tract (right) 0.431 0.155 
Medial lemniscus (left) 0.353 0.127 
Medial lemniscus (right) 0.353 0.130 
Forceps major 0.460 0.166 
Forceps minor 0.346 0.125 
Middle cerebellar peduncle 0.381 0.171 
Table S4. Descriptive statistics of FA values (mean and standard deviation) for individuals 
excluded from the study (N = 19).  
 
Demographic data and MD descriptive statistics of individuals excluded from the study 
(N = 30) 
N female = 18; N male = 12; mean age: 70.29 +/- 4.66 years; age range: 58.92 – 77.42 
Mean Diffusivity  
 Outlier dataset (N = 30) 
White matter tract Mean SD 
Cingulate gyrus part of cingulum (left) 0.0007 0.0002 
Cingulate gyrus part of cingulum (right) 0.0007 0.0002 
Parahippocampal part of cingulum (left) 0.0009 0.0002 
Parahippocampal part of cingulum (right) 0.0009 0.0002 
Inferior fronto-occipital fasciculus (left) 0.0008 0.0002 
Inferior fronto-occipital fasciculus (right) 0.0008 0.0002 
Inferior longitudinal fasciculus (left) 0.0008 0.0002 
Inferior longitudinal fasciculus (right) 0.0008 0.0002 
Superior longitudinal fasciculus (left) 0.0008 0.0002 
Superior longitudinal fasciculus (right) 0.0008 0.0002 
Uncinate fasciculus (left) 0.0008 0.0002 
Uncinate fasciculus (right) 0.0008 0.0002 
Anterior thalamic radiation (left) 0.0008 0.0002 
Anterior thalamic radiation (right) 0.0008 0.0002 
Posterior thalamic radiation (left) 0.0009 0.0002 
Posterior thalamic radiation (right) 0.0009 0.0002 
Superior thalamic radiation (left) 0.0007 0.0002 
Superior thalamic radiation (right) 0.0007 0.0002 
Acoustic radiation (left) 0.0008 0.0002 




Corticospinal tract (left) 0.0007 0.0002 
Corticospinal tract (right) 0.0007 0.0002 
Medial lemniscus (left) 0.0008 0.0002 
Medial lemniscus (right) 0.0008 0.0002 
Forceps major 0.0009 0.0002 
Forceps minor 0.0008 0.0002 
Middle cerebellar peduncle 0.0007 0.0002 
Table S5. Descriptive statistics of MD values (mean and standard deviation) for individuals 
excluded from the study (N = 30). 
 
Statistical analysis of FA and MD values containing: 
Unpruned NETRIN1- and genomic-PRS with outliers included (6,420) and outliers 
excluded (6,401 for FA and 6,390 for MD) at all 5 thresholds (0.01, 0.05, 0.1, 0.5, 1) 
PGRS THRESHOLD: 0.01 Value Std. Error t-value p-value 
NETRIN1 acoustic radiation -0.002 0.011 -0.166 0.868 
NETRIN1 anterior_thalamic_radiation -0.021 0.011 -1.833 0.067 
NETRIN1 cingulate_gyrus_part_of_cingulum -0.013 0.011 -1.255 0.209 
NETRIN1 parahippocampal_part_of_cingulum -0.006 0.011 -0.526 0.599 
NETRIN1 corticospinal_tract -0.019 0.011 -1.701 0.089 
NETRIN1 inferior_fronto_occipital_fasciculus -0.019 0.012 -1.647 0.100 
NETRIN1 inferior_longitudinal_fasciculus -0.021 0.012 -1.813 0.070 
NETRIN1 medial_lemniscus -0.008 0.010 -0.735 0.462 
NETRIN1 posterior_thalamic_radiation -0.011 0.011 -0.981 0.326 
NETRIN1 superior_longitudinal_fasciculus -0.026 0.012 -2.254 0.024 
NETRIN1 superior_thalamic_radiation -0.015 0.012 -1.251 0.211 
NETRIN1 uncinate_fasciculus -0.018 0.011 -1.680 0.093 
NETRIN1 bl.FA.wm.forceps_major -0.017 0.012 -1.409 0.159 
NETRIN1 bl.FA.wm.forceps_minor -0.011 0.012 -0.934 0.351 
NETRIN1 bl.FA.wm.middle_cerebellar_peduncle -0.029 0.012 -2.333 0.020 
Genomic acoustic_radiation -0.011 0.011 -1.033 0.301 
Genomic anterior_thalamic_radiation -0.015 0.012 -1.315 0.188 
Genomic cingulate_gyrus_part_of_cingulum -0.016 0.011 -1.528 0.127 
Genomic parahippocampal_part_of_cingulum -0.019 0.011 -1.779 0.075 
Genomic corticospinal_tract -0.008 0.011 -0.666 0.505 
Genomic inferior_fronto_occipital_fasciculus -0.023 0.012 -2.008 0.045 
Genomic inferior_longitudinal_fasciculus -0.023 0.012 -1.959 0.050 
Genomic medial_lemniscus 0.003 0.010 0.306 0.760 
Genomic posterior_thalamic_radiation -0.021 0.011 -1.873 0.061 
Genomic superior_longitudinal_fasciculus -0.026 0.012 -2.244 0.025 
Genomic superior_thalamic_radiation -0.010 0.012 -0.867 0.386 
Genomic uncinate_fasciculus -0.028 0.011 -2.545 0.011 
Genomic bl.FA.wm.forceps_major -0.037 0.012 -3.042 0.002 
Genomic bl.FA.wm.forceps_minor -0.031 0.012 -2.600 0.009 
Genomic bl.FA.wm.middle_cerebellar_peduncle -0.009 0.012 -0.730 0.465 
     
PGRS THRESHOLD: 0.05 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation 0.009 0.011 0.819 0.413 
NETRIN1 anterior_thalamic_radiation -0.015 0.011 -1.282 0.200 




NETRIN1 parahippocampal_part_of_cingulum -0.013 0.011 -1.197 0.232 
NETRIN1 corticospinal_tract -0.003 0.011 -0.276 0.782 
NETRIN1 inferior_fronto_occipital_fasciculus -0.005 0.011 -0.473 0.636 
NETRIN1 inferior_longitudinal_fasciculus -0.010 0.011 -0.841 0.400 
NETRIN1 medial_lemniscus -0.005 0.010 -0.456 0.649 
NETRIN1 posterior_thalamic_radiation -0.002 0.011 -0.205 0.838 
NETRIN1 superior_longitudinal_fasciculus -0.015 0.012 -1.265 0.206 
NETRIN1 superior_thalamic_radiation -0.001 0.012 -0.049 0.961 
NETRIN1 uncinate_fasciculus -0.009 0.011 -0.876 0.381 
NETRIN1 bl.FA.wm.forceps_major -0.008 0.012 -0.644 0.520 
NETRIN1 bl.FA.wm.forceps_minor -0.005 0.012 -0.397 0.691 
NETRIN1 bl.FA.wm.middle_cerebellar_peduncle -0.018 0.012 -1.461 0.144 
Genomic acoustic_radiation -0.012 0.011 -1.151 0.250 
Genomic anterior_thalamic_radiation -0.017 0.011 -1.459 0.145 
Genomic cingulate_gyrus_part_of_cingulum -0.019 0.011 -1.739 0.082 
Genomic parahippocampal_part_of_cingulum -0.019 0.011 -1.771 0.077 
Genomic corticospinal_tract -0.012 0.011 -1.037 0.300 
Genomic inferior_fronto_occipital_fasciculus -0.026 0.012 -2.292 0.022 
Genomic inferior_longitudinal_fasciculus -0.026 0.012 -2.252 0.024 
Genomic medial_lemniscus 0.000 0.010 0.037 0.970 
Genomic posterior_thalamic_radiation -0.026 0.011 -2.357 0.018 
Genomic superior_longitudinal_fasciculus -0.029 0.012 -2.500 0.012 
Genomic superior_thalamic_radiation -0.015 0.012 -1.296 0.195 
Genomic uncinate_fasciculus -0.030 0.011 -2.725 0.006 
Genomic bl.FA.wm.forceps_major -0.037 0.012 -3.083 0.002 
Genomic bl.FA.wm.forceps_minor -0.034 0.012 -2.834 0.005 
Genomic bl.FA.wm.middle_cerebellar_peduncle -0.012 0.012 -0.983 0.326 
     
PGRS THRESHOLD: 0.1 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation 0.005 0.011 0.443 0.658 
NETRIN1 anterior_thalamic_radiation -0.018 0.011 -1.580 0.114 
NETRIN1 cingulate_gyrus_part_of_cingulum -0.016 0.011 -1.528 0.127 
NETRIN1 parahippocampal_part_of_cingulum -0.006 0.011 -0.580 0.562 
NETRIN1 corticospinal_tract -0.004 0.011 -0.314 0.753 
NETRIN1 inferior_fronto_occipital_fasciculus -0.013 0.011 -1.090 0.276 
NETRIN1 inferior_longitudinal_fasciculus -0.013 0.012 -1.091 0.275 
NETRIN1 medial_lemniscus -0.016 0.010 -1.569 0.117 
NETRIN1 posterior_thalamic_radiation -0.005 0.011 -0.481 0.631 
NETRIN1 superior_longitudinal_fasciculus -0.024 0.012 -2.065 0.039 
NETRIN1 superior_thalamic_radiation -0.010 0.012 -0.827 0.408 
NETRIN1 uncinate_fasciculus -0.008 0.011 -0.756 0.450 
NETRIN1 bl.FA.wm.forceps_major -0.014 0.012 -1.145 0.252 
NETRIN1 bl.FA.wm.forceps_minor -0.011 0.012 -0.934 0.350 
NETRIN1 bl.FA.wm.middle_cerebellar_peduncle -0.013 0.012 -1.049 0.294 
Genomic acoustic_radiation -0.012 0.011 -1.147 0.251 
Genomic anterior_thalamic_radiation -0.014 0.011 -1.186 0.236 
Genomic cingulate_gyrus_part_of_cingulum -0.018 0.011 -1.699 0.089 
Genomic parahippocampal_part_of_cingulum -0.017 0.011 -1.552 0.121 
Genomic corticospinal_tract -0.016 0.011 -1.379 0.168 
Genomic inferior_fronto_occipital_fasciculus -0.025 0.012 -2.177 0.030 
Genomic inferior_longitudinal_fasciculus -0.024 0.012 -2.121 0.034 
Genomic medial_lemniscus 0.001 0.010 0.139 0.890 
Genomic posterior_thalamic_radiation -0.022 0.011 -2.002 0.045 
Genomic superior_longitudinal_fasciculus -0.026 0.012 -2.267 0.023 




Genomic uncinate_fasciculus -0.032 0.011 -2.915 0.004 
Genomic bl.FA.wm.forceps_major -0.033 0.012 -2.753 0.006 
Genomic bl.FA.wm.forceps_minor -0.031 0.012 -2.572 0.010 
Genomic bl.FA.wm.middle_cerebellar_peduncle -0.018 0.012 -1.465 0.143 
PGRS THRESHOLD: 1 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation 0.003 0.011 0.294 0.769 
NETRIN1 anterior_thalamic_radiation -0.023 0.011 -2.051 0.040 
NETRIN1 cingulate_gyrus_part_of_cingulum -0.029 0.011 -2.720 0.007 
NETRIN1 parahippocampal_part_of_cingulum -0.007 0.011 -0.692 0.489 
NETRIN1 corticospinal_tract 0.001 0.011 0.120 0.905 
NETRIN1 inferior_fronto_occipital_fasciculus -0.024 0.011 -2.070 0.039 
NETRIN1 inferior_longitudinal_fasciculus -0.023 0.011 -1.978 0.048 
NETRIN1 medial_lemniscus -0.008 0.010 -0.757 0.449 
NETRIN1 posterior_thalamic_radiation -0.015 0.011 -1.360 0.174 
NETRIN1 superior_longitudinal_fasciculus -0.035 0.012 -3.017 0.003 
NETRIN1 superior_thalamic_radiation -0.006 0.012 -0.517 0.605 
NETRIN1 uncinate_fasciculus -0.019 0.011 -1.799 0.072 
NETRIN1 forceps_major -0.016 0.012 -1.333 0.183 
NETRIN1 forceps_minor -0.018 0.012 -1.537 0.124 
NETRIN1 middle_cerebellar_peduncle -0.016 0.012 -1.294 0.196 
Genomic acoustic_radiation -0.013 0.011 -1.230 0.219 
Genomic anterior_thalamic_radiation -0.016 0.011 -1.386 0.166 
Genomic cingulate_gyrus_part_of_cingulum -0.021 0.011 -1.943 0.052 
Genomic parahippocampal_part_of_cingulum -0.022 0.011 -2.022 0.043 
Genomic corticospinal_tract -0.018 0.011 -1.604 0.109 
Genomic inferior_fronto_occipital_fasciculus -0.028 0.012 -2.444 0.015 
Genomic inferior_longitudinal_fasciculus -0.025 0.012 -2.135 0.033 
Genomic medial_lemniscus -0.004 0.010 -0.401 0.689 
Genomic posterior_thalamic_radiation -0.022 0.011 -1.923 0.054 
Genomic superior_longitudinal_fasciculus -0.022 0.012 -1.927 0.054 
Genomic superior_thalamic_radiation -0.014 0.012 -1.202 0.229 
Genomic uncinate_fasciculus -0.032 0.011 -2.957 0.003 
Genomic forceps_major -0.031 0.012 -2.589 0.010 
Genomic forceps_minor -0.031 0.012 -2.573 0.010 
Genomic middle_cerebellar_peduncle -0.020 0.012 -1.585 0.113 
Table S6. The effect of unpruned NETRIN1- and Genomic-PRS at thresholds 0.01, 0.05, 
0.1, 0.5 and 1 on individual white matter tracts (FA) (N = 6,401). 
 
PGRS THRESHOLD: 0.01 Value Std. Error t-value p-value 
NETRIN1 gFA -0.025 0.012 -2.065 0.039 
NETRIN1 Association fibres -0.024 0.012 -2.024 0.043 
NETRIN1 Thalamic radiations -0.020 0.012 -1.615 0.106 
NETRIN1 Projection fibres -0.024 0.012 -1.963 0.050 
Genomic gFA -0.029 0.012 -2.431 0.015 
Genomic Association fibres -0.031 0.012 -2.574 0.010 
Genomic Thalamic radiations -0.020 0.012 -1.685 0.092 
Genomic Projection fibres -0.021 0.012 -1.716 0.086 
     
PGRS THRESHOLD: 0.05 Value Std. Error t-value p-value 
NETRIN1 gFA -0.012 0.012 -1.030 0.303 
NETRIN1 Association fibres -0.016 0.012 -1.333 0.183 
NETRIN1 Thalamic radiations -0.007 0.012 -0.590 0.555 
NETRIN1 Projection fibres -0.007 0.012 -0.552 0.581 




Genomic Association fibres -0.034 0.012 -2.845 0.004 
Genomic Thalamic radiations -0.026 0.012 -2.128 0.033 
Genomic Projection fibres -0.025 0.012 -2.073 0.038 
     
PGRS THRESHOLD: 0.1 Value Std. Error t-value p-value 
NETRIN1 gFA -0.018 0.012 -1.494 0.135 
NETRIN1 Association fibres -0.020 0.012 -1.684 0.092 
NETRIN1 Thalamic radiations -0.014 0.012 -1.125 0.261 
NETRIN1 Projection fibres -0.012 0.012 -1.032 0.302 
Genomic gFA -0.032 0.012 -2.656 0.008 
Genomic Association fibres -0.032 0.012 -2.728 0.006 
Genomic Thalamic radiations -0.022 0.012 -1.820 0.069 
Genomic Projection fibres -0.026 0.012 -2.201 0.028 
     
PGRS THRESHOLD: 1 Value Std. Error t-value p-value 
NETRIN1 gFA -0.027 0.012 -2.288 0.022 
NETRIN1 Association fibres -0.034 0.012 -2.903 0.004 
NETRIN1 Thalamic radiations -0.019 0.012 -1.590 0.112 
NETRIN1 Projection fibres -0.011 0.012 -0.881 0.379 
Genomic gFA -0.034 0.012 -2.824 0.005 
Genomic Association fibres -0.035 0.012 -2.927 0.003 
Genomic Thalamic radiations -0.023 0.012 -1.863 0.062 
Genomic Projection fibres -0.029 0.012 -2.443 0.015 
Table S7. The effect of unpruned NETRIN1- and Genomic-PRS at thresholds 0.01, 0.05, 
0.1, 0.5 and 1 on tract categories (FA) (N = 6,401). 
 
PGRS THRESHOLD: 0.5 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation 0.002 0.011 0.222 0.824 
NETRIN1 anterior_thalamic_radiation -0.021 0.012 -1.800 0.072 
NETRIN1 cingulate_gyrus_part_of_cingulum -0.024 0.011 -2.199 0.028 
NETRIN1 parahippocampal_part_of_cingulum -0.008 0.011 -0.731 0.465 
NETRIN1 corticospinal_tract 0.001 0.011 0.125 0.900 
NETRIN1 inferior_fronto_occipital_fasciculus -0.022 0.012 -1.899 0.058 
NETRIN1 inferior_longitudinal_fasciculus -0.021 0.012 -1.853 0.064 
NETRIN1 medial_lemniscus -0.009 0.010 -0.826 0.409 
NETRIN1 posterior_thalamic_radiation -0.013 0.011 -1.162 0.245 
NETRIN1 superior_longitudinal_fasciculus -0.034 0.012 -2.897 0.004 
NETRIN1 superior_thalamic_radiation -0.006 0.012 -0.466 0.641 
NETRIN1 uncinate_fasciculus -0.019 0.011 -1.698 0.090 
NETRIN1 forceps_major -0.014 0.012 -1.197 0.231 
NETRIN1 forceps_minor -0.018 0.012 -1.489 0.136 
NETRIN1 middle_cerebellar_peduncle -0.016 0.012 -1.270 0.204 
Genomic acoustic_radiation -0.016 0.011 -1.464 0.143 
Genomic anterior_thalamic_radiation -0.018 0.012 -1.530 0.126 
Genomic cingulate_gyrus_part_of_cingulum -0.020 0.011 -1.859 0.063 
Genomic parahippocampal_part_of_cingulum -0.022 0.011 -2.042 0.041 
Genomic corticospinal_tract -0.022 0.012 -1.878 0.060 
Genomic inferior_fronto_occipital_fasciculus -0.030 0.012 -2.579 0.010 
Genomic inferior_longitudinal_fasciculus -0.026 0.012 -2.258 0.024 
Genomic medial_lemniscus -0.006 0.011 -0.580 0.562 
Genomic posterior_thalamic_radiation -0.025 0.011 -2.224 0.026 
Genomic superior_longitudinal_fasciculus -0.025 0.012 -2.095 0.036 
Genomic superior_thalamic_radiation -0.018 0.012 -1.487 0.137 




Genomic forceps_major -0.034 0.012 -2.781 0.005 
Genomic forceps_minor -0.033 0.012 -2.717 0.007 
Genomic middle_cerebellar_peduncle -0.023 0.012 -1.828 0.068 
Table S8. The effect of unpruned NETRIN1- and Genomic-PRS at threshold 0.5 on 
individual white matter tracts (FA) (N = 6,420). 
 
PGRS THRESHOLD: 0.5 Value Std. Error t-value p-value 
NETRIN1 gFA -0.002 0.001 -2.197 0.028 
NETRIN1 Association fibres -0.002 0.001 -2.762 0.006 
NETRIN1 Thalamic radiations -0.001 0.000 -1.482 0.138 
NETRIN1 Projection fibres 0.000 0.001 -0.904 0.366 
Genomic gFA -0.002 0.001 -2.769 0.006 
Genomic Association fibres -0.002 0.001 -2.836 0.005 
Genomic Thalamic radiations -0.001 0.000 -1.855 0.064 
Genomic Projection fibres -0.001 0.001 -2.415 0.016 
Table S9. The effect of unpruned NETRIN1- and Genomic-PRS at threshold 0.5 on tract 
categories (FA) (N = 6,420). 
 
PGRS THRESHOLD: 0.01 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation 0.008 0.011 0.772 0.440 
NETRIN1 anterior_thalamic_radiation 0.018 0.011 1.694 0.090 
NETRIN1 cingulate_gyrus_part_of_cingulum 0.013 0.011 1.257 0.209 
NETRIN1 parahippocampal_part_of_cingulum -0.007 0.011 -0.621 0.535 
NETRIN1 corticospinal_tract 0.003 0.011 0.270 0.787 
NETRIN1 inferior_fronto_occipital_fasciculus 0.021 0.011 1.905 0.057 
NETRIN1 inferior_longitudinal_fasciculus 0.019 0.011 1.727 0.084 
NETRIN1 medial_lemniscus 0.007 0.011 0.659 0.510 
NETRIN1 posterior_thalamic_radiation 0.016 0.011 1.466 0.143 
NETRIN1 superior_longitudinal_fasciculus 0.023 0.011 2.046 0.041 
NETRIN1 superior_thalamic_radiation 0.016 0.010 1.589 0.112 
NETRIN1 uncinate_fasciculus 0.011 0.010 1.033 0.302 
NETRIN1 bl.MD.wm.forceps_major 0.013 0.012 1.083 0.279 
NETRIN1 bl.MD.wm.forceps_minor 0.022 0.012 1.946 0.052 
NETRIN1 bl.MD.wm.middle_cerebellar_peduncle 0.003 0.012 0.239 0.811 
Genomic acoustic_radiation 0.015 0.011 1.453 0.146 
Genomic anterior_thalamic_radiation 0.020 0.011 1.878 0.060 
Genomic cingulate_gyrus_part_of_cingulum 0.038 0.011 3.529 0.000 
Genomic parahippocampal_part_of_cingulum 0.030 0.011 2.846 0.004 
Genomic corticospinal_tract 0.030 0.011 2.654 0.008 
Genomic inferior_fronto_occipital_fasciculus 0.032 0.011 2.879 0.004 
Genomic inferior_longitudinal_fasciculus 0.029 0.011 2.618 0.009 
Genomic medial_lemniscus 0.012 0.011 1.145 0.252 
Genomic posterior_thalamic_radiation 0.016 0.011 1.493 0.135 
Genomic superior_longitudinal_fasciculus 0.028 0.011 2.490 0.013 
Genomic superior_thalamic_radiation 0.023 0.010 2.320 0.020 
Genomic uncinate_fasciculus 0.033 0.010 3.148 0.002 
Genomic bl.MD.wm.forceps_major 0.033 0.012 2.733 0.006 
Genomic bl.MD.wm.forceps_minor 0.020 0.012 1.692 0.091 
Genomic bl.MD.wm.middle_cerebellar_peduncle 0.004 0.012 0.362 0.718 
     
PGRS THRESHOLD: 0.05 Value Std. Error t-value p-value 




NETRIN1 anterior_thalamic_radiation 0.015 0.011 1.426 0.154 
NETRIN1 cingulate_gyrus_part_of_cingulum 0.014 0.011 1.354 0.176 
NETRIN1 parahippocampal_part_of_cingulum 0.004 0.011 0.347 0.729 
NETRIN1 corticospinal_tract -0.003 0.011 -0.226 0.821 
NETRIN1 inferior_fronto_occipital_fasciculus 0.015 0.011 1.303 0.193 
NETRIN1 inferior_longitudinal_fasciculus 0.017 0.011 1.538 0.124 
NETRIN1 medial_lemniscus 0.002 0.011 0.160 0.873 
NETRIN1 posterior_thalamic_radiation 0.016 0.011 1.509 0.131 
NETRIN1 superior_longitudinal_fasciculus 0.023 0.011 1.998 0.046 
NETRIN1 superior_thalamic_radiation 0.014 0.010 1.420 0.156 
NETRIN1 uncinate_fasciculus 0.008 0.010 0.752 0.452 
NETRIN1 bl.MD.wm.forceps_major 0.014 0.012 1.172 0.241 
NETRIN1 bl.MD.wm.forceps_minor 0.015 0.012 1.292 0.196 
NETRIN1 bl.MD.wm.middle_cerebellar_peduncle -0.002 0.012 -0.138 0.890 
Genomic acoustic_radiation 0.021 0.011 1.959 0.050 
Genomic anterior_thalamic_radiation 0.025 0.011 2.359 0.018 
Genomic cingulate_gyrus_part_of_cingulum 0.040 0.011 3.734 0.000 
Genomic parahippocampal_part_of_cingulum 0.033 0.011 3.108 0.002 
Genomic corticospinal_tract 0.034 0.011 2.999 0.003 
Genomic inferior_fronto_occipital_fasciculus 0.037 0.011 3.327 0.001 
Genomic inferior_longitudinal_fasciculus 0.032 0.011 2.890 0.004 
Genomic medial_lemniscus 0.012 0.011 1.091 0.275 
Genomic posterior_thalamic_radiation 0.016 0.011 1.527 0.127 
Genomic superior_longitudinal_fasciculus 0.032 0.011 2.819 0.005 
Genomic superior_thalamic_radiation 0.028 0.010 2.812 0.005 
Genomic uncinate_fasciculus 0.032 0.010 3.116 0.002 
Genomic bl.MD.wm.forceps_major 0.032 0.012 2.663 0.008 
Genomic bl.MD.wm.forceps_minor 0.024 0.012 2.103 0.036 
Genomic bl.MD.wm.middle_cerebellar_peduncle 0.006 0.012 0.515 0.607 
     
PGRS THRESHOLD: 0.1 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation -0.005 0.010 -0.458 0.647 
NETRIN1 anterior_thalamic_radiation 0.020 0.011 1.868 0.062 
NETRIN1 cingulate_gyrus_part_of_cingulum 0.014 0.011 1.334 0.182 
NETRIN1 parahippocampal_part_of_cingulum -0.007 0.011 -0.710 0.478 
NETRIN1 corticospinal_tract 0.002 0.011 0.204 0.838 
NETRIN1 inferior_fronto_occipital_fasciculus 0.020 0.011 1.800 0.072 
NETRIN1 inferior_longitudinal_fasciculus 0.020 0.011 1.832 0.067 
NETRIN1 medial_lemniscus 0.011 0.011 1.018 0.309 
NETRIN1 posterior_thalamic_radiation 0.018 0.011 1.638 0.102 
NETRIN1 superior_longitudinal_fasciculus 0.030 0.011 2.611 0.009 
NETRIN1 superior_thalamic_radiation 0.021 0.010 2.073 0.038 
NETRIN1 uncinate_fasciculus 0.009 0.010 0.879 0.379 
NETRIN1 forceps_major 0.017 0.012 1.407 0.159 
NETRIN1 forceps_minor 0.018 0.012 1.597 0.110 
NETRIN1 middle_cerebellar_peduncle 0.004 0.012 0.298 0.766 
Genomic acoustic_radiation 0.022 0.011 2.107 0.035 
Genomic anterior_thalamic_radiation 0.023 0.011 2.143 0.032 
Genomic cingulate_gyrus_part_of_cingulum 0.038 0.011 3.601 0.000 
Genomic parahippocampal_part_of_cingulum 0.033 0.011 3.098 0.002 
Genomic corticospinal_tract 0.032 0.011 2.802 0.005 
Genomic inferior_fronto_occipital_fasciculus 0.034 0.011 3.081 0.002 
Genomic inferior_longitudinal_fasciculus 0.030 0.011 2.689 0.007 
Genomic medial_lemniscus 0.005 0.011 0.489 0.625 




Genomic superior_longitudinal_fasciculus 0.030 0.011 2.617 0.009 
Genomic superior_thalamic_radiation 0.024 0.010 2.442 0.015 
Genomic uncinate_fasciculus 0.034 0.010 3.320 0.001 
Genomic forceps_major 0.028 0.012 2.358 0.018 
Genomic forceps_minor 0.021 0.012 1.783 0.075 
Genomic middle_cerebellar_peduncle 0.008 0.012 0.666 0.505 
     
PGRS THRESHOLD: 1 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation 0.004 0.010 0.347 0.729 
NETRIN1 anterior_thalamic_radiation 0.028 0.011 2.669 0.008 
NETRIN1 cingulate_gyrus_part_of_cingulum 0.022 0.011 2.023 0.043 
NETRIN1 parahippocampal_part_of_cingulum 0.000 0.011 -0.023 0.981 
NETRIN1 corticospinal_tract 0.017 0.011 1.525 0.127 
NETRIN1 inferior_fronto_occipital_fasciculus 0.028 0.011 2.551 0.011 
NETRIN1 inferior_longitudinal_fasciculus 0.029 0.011 2.553 0.011 
NETRIN1 medial_lemniscus 0.005 0.011 0.428 0.669 
NETRIN1 posterior_thalamic_radiation 0.026 0.011 2.453 0.014 
NETRIN1 superior_longitudinal_fasciculus 0.033 0.011 2.953 0.003 
NETRIN1 superior_thalamic_radiation 0.027 0.010 2.763 0.006 
NETRIN1 uncinate_fasciculus 0.020 0.010 1.900 0.058 
NETRIN1 forceps_major 0.018 0.012 1.519 0.129 
NETRIN1 forceps_minor 0.021 0.012 1.791 0.073 
NETRIN1 middle_cerebellar_peduncle 0.011 0.012 0.890 0.373 
Genomic acoustic_radiation 0.019 0.011 1.841 0.066 
Genomic anterior_thalamic_radiation 0.021 0.011 2.021 0.043 
Genomic cingulate_gyrus_part_of_cingulum 0.036 0.011 3.332 0.001 
Genomic parahippocampal_part_of_cingulum 0.034 0.011 3.223 0.001 
Genomic corticospinal_tract 0.023 0.011 1.997 0.046 
Genomic inferior_fronto_occipital_fasciculus 0.032 0.011 2.828 0.005 
Genomic inferior_longitudinal_fasciculus 0.025 0.011 2.262 0.024 
Genomic medial_lemniscus 0.005 0.011 0.470 0.639 
Genomic posterior_thalamic_radiation 0.002 0.011 0.142 0.887 
Genomic superior_longitudinal_fasciculus 0.024 0.011 2.156 0.031 
Genomic superior_thalamic_radiation 0.018 0.010 1.804 0.071 
Genomic uncinate_fasciculus 0.030 0.010 2.844 0.004 
Genomic forceps_major 0.029 0.012 2.447 0.014 
Genomic forceps_minor 0.021 0.012 1.858 0.063 
Genomic middle_cerebellar_peduncle 0.012 0.012 0.965 0.335 
Table S10. The effect of unpruned NETRIN1- and Genomic-PRS at thresholds 0.01, 0.05, 
0.1, 0.5 and 1 on individual white matter tracts (MD) (N = 6,390). 
 
PGRS THRESHOLD: 0.01 Value Std. Error t-value p-value 
NETRIN1 gMD 0.018 0.012 1.574 0.116 
NETRIN1 Association fibres 0.013 0.012 1.086 0.277 
NETRIN1 Thalamic radiations 0.019 0.011 1.781 0.075 
NETRIN1 Projection fibres 0.013 0.012 1.087 0.277 
Genomic gMD 0.037 0.012 3.248 0.001 
Genomic Association fibres 0.043 0.012 3.707 0.000 
Genomic Thalamic radiations 0.022 0.011 2.027 0.043 
Genomic Projection fibres 0.026 0.012 2.180 0.029 
     
PGRS THRESHOLD: 0.05 Value Std. Error t-value p-value 
NETRIN1 gMD 0.016 0.011 1.380 0.168 




NETRIN1 Thalamic radiations 0.018 0.011 1.669 0.095 
NETRIN1 Projection fibres 0.004 0.012 0.322 0.748 
Genomic gMD 0.041 0.011 3.607 0.000 
Genomic Association fibres 0.047 0.012 4.033 0.000 
Genomic Thalamic radiations 0.025 0.011 2.334 0.020 
Genomic Projection fibres 0.030 0.012 2.478 0.013 
     
PGRS THRESHOLD: 0.1 Value Std. Error t-value p-value 
NETRIN1 gMD 0.018 0.011 1.596 0.111 
NETRIN1 Association fibres 0.013 0.012 1.106 0.269 
NETRIN1 Thalamic radiations 0.022 0.011 2.055 0.040 
NETRIN1 Projection fibres 0.011 0.012 0.920 0.358 
Genomic gMD 0.038 0.011 3.342 0.001 
Genomic Association fibres 0.046 0.012 3.934 0.000 
Genomic Thalamic radiations 0.020 0.011 1.822 0.069 
Genomic Projection fibres 0.029 0.012 2.391 0.017 
     
PGRS THRESHOLD: 1 Value Std. Error t-value p-value 
NETRIN1 gMD 0.029 0.011 2.524 0.012 
NETRIN1 Association fibres 0.023 0.012 2.014 0.044 
NETRIN1 Thalamic radiations 0.031 0.011 2.944 0.003 
NETRIN1 Projection fibres 0.020 0.012 1.686 0.092 
Genomic gMD 0.034 0.011 2.974 0.003 
Genomic Association fibres 0.043 0.012 3.666 0.000 
Genomic Thalamic radiations 0.013 0.011 1.229 0.219 
Genomic Projection fibres 0.030 0.012 2.494 0.013 
Table S11. The effect of unpruned NETRIN1- and Genomic-PRS at thresholds 0.01, 0.05, 
0.1, 0.5 and 1 on tract categories (MD) (N = 6,390). 
 
PGRS THRESHOLD: 0.5 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation 0.005 0.011 0.484 0.628 
NETRIN1 anterior_thalamic_radiation 0.023 0.011 2.171 0.030 
NETRIN1 cingulate_gyrus_part_of_cingulum 0.019 0.011 1.682 0.093 
NETRIN1 parahippocampal_part_of_cingulum 0.000 0.011 -0.004 0.997 
NETRIN1 corticospinal_tract 0.014 0.012 1.232 0.218 
NETRIN1 inferior_fronto_occipital_fasciculus 0.025 0.011 2.242 0.025 
NETRIN1 inferior_longitudinal_fasciculus 0.027 0.011 2.377 0.017 
NETRIN1 medial_lemniscus 0.003 0.011 0.288 0.774 
NETRIN1 posterior_thalamic_radiation 0.024 0.011 2.213 0.027 
NETRIN1 superior_longitudinal_fasciculus 0.030 0.011 2.649 0.008 
NETRIN1 superior_thalamic_radiation 0.024 0.010 2.345 0.019 
NETRIN1 uncinate_fasciculus 0.017 0.011 1.559 0.119 
NETRIN1 forceps_major 0.019 0.012 1.599 0.110 
NETRIN1 forceps_minor 0.019 0.012 1.592 0.111 
NETRIN1 middle_cerebellar_peduncle 0.012 0.012 0.984 0.325 
Genomic acoustic_radiation 0.010 0.011 0.949 0.342 
Genomic anterior_thalamic_radiation 0.011 0.011 1.009 0.313 
Genomic cingulate_gyrus_part_of_cingulum 0.021 0.011 1.852 0.064 
Genomic parahippocampal_part_of_cingulum 0.027 0.011 2.485 0.013 
Genomic corticospinal_tract 0.009 0.012 0.800 0.424 
Genomic inferior_fronto_occipital_fasciculus 0.019 0.011 1.630 0.103 
Genomic inferior_longitudinal_fasciculus 0.013 0.011 1.138 0.255 
Genomic medial_lemniscus -0.004 0.011 -0.378 0.705 




Genomic superior_longitudinal_fasciculus 0.013 0.012 1.113 0.266 
Genomic superior_thalamic_radiation 0.007 0.011 0.653 0.514 
Genomic uncinate_fasciculus 0.017 0.011 1.588 0.112 
Genomic forceps_major 0.020 0.012 1.624 0.104 
Genomic forceps_minor 0.012 0.012 0.982 0.326 
Genomic middle_cerebellar_peduncle 0.005 0.012 0.437 0.662 
Table S12. The effect of unpruned NETRIN1- and Genomic-PRS at threshold 0.5 on tract 
categories (MD) (N = 6,420). 
 
PGRS THRESHOLD: 0.5 Value Std. Error t-value p-value 
NETRIN1 gMD 3.4E-06 1.4E-06 2.4E+00 1.6E-02 
NETRIN1 Association fibres 2.0E-06 1.1E-06 1.9E+00 5.8E-02 
NETRIN1 Thalamic radiations 2.2E-06 7.9E-07 2.8E+00 5.4E-03 
NETRIN1 Projection fibres 1.4E-06 8.0E-07 1.8E+00 7.7E-02 
Genomic gMD 4.2E-06 1.4E-06 2.9E+00 3.5E-03 
Genomic Association fibres 3.9E-06 1.1E-06 3.6E+00 3.3E-04 
Genomic Thalamic radiations 9.8E-07 7.9E-07 1.2E+00 2.2E-01 
Genomic Projection fibres 1.9E-06 8.1E-07 2.4E+00 1.7E-02 
Table S13. The effect of unpruned NETRIN1- and Genomic-PRS at threshold 0.5 on tract 
categories (MD) (N = 6,320). 
 
Pruned NETRIN1- and Genomic-PRS with outliers included (6,420) and outliers 
excluded (6,401 for FA and 6,390 for MD) at all 5 thresholds (0.01, 0.05, 0.1, 0.5, 1) 
 
PGRS THRESHOLD: 0.01 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation -0.004 0.011 -0.349 0.727 
NETRIN1 anterior_thalamic_radiation -0.020 0.011 -1.709 0.087 
NETRIN1 cingulate_gyrus_part_of_cingulum -0.008 0.011 -0.704 0.482 
NETRIN1 parahippocampal_part_of_cingulum -0.007 0.011 -0.641 0.521 
NETRIN1 corticospinal_tract -0.022 0.011 -1.923 0.055 
NETRIN1 inferior_fronto_occipital_fasciculus -0.024 0.012 -2.058 0.040 
NETRIN1 inferior_longitudinal_fasciculus -0.024 0.012 -2.047 0.041 
NETRIN1 medial_lemniscus -0.012 0.010 -1.131 0.258 
NETRIN1 posterior_thalamic_radiation -0.014 0.011 -1.238 0.216 
NETRIN1 superior_longitudinal_fasciculus -0.028 0.012 -2.408 0.016 
NETRIN1 superior_thalamic_radiation -0.020 0.012 -1.677 0.094 
NETRIN1 uncinate_fasciculus -0.023 0.011 -2.156 0.031 
NETRIN1 bl.FA.wm.forceps_major -0.014 0.012 -1.137 0.255 
NETRIN1 bl.FA.wm.forceps_minor -0.009 0.012 -0.784 0.433 
NETRIN1 bl.FA.wm.middle_cerebellar_peduncle -0.028 0.012 -2.257 0.024 
Genomic acoustic_radiation -0.010 0.011 -0.942 0.346 
Genomic anterior_thalamic_radiation -0.017 0.011 -1.440 0.150 
Genomic cingulate_gyrus_part_of_cingulum -0.008 0.011 -0.785 0.432 
Genomic parahippocampal_part_of_cingulum 0.009 0.011 0.810 0.418 
Genomic corticospinal_tract -0.010 0.011 -0.889 0.374 
Genomic inferior_fronto_occipital_fasciculus -0.014 0.012 -1.249 0.212 
Genomic inferior_longitudinal_fasciculus -0.012 0.012 -1.023 0.306 




Genomic posterior_thalamic_radiation -0.011 0.011 -0.965 0.335 
Genomic superior_longitudinal_fasciculus -0.013 0.012 -1.080 0.280 
Genomic superior_thalamic_radiation -0.016 0.012 -1.332 0.183 
Genomic uncinate_fasciculus -0.019 0.011 -1.793 0.073 
Genomic bl.FA.wm.forceps_major -0.013 0.012 -1.086 0.278 
Genomic bl.FA.wm.forceps_minor -0.018 0.012 -1.475 0.140 
Genomic bl.FA.wm.middle_cerebellar_peduncle 0.017 0.012 1.369 0.171 
     
PGRS THRESHOLD: 0.05 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation 0.008 0.011 0.770 0.441 
NETRIN1 anterior_thalamic_radiation -0.012 0.011 -1.047 0.295 
NETRIN1 cingulate_gyrus_part_of_cingulum -0.007 0.011 -0.627 0.531 
NETRIN1 parahippocampal_part_of_cingulum -0.014 0.011 -1.335 0.182 
NETRIN1 corticospinal_tract -0.002 0.011 -0.146 0.884 
NETRIN1 inferior_fronto_occipital_fasciculus -0.007 0.011 -0.590 0.555 
NETRIN1 inferior_longitudinal_fasciculus -0.010 0.011 -0.865 0.387 
NETRIN1 medial_lemniscus -0.006 0.010 -0.574 0.566 
NETRIN1 posterior_thalamic_radiation -0.003 0.011 -0.304 0.761 
NETRIN1 superior_longitudinal_fasciculus -0.015 0.012 -1.290 0.197 
NETRIN1 superior_thalamic_radiation -0.003 0.012 -0.275 0.783 
NETRIN1 uncinate_fasciculus -0.011 0.011 -1.030 0.303 
NETRIN1 bl.FA.wm.forceps_major -0.004 0.012 -0.292 0.770 
NETRIN1 bl.FA.wm.forceps_minor -0.002 0.012 -0.178 0.858 
NETRIN1 bl.FA.wm.middle_cerebellar_peduncle -0.015 0.012 -1.200 0.230 
Genomic acoustic_radiation -0.005 0.011 -0.462 0.644 
Genomic anterior_thalamic_radiation -0.010 0.011 -0.901 0.367 
Genomic cingulate_gyrus_part_of_cingulum -0.004 0.011 -0.350 0.726 
Genomic parahippocampal_part_of_cingulum 0.001 0.011 0.103 0.918 
Genomic corticospinal_tract -0.014 0.011 -1.272 0.203 
Genomic inferior_fronto_occipital_fasciculus -0.016 0.011 -1.351 0.177 
Genomic inferior_longitudinal_fasciculus -0.015 0.011 -1.281 0.200 
Genomic medial_lemniscus -0.006 0.010 -0.569 0.569 
Genomic posterior_thalamic_radiation -0.019 0.011 -1.716 0.086 
Genomic superior_longitudinal_fasciculus -0.012 0.012 -1.076 0.282 
Genomic superior_thalamic_radiation -0.019 0.012 -1.596 0.110 
Genomic uncinate_fasciculus -0.017 0.011 -1.557 0.119 
Genomic bl.FA.wm.forceps_major -0.013 0.012 -1.093 0.275 
Genomic bl.FA.wm.forceps_minor -0.014 0.012 -1.186 0.236 
Genomic bl.FA.wm.middle_cerebellar_peduncle -0.003 0.012 -0.271 0.786 
     
PGRS THRESHOLD: 0.1 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation 0.005 0.011 0.452 0.652 
NETRIN1 anterior_thalamic_radiation -0.017 0.011 -1.442 0.149 
NETRIN1 cingulate_gyrus_part_of_cingulum -0.013 0.011 -1.238 0.216 
NETRIN1 parahippocampal_part_of_cingulum -0.007 0.011 -0.681 0.496 
NETRIN1 corticospinal_tract -0.003 0.011 -0.225 0.822 
NETRIN1 inferior_fronto_occipital_fasciculus -0.016 0.012 -1.381 0.167 
NETRIN1 inferior_longitudinal_fasciculus -0.014 0.012 -1.221 0.222 
NETRIN1 medial_lemniscus -0.018 0.010 -1.730 0.084 
NETRIN1 posterior_thalamic_radiation -0.007 0.011 -0.601 0.548 
NETRIN1 superior_longitudinal_fasciculus -0.026 0.012 -2.205 0.027 
NETRIN1 superior_thalamic_radiation -0.010 0.012 -0.871 0.384 
NETRIN1 uncinate_fasciculus -0.010 0.011 -0.896 0.370 
NETRIN1 forceps_major -0.012 0.012 -1.004 0.316 




NETRIN1 middle_cerebellar_peduncle -0.011 0.012 -0.922 0.356 
Genomic acoustic_radiation 0.001 0.011 0.080 0.936 
Genomic anterior_thalamic_radiation 0.002 0.011 0.146 0.884 
Genomic cingulate_gyrus_part_of_cingulum -0.001 0.011 -0.075 0.940 
Genomic parahippocampal_part_of_cingulum -0.002 0.011 -0.188 0.851 
Genomic corticospinal_tract -0.015 0.011 -1.345 0.179 
Genomic inferior_fronto_occipital_fasciculus -0.008 0.011 -0.723 0.469 
Genomic inferior_longitudinal_fasciculus -0.009 0.012 -0.760 0.447 
Genomic medial_lemniscus -0.001 0.010 -0.131 0.896 
Genomic posterior_thalamic_radiation -0.009 0.011 -0.770 0.441 
Genomic superior_longitudinal_fasciculus -0.007 0.012 -0.580 0.562 
Genomic superior_thalamic_radiation -0.011 0.012 -0.951 0.342 
Genomic uncinate_fasciculus -0.017 0.011 -1.572 0.116 
Genomic forceps_major -0.008 0.012 -0.632 0.528 
Genomic forceps_minor -0.006 0.012 -0.518 0.605 
Genomic middle_cerebellar_peduncle -0.016 0.012 -1.281 0.200 
     
PGRS THRESHOLD: 0.5 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation 0.006 0.011 0.520 0.603 
NETRIN1 anterior_thalamic_radiation -0.021 0.011 -1.811 0.070 
NETRIN1 cingulate_gyrus_part_of_cingulum -0.023 0.011 -2.201 0.028 
NETRIN1 parahippocampal_part_of_cingulum -0.006 0.011 -0.583 0.560 
NETRIN1 corticospinal_tract 0.002 0.011 0.204 0.839 
NETRIN1 inferior_fronto_occipital_fasciculus -0.021 0.011 -1.824 0.068 
NETRIN1 inferior_longitudinal_fasciculus -0.021 0.012 -1.790 0.074 
NETRIN1 medial_lemniscus -0.011 0.010 -1.061 0.289 
NETRIN1 posterior_thalamic_radiation -0.011 0.011 -0.981 0.327 
NETRIN1 superior_longitudinal_fasciculus -0.035 0.012 -3.031 0.002 
NETRIN1 superior_thalamic_radiation -0.006 0.012 -0.521 0.603 
NETRIN1 uncinate_fasciculus -0.018 0.011 -1.702 0.089 
NETRIN1 forceps_major -0.009 0.012 -0.740 0.459 
NETRIN1 forceps_minor -0.013 0.012 -1.071 0.284 
NETRIN1 middle_cerebellar_peduncle -0.017 0.012 -1.363 0.173 
Genomic acoustic_radiation -0.005 0.011 -0.488 0.625 
Genomic anterior_thalamic_radiation -0.007 0.011 -0.607 0.544 
Genomic cingulate_gyrus_part_of_cingulum -0.008 0.011 -0.780 0.435 
Genomic parahippocampal_part_of_cingulum -0.013 0.011 -1.189 0.235 
Genomic corticospinal_tract -0.022 0.011 -1.926 0.054 
Genomic inferior_fronto_occipital_fasciculus -0.018 0.011 -1.581 0.114 
Genomic inferior_longitudinal_fasciculus -0.014 0.012 -1.242 0.214 
Genomic medial_lemniscus -0.011 0.010 -1.055 0.291 
Genomic posterior_thalamic_radiation -0.015 0.011 -1.346 0.178 
Genomic superior_longitudinal_fasciculus -0.012 0.012 -1.014 0.311 
Genomic superior_thalamic_radiation -0.016 0.012 -1.381 0.167 
Genomic uncinate_fasciculus -0.023 0.011 -2.172 0.030 
Genomic forceps_major -0.015 0.012 -1.270 0.204 
Genomic forceps_minor -0.014 0.012 -1.184 0.237 
Genomic middle_cerebellar_peduncle -0.016 0.012 -1.334 0.182 
     
PGRS THRESHOLD: 1 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation 0.006 0.011 0.554 0.579 
NETRIN1 anterior_thalamic_radiation -0.022 0.011 -1.896 0.058 
NETRIN1 cingulate_gyrus_part_of_cingulum -0.026 0.011 -2.428 0.015 
NETRIN1 parahippocampal_part_of_cingulum -0.006 0.011 -0.558 0.577 




NETRIN1 inferior_fronto_occipital_fasciculus -0.020 0.011 -1.765 0.078 
NETRIN1 inferior_longitudinal_fasciculus -0.019 0.011 -1.629 0.103 
NETRIN1 medial_lemniscus -0.011 0.010 -1.020 0.308 
NETRIN1 posterior_thalamic_radiation -0.011 0.011 -0.991 0.322 
NETRIN1 superior_longitudinal_fasciculus -0.034 0.012 -2.959 0.003 
NETRIN1 superior_thalamic_radiation -0.007 0.012 -0.582 0.560 
NETRIN1 uncinate_fasciculus -0.018 0.011 -1.635 0.102 
NETRIN1 forceps_major -0.008 0.012 -0.678 0.497 
NETRIN1 forceps_minor -0.013 0.012 -1.116 0.264 
NETRIN1 middle_cerebellar_peduncle -0.015 0.012 -1.195 0.232 
Genomic acoustic_radiation -0.005 0.011 -0.502 0.616 
Genomic anterior_thalamic_radiation -0.009 0.011 -0.755 0.450 
Genomic cingulate_gyrus_part_of_cingulum -0.010 0.011 -0.976 0.329 
Genomic parahippocampal_part_of_cingulum -0.015 0.011 -1.373 0.170 
Genomic corticospinal_tract -0.021 0.011 -1.826 0.068 
Genomic inferior_fronto_occipital_fasciculus -0.018 0.011 -1.588 0.112 
Genomic inferior_longitudinal_fasciculus -0.014 0.011 -1.231 0.218 
Genomic medial_lemniscus -0.011 0.010 -1.044 0.296 
Genomic posterior_thalamic_radiation -0.013 0.011 -1.151 0.250 
Genomic superior_longitudinal_fasciculus -0.010 0.012 -0.848 0.396 
Genomic superior_thalamic_radiation -0.015 0.012 -1.263 0.207 
Genomic uncinate_fasciculus -0.024 0.011 -2.174 0.030 
Genomic forceps_major -0.014 0.012 -1.167 0.243 
Genomic forceps_minor -0.012 0.012 -1.017 0.309 
Genomic middle_cerebellar_peduncle -0.017 0.012 -1.344 0.179 
Table S14. The effect of pruned NETRIN1- and Genomic-PRS at thresholds 0.01, 0.05, 0.1, 
0.5 and 1 on individual white matter tracts (FA) (N = 6,401). 
 
PGRS THRESHOLD: 0.01 Value Std. Error t-value p-value 
NETRIN1 gFA -0.026 0.012 -2.186 0.029 
NETRIN1 Association fibres -0.025 0.012 -2.066 0.039 
NETRIN1 Thalamic radiations -0.022 0.012 -1.853 0.064 
NETRIN1 Projection fibres -0.025 0.012 -2.098 0.036 
Genomic gFA -0.015 0.012 -1.226 0.220 
Genomic Association fibres -0.013 0.012 -1.068 0.285 
Genomic Thalamic radiations -0.018 0.012 -1.488 0.137 
Genomic Projection fibres -0.009 0.012 -0.766 0.444 
     
PGRS THRESHOLD: 0.05 Value Std. Error t-value p-value 
NETRIN1 gFA -0.011 0.012 -0.943 0.346 
NETRIN1 Association fibres -0.015 0.012 -1.245 0.213 
NETRIN1 Thalamic radiations -0.008 0.012 -0.635 0.526 
NETRIN1 Projection fibres -0.004 0.012 -0.367 0.714 
Genomic gFA -0.017 0.012 -1.385 0.166 
Genomic Association fibres -0.013 0.012 -1.074 0.283 
Genomic Thalamic radiations -0.021 0.012 -1.740 0.082 
Genomic Projection fibres -0.015 0.012 -1.283 0.200 
     
PGRS THRESHOLD: 0.1 Value Std. Error t-value p-value 
NETRIN1 gFA -0.018 0.012 -1.518 0.129 
NETRIN1 Association fibres -0.020 0.012 -1.720 0.085 
NETRIN1 Thalamic radiations -0.014 0.012 -1.147 0.251 
NETRIN1 Projection fibres -0.012 0.012 -0.981 0.327 




Genomic Association fibres -0.008 0.012 -0.714 0.476 
Genomic Thalamic radiations -0.008 0.012 -0.666 0.505 
Genomic Projection fibres -0.013 0.012 -1.105 0.269 
     
PGRS THRESHOLD: 0.5 Value Std. Error t-value p-value 
NETRIN1 gFA -0.023 0.012 -1.966 0.049 
NETRIN1 Association fibres -0.031 0.012 -2.567 0.010 
NETRIN1 Thalamic radiations -0.016 0.012 -1.327 0.184 
NETRIN1 Projection fibres -0.008 0.012 -0.668 0.504 
Genomic gFA -0.021 0.012 -1.794 0.073 
Genomic Association fibres -0.020 0.012 -1.656 0.098 
Genomic Thalamic radiations -0.017 0.012 -1.376 0.169 
Genomic Projection fibres -0.024 0.012 -1.983 0.047 
     
PGRS THRESHOLD: 1 Value Std. Error t-value p-value 
NETRIN1 gFA -0.024 0.012 -1.991 0.047 
NETRIN1 Association fibres -0.031 0.012 -2.585 0.010 
NETRIN1 Thalamic radiations -0.017 0.012 -1.387 0.166 
NETRIN1 Projection fibres -0.009 0.012 -0.715 0.475 
Genomic gFA -0.021 0.012 -1.793 0.073 
Genomic Association fibres -0.021 0.012 -1.741 0.082 
Genomic Thalamic radiations -0.016 0.012 -1.296 0.195 
Genomic Projection fibres -0.023 0.012 -1.899 0.058 
Table S15. The effect of pruned NETRIN1- and Genomic-PRS at thresholds 0.01, 0.05, 0.1, 
0.5 and 1 on tract categories (FA) (N = 6,401). 
PGRS THRESHOLD: 0.5 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation 0.002 0.011 0.198 0.843 
NETRIN1 anterior_thalamic_radiation -0.022 0.012 -1.922 0.055 
NETRIN1 cingulate_gyrus_part_of_cingulum -0.024 0.011 -2.234 0.025 
NETRIN1 parahippocampal_part_of_cingulum -0.007 0.011 -0.644 0.520 
NETRIN1 corticospinal_tract -0.001 0.011 -0.100 0.920 
NETRIN1 inferior_fronto_occipital_fasciculus -0.023 0.012 -1.957 0.050 
NETRIN1 inferior_longitudinal_fasciculus -0.022 0.012 -1.865 0.062 
NETRIN1 medial_lemniscus -0.013 0.011 -1.240 0.215 
NETRIN1 posterior_thalamic_radiation -0.013 0.011 -1.120 0.263 
NETRIN1 superior_longitudinal_fasciculus -0.035 0.012 -3.029 0.002 
NETRIN1 superior_thalamic_radiation -0.008 0.012 -0.693 0.488 
NETRIN1 uncinate_fasciculus -0.020 0.011 -1.841 0.066 
NETRIN1 forceps_major -0.011 0.012 -0.908 0.364 
NETRIN1 forceps_minor -0.016 0.012 -1.299 0.194 
NETRIN1 middle_cerebellar_peduncle -0.017 0.012 -1.360 0.174 
Genomic acoustic_radiation -0.008 0.011 -0.773 0.439 
Genomic anterior_thalamic_radiation -0.010 0.012 -0.894 0.371 
Genomic cingulate_gyrus_part_of_cingulum -0.010 0.011 -0.925 0.355 
Genomic parahippocampal_part_of_cingulum -0.014 0.011 -1.309 0.191 
Genomic corticospinal_tract -0.025 0.012 -2.154 0.031 
Genomic inferior_fronto_occipital_fasciculus -0.021 0.012 -1.758 0.079 
Genomic inferior_longitudinal_fasciculus -0.017 0.012 -1.436 0.151 
Genomic medial_lemniscus -0.015 0.011 -1.382 0.167 
Genomic posterior_thalamic_radiation -0.018 0.011 -1.586 0.113 
Genomic superior_longitudinal_fasciculus -0.014 0.012 -1.193 0.233 
Genomic superior_thalamic_radiation -0.019 0.012 -1.613 0.107 
Genomic uncinate_fasciculus -0.025 0.011 -2.284 0.022 




Genomic forceps_minor -0.017 0.012 -1.370 0.171 
Genomic middle_cerebellar_peduncle -0.019 0.012 -1.545 0.122 
Table S16. The effect of pruned NETRIN1- and Genomic-PRS at threshold 0.5 on 
individual white matter tracts (FA) (N = 6,420). 
 
PGRS THRESHOLD: 0.5 Value Std. Error t-value p-value 
NETRIN1 gFA -0.002 0.001 -1.966 0.049 
NETRIN1 Association fibres -0.002 0.001 -2.567 0.010 
NETRIN1 Thalamic radiations -0.001 0.000 -1.327 0.184 
NETRIN1 Projection fibres 0.000 0.001 -0.668 0.504 
Genomic gFA -0.002 0.001 -1.794 0.073 
Genomic Association fibres -0.001 0.001 -1.656 0.098 
Genomic Thalamic radiations -0.001 0.000 -1.376 0.169 
Genomic Projection fibres -0.001 0.001 -1.983 0.047 
Table S17. The effect of unpruned NETRIN1- and Genomic-PRS at threshold 0.5 on tract 
categories (FA) (N = 6,420). 
 
PGRS THRESHOLD: 0.01 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation 0.006 0.011 0.544 0.586 
NETRIN1 anterior_thalamic_radiation 0.008 0.011 0.773 0.439 
NETRIN1 cingulate_gyrus_part_of_cingulum 0.013 0.011 1.241 0.215 
NETRIN1 parahippocampal_part_of_cingulum -0.012 0.011 -1.116 0.264 
NETRIN1 corticospinal_tract -0.002 0.011 -0.206 0.837 
NETRIN1 inferior_fronto_occipital_fasciculus 0.017 0.011 1.482 0.138 
NETRIN1 inferior_longitudinal_fasciculus 0.017 0.011 1.543 0.123 
NETRIN1 medial_lemniscus 0.013 0.011 1.225 0.220 
NETRIN1 posterior_thalamic_radiation 0.008 0.011 0.773 0.439 
NETRIN1 superior_longitudinal_fasciculus 0.018 0.011 1.556 0.120 
NETRIN1 superior_thalamic_radiation 0.008 0.010 0.851 0.395 
NETRIN1 uncinate_fasciculus 0.014 0.010 1.387 0.165 
NETRIN1 bl.MD.wm.forceps_major 0.009 0.012 0.741 0.459 
NETRIN1 bl.MD.wm.forceps_minor 0.016 0.012 1.390 0.165 
NETRIN1 bl.MD.wm.middle_cerebellar_peduncle -0.004 0.012 -0.350 0.726 
Genomic acoustic_radiation -0.004 0.011 -0.353 0.724 
Genomic anterior_thalamic_radiation 0.019 0.011 1.833 0.067 
Genomic cingulate_gyrus_part_of_cingulum 0.024 0.011 2.263 0.024 
Genomic parahippocampal_part_of_cingulum 0.008 0.011 0.715 0.475 
Genomic corticospinal_tract 0.012 0.011 1.041 0.298 
Genomic inferior_fronto_occipital_fasciculus 0.019 0.011 1.711 0.087 
Genomic inferior_longitudinal_fasciculus 0.008 0.011 0.758 0.449 
Genomic medial_lemniscus 0.001 0.011 0.117 0.907 
Genomic posterior_thalamic_radiation -0.001 0.011 -0.100 0.920 
Genomic superior_longitudinal_fasciculus 0.017 0.011 1.503 0.133 
Genomic superior_thalamic_radiation 0.018 0.010 1.831 0.067 
Genomic uncinate_fasciculus 0.023 0.010 2.213 0.027 
Genomic bl.MD.wm.forceps_major 0.014 0.012 1.138 0.255 
Genomic bl.MD.wm.forceps_minor 0.018 0.012 1.602 0.109 
Genomic bl.MD.wm.middle_cerebellar_peduncle 0.010 0.012 0.821 0.411 
     
PGRS THRESHOLD: 0.05 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation -0.010 0.010 -0.947 0.344 




NETRIN1 cingulate_gyrus_part_of_cingulum 0.014 0.011 1.273 0.203 
NETRIN1 parahippocampal_part_of_cingulum 0.001 0.011 0.082 0.935 
NETRIN1 corticospinal_tract -0.006 0.011 -0.575 0.565 
NETRIN1 inferior_fronto_occipital_fasciculus 0.010 0.011 0.883 0.377 
NETRIN1 inferior_longitudinal_fasciculus 0.014 0.011 1.274 0.203 
NETRIN1 medial_lemniscus 0.004 0.011 0.395 0.693 
NETRIN1 posterior_thalamic_radiation 0.011 0.011 0.993 0.321 
NETRIN1 superior_longitudinal_fasciculus 0.018 0.011 1.549 0.122 
NETRIN1 superior_thalamic_radiation 0.007 0.010 0.741 0.458 
NETRIN1 uncinate_fasciculus 0.008 0.010 0.780 0.435 
NETRIN1 bl.MD.wm.forceps_major 0.011 0.012 0.937 0.349 
NETRIN1 bl.MD.wm.forceps_minor 0.009 0.012 0.752 0.452 
NETRIN1 bl.MD.wm.middle_cerebellar_peduncle -0.007 0.012 -0.600 0.549 
Genomic acoustic_radiation 0.004 0.010 0.428 0.669 
Genomic anterior_thalamic_radiation 0.018 0.011 1.754 0.079 
Genomic cingulate_gyrus_part_of_cingulum 0.021 0.011 1.993 0.046 
Genomic parahippocampal_part_of_cingulum 0.013 0.011 1.222 0.222 
Genomic corticospinal_tract 0.019 0.011 1.674 0.094 
Genomic inferior_fronto_occipital_fasciculus 0.024 0.011 2.168 0.030 
Genomic inferior_longitudinal_fasciculus 0.013 0.011 1.160 0.246 
Genomic medial_lemniscus 0.008 0.011 0.724 0.469 
Genomic posterior_thalamic_radiation 0.001 0.011 0.091 0.928 
Genomic superior_longitudinal_fasciculus 0.017 0.011 1.492 0.136 
Genomic superior_thalamic_radiation 0.017 0.010 1.735 0.083 
Genomic uncinate_fasciculus 0.015 0.010 1.418 0.156 
Genomic bl.MD.wm.forceps_major 0.016 0.012 1.298 0.194 
Genomic bl.MD.wm.forceps_minor 0.020 0.012 1.703 0.089 
Genomic bl.MD.wm.middle_cerebellar_peduncle 0.010 0.012 0.791 0.429 
     
PGRS THRESHOLD: 0.1 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation -0.008 0.011 -0.727 0.468 
NETRIN1 anterior_thalamic_radiation 0.014 0.011 1.297 0.195 
NETRIN1 cingulate_gyrus_part_of_cingulum 0.014 0.011 1.352 0.176 
NETRIN1 parahippocampal_part_of_cingulum -0.009 0.011 -0.899 0.369 
NETRIN1 corticospinal_tract -0.001 0.011 -0.071 0.943 
NETRIN1 inferior_fronto_occipital_fasciculus 0.018 0.011 1.641 0.101 
NETRIN1 inferior_longitudinal_fasciculus 0.020 0.011 1.774 0.076 
NETRIN1 medial_lemniscus 0.015 0.011 1.377 0.169 
NETRIN1 posterior_thalamic_radiation 0.014 0.011 1.334 0.182 
NETRIN1 superior_longitudinal_fasciculus 0.027 0.011 2.413 0.016 
NETRIN1 superior_thalamic_radiation 0.016 0.010 1.652 0.099 
NETRIN1 uncinate_fasciculus 0.010 0.010 0.991 0.321 
NETRIN1 forceps_major 0.014 0.012 1.205 0.228 
NETRIN1 forceps_minor 0.015 0.012 1.284 0.199 
NETRIN1 middle_cerebellar_peduncle 0.004 0.012 0.359 0.720 
Genomic acoustic_radiation 0.002 0.011 0.161 0.872 
Genomic anterior_thalamic_radiation 0.011 0.011 1.023 0.306 
Genomic cingulate_gyrus_part_of_cingulum 0.014 0.011 1.306 0.191 
Genomic parahippocampal_part_of_cingulum 0.016 0.011 1.537 0.124 
Genomic corticospinal_tract 0.013 0.011 1.167 0.243 
Genomic inferior_fronto_occipital_fasciculus 0.014 0.011 1.228 0.219 
Genomic inferior_longitudinal_fasciculus 0.006 0.011 0.516 0.606 
Genomic medial_lemniscus -0.003 0.011 -0.323 0.747 
Genomic posterior_thalamic_radiation -0.008 0.011 -0.791 0.429 




Genomic superior_thalamic_radiation 0.008 0.010 0.776 0.438 
Genomic uncinate_fasciculus 0.013 0.010 1.246 0.213 
Genomic forceps_major 0.009 0.012 0.751 0.453 
Genomic forceps_minor 0.010 0.012 0.852 0.394 
Genomic middle_cerebellar_peduncle 0.009 0.012 0.712 0.476 
     
PGRS THRESHOLD: 0.5 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation -0.002 0.010 -0.187 0.852 
NETRIN1 anterior_thalamic_radiation 0.020 0.011 1.854 0.064 
NETRIN1 cingulate_gyrus_part_of_cingulum 0.017 0.011 1.586 0.113 
NETRIN1 parahippocampal_part_of_cingulum -0.009 0.011 -0.813 0.416 
NETRIN1 corticospinal_tract 0.008 0.011 0.694 0.488 
NETRIN1 inferior_fronto_occipital_fasciculus 0.025 0.011 2.193 0.028 
NETRIN1 inferior_longitudinal_fasciculus 0.025 0.011 2.221 0.026 
NETRIN1 medial_lemniscus 0.004 0.011 0.338 0.736 
NETRIN1 posterior_thalamic_radiation 0.020 0.011 1.878 0.060 
NETRIN1 superior_longitudinal_fasciculus 0.030 0.011 2.603 0.009 
NETRIN1 superior_thalamic_radiation 0.020 0.010 2.051 0.040 
NETRIN1 uncinate_fasciculus 0.015 0.010 1.421 0.155 
NETRIN1 forceps_major 0.014 0.012 1.181 0.237 
NETRIN1 forceps_minor 0.014 0.012 1.202 0.229 
NETRIN1 middle_cerebellar_peduncle 0.009 0.012 0.759 0.448 
Genomic acoustic_radiation -0.002 0.010 -0.177 0.860 
Genomic anterior_thalamic_radiation 0.013 0.011 1.216 0.224 
Genomic cingulate_gyrus_part_of_cingulum 0.014 0.011 1.359 0.174 
Genomic parahippocampal_part_of_cingulum 0.018 0.011 1.678 0.093 
Genomic corticospinal_tract 0.002 0.011 0.205 0.838 
Genomic inferior_fronto_occipital_fasciculus 0.014 0.011 1.238 0.216 
Genomic inferior_longitudinal_fasciculus 0.006 0.011 0.495 0.621 
Genomic medial_lemniscus -0.002 0.011 -0.204 0.839 
Genomic posterior_thalamic_radiation -0.010 0.011 -0.972 0.331 
Genomic superior_longitudinal_fasciculus 0.008 0.011 0.667 0.505 
Genomic superior_thalamic_radiation 0.006 0.010 0.582 0.561 
Genomic uncinate_fasciculus 0.010 0.010 0.960 0.337 
Genomic forceps_major 0.014 0.012 1.202 0.230 
Genomic forceps_minor 0.016 0.012 1.425 0.154 
Genomic middle_cerebellar_peduncle 0.011 0.012 0.870 0.384 
     
PGRS THRESHOLD: 1 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation -0.003 0.010 -0.333 0.739 
NETRIN1 anterior_thalamic_radiation 0.022 0.011 2.070 0.039 
NETRIN1 cingulate_gyrus_part_of_cingulum 0.018 0.011 1.698 0.089 
NETRIN1 parahippocampal_part_of_cingulum -0.006 0.011 -0.608 0.543 
NETRIN1 corticospinal_tract 0.009 0.011 0.789 0.430 
NETRIN1 inferior_fronto_occipital_fasciculus 0.024 0.011 2.176 0.030 
NETRIN1 inferior_longitudinal_fasciculus 0.023 0.011 2.018 0.044 
NETRIN1 medial_lemniscus 0.004 0.011 0.355 0.723 
NETRIN1 posterior_thalamic_radiation 0.020 0.011 1.875 0.061 
NETRIN1 superior_longitudinal_fasciculus 0.029 0.011 2.576 0.010 
NETRIN1 superior_thalamic_radiation 0.021 0.010 2.132 0.033 
NETRIN1 uncinate_fasciculus 0.016 0.010 1.562 0.118 
NETRIN1 forceps_major 0.013 0.012 1.067 0.286 
NETRIN1 forceps_minor 0.016 0.012 1.403 0.161 
NETRIN1 middle_cerebellar_peduncle 0.008 0.012 0.664 0.507 




Genomic anterior_thalamic_radiation 0.013 0.011 1.202 0.229 
Genomic cingulate_gyrus_part_of_cingulum 0.014 0.011 1.292 0.196 
Genomic parahippocampal_part_of_cingulum 0.019 0.011 1.780 0.075 
Genomic corticospinal_tract 0.003 0.011 0.258 0.796 
Genomic inferior_fronto_occipital_fasciculus 0.013 0.011 1.167 0.243 
Genomic inferior_longitudinal_fasciculus 0.005 0.011 0.471 0.638 
Genomic medial_lemniscus -0.004 0.011 -0.396 0.692 
Genomic posterior_thalamic_radiation -0.013 0.011 -1.172 0.241 
Genomic superior_longitudinal_fasciculus 0.006 0.011 0.549 0.583 
Genomic superior_thalamic_radiation 0.005 0.010 0.464 0.643 
Genomic uncinate_fasciculus 0.010 0.010 0.983 0.326 
Genomic forceps_major 0.015 0.012 1.282 0.200 
Genomic forceps_minor 0.012 0.012 1.044 0.296 
Genomic middle_cerebellar_peduncle 0.012 0.012 1.006 0.314 
Table S18. The effect of pruned NETRIN1- and Genomic-PRS at thresholds 0.01, 0.05, 0.1, 
0.5 and 1 on individual white matter tracts (MD) (N = 6,390). 
 
PGRS THRESHOLD: 0.01 Value Std. Error t-value p-value 
NETRIN1 gMD 0.011 0.012 0.998 0.318 
NETRIN1 Association fibres 0.009 0.012 0.737 0.461 
NETRIN1 Thalamic radiations 0.010 0.011 0.896 0.370 
NETRIN1 Projection fibres 0.005 0.012 0.429 0.668 
Genomic gMD 0.018 0.011 1.546 0.122 
Genomic Association fibres 0.020 0.012 1.690 0.091 
Genomic Thalamic radiations 0.011 0.011 1.041 0.298 
Genomic Projection fibres 0.015 0.012 1.205 0.228 
     
PGRS THRESHOLD: 0.05 Value Std. Error t-value p-value 
NETRIN1 gMD 0.010 0.011 0.844 0.399 
NETRIN1 Association fibres 0.012 0.012 0.995 0.320 
NETRIN1 Thalamic radiations 0.010 0.011 0.916 0.360 
NETRIN1 Projection fibres -0.003 0.012 -0.268 0.789 
Genomic gMD 0.021 0.011 1.798 0.072 
Genomic Association fibres 0.022 0.012 1.913 0.056 
Genomic Thalamic radiations 0.012 0.011 1.091 0.276 
Genomic Projection fibres 0.019 0.012 1.595 0.111 
     
PGRS THRESHOLD: 0.1 Value Std. Error t-value p-value 
NETRIN1 gMD 0.015 0.011 1.327 0.184 
NETRIN1 Association fibres 0.011 0.012 0.970 0.332 
NETRIN1 Thalamic radiations 0.017 0.011 1.583 0.114 
NETRIN1 Projection fibres 0.010 0.012 0.796 0.426 
Genomic gMD 0.012 0.011 1.064 0.287 
Genomic Association fibres 0.018 0.012 1.539 0.124 
Genomic Thalamic radiations 0.001 0.011 0.120 0.904 
Genomic Projection fibres 0.012 0.012 1.010 0.312 
     
PGRS THRESHOLD: 0.5 Value Std. Error t-value p-value 
NETRIN1 gMD 0.020 0.011 1.783 0.075 
NETRIN1 Association fibres 0.015 0.012 1.328 0.184 
NETRIN1 Thalamic radiations 0.023 0.011 2.169 0.030 
NETRIN1 Projection fibres 0.014 0.012 1.171 0.242 
Genomic gMD 0.012 0.011 1.045 0.296 




Genomic Thalamic radiations 0.001 0.011 0.050 0.960 
Genomic Projection fibres 0.014 0.012 1.174 0.240 
     
PGRS THRESHOLD: 1 Value Std. Error t-value p-value 
NETRIN1 gMD 0.021 0.011 1.829 0.068 
NETRIN1 Association fibres 0.016 0.012 1.412 0.158 
NETRIN1 Thalamic radiations 0.024 0.011 2.263 0.024 
NETRIN1 Projection fibres 0.013 0.012 1.060 0.289 
Genomic gMD 0.011 0.011 0.979 0.328 
Genomic Association fibres 0.018 0.012 1.533 0.125 
Genomic Thalamic radiations -0.001 0.011 -0.091 0.928 
Genomic Projection fibres 0.015 0.012 1.206 0.228 
Table S19. The effect of pruned NETRIN1- and Genomic-PRS at thresholds 0.01, 0.05, 0.1, 
0.5 and 1 on tract categories (MD) (N = 6,390). 
 
PGRS THRESHOLD: 0.5 Value Std. Error t-value p-value 
NETRIN1 acoustic_radiation -0.002 0.011 -0.223 0.824 
NETRIN1 anterior_thalamic_radiation 0.015 0.011 1.434 0.151 
NETRIN1 cingulate_gyrus_part_of_cingulum 0.013 0.011 1.153 0.249 
NETRIN1 parahippocampal_part_of_cingulum -0.008 0.011 -0.762 0.446 
NETRIN1 corticospinal_tract 0.004 0.012 0.341 0.733 
NETRIN1 inferior_fronto_occipital_fasciculus 0.020 0.011 1.764 0.078 
NETRIN1 inferior_longitudinal_fasciculus 0.020 0.011 1.779 0.075 
NETRIN1 medial_lemniscus 0.001 0.011 0.059 0.953 
NETRIN1 posterior_thalamic_radiation 0.017 0.011 1.588 0.112 
NETRIN1 superior_longitudinal_fasciculus 0.023 0.011 2.036 0.042 
NETRIN1 superior_thalamic_radiation 0.015 0.010 1.456 0.145 
NETRIN1 uncinate_fasciculus 0.012 0.011 1.102 0.271 
NETRIN1 forceps_major 0.014 0.012 1.146 0.252 
NETRIN1 forceps_minor 0.011 0.012 0.949 0.342 
NETRIN1 middle_cerebellar_peduncle 0.007 0.012 0.573 0.567 
Genomic acoustic_radiation -0.009 0.011 -0.817 0.414 
Genomic anterior_thalamic_radiation 0.003 0.011 0.261 0.794 
Genomic cingulate_gyrus_part_of_cingulum 0.003 0.011 0.234 0.815 
Genomic parahippocampal_part_of_cingulum 0.010 0.011 0.980 0.327 
Genomic corticospinal_tract -0.008 0.012 -0.656 0.512 
Genomic inferior_fronto_occipital_fasciculus 0.002 0.011 0.164 0.870 
Genomic inferior_longitudinal_fasciculus -0.005 0.011 -0.427 0.669 
Genomic medial_lemniscus -0.009 0.011 -0.790 0.430 
Genomic posterior_thalamic_radiation -0.018 0.011 -1.651 0.099 
Genomic superior_longitudinal_fasciculus -0.002 0.012 -0.187 0.851 
Genomic superior_thalamic_radiation -0.004 0.011 -0.335 0.738 
Genomic uncinate_fasciculus 0.000 0.011 -0.035 0.972 
Genomic forceps_major 0.005 0.012 0.440 0.660 
Genomic forceps_minor 0.004 0.012 0.352 0.725 
Genomic middle_cerebellar_peduncle 0.006 0.012 0.455 0.649 
Table S20. The effect of unpruned NETRIN1- and Genomic-PRS at threshold 0.5 on 







PGRS THRESHOLD: 0.5 Value Std. Error t-value p-value 
NETRIN1 gMD 2.53E-06 1.42E-06 1.78E+00 7.47E-02 
NETRIN1 Association fibres 1.43E-06 1.08E-06 1.33E+00 1.84E-01 
NETRIN1 Thalamic radiations 1.71E-06 7.87E-07 2.17E+00 3.01E-02 
NETRIN1 Projection fibres 9.36E-07 8.00E-07 1.17E+00 2.42E-01 
Genomic gMD 1.50E-06 1.43E-06 1.04E+00 2.96E-01 
Genomic Association fibres 1.66E-06 1.09E-06 1.53E+00 1.27E-01 
Genomic Thalamic radiations 3.99E-08 7.93E-07 5.02E-02 9.60E-01 
Genomic Projection fibres 9.47E-07 8.06E-07 1.17E+00 2.40E-01 
Table S21. The effect of unpruned NETRIN1- and Genomic-PRS at threshold 0.5 on tract 
categories (MD) (N = 6,420). 
 
Results depicted in tables S6 – S21 indicate secondary analyses which complement the 
primary analyses. These consist firstly of the effect unpruned NETRIN1- and genomic-
PRS on FA and MD values, conducted on both the full dataset (N = 6,420) and the 
dataset with excluded outliers (N = 6,401 and 6,390 for FA and MD, respectively). 
Secondly, the effect of pruned NETRIN1- and genomic-PRS on FA and MD values 
was also investigated, again conducted on both the full dataset and dataset with 
excluded outliers. The analyses consist of PRS at all five p-value thresholds (0.01, 
0.05, 0.1, 0.5 and 1). A similar pattern is observed for significance in white matter 
tracts associated with both PRS lists across PRS thresholds within the dataset with 
outliers removed. Some tracts remain significant within the full sample dataset as 
compared to the sample with outliers removed at PRS threshold 0.5, however there is 
a trend towards more significant results when outliers are removed. Please refer to 
tables S8-S9, S12-S13, S16-S17 and S20-S21 for an account of results at PRS 
threshold 0.5 within the full dataset, which are directly comparable to the primary 











White matter tracts significantly associated with both NETRIN1-PRS and genomic-PRS. 
Fractional anisotropy 
Tract categories 
Significantly lower FA values in association fibres were found for both NETRIN1-PRS (β = -




Significantly higher gMD was associated with both NETRIN1-PRS (β = 0.027, pcorrected = 
0.031) and genomic-PRS (β = 0.033, pcorrected = 0.006). 
Individual white matter tracts 
Significantly higher MD in the inferior fronto-occipital fasciculus was found for both 















Appendix 3: Supplementary materials for Chapter 4: Genetic and epigenetic 
prediction of Major Depressive Disorder and associations with white matter 
microstructure in Generation Scotland 
Details of exclusion process in TBSS pre-processing pipeline 
 
Figure S1. At time of pre-processing, 983 individuals had raw DTI data available. The 
figure above indicates the two visual QC steps. At the DTIFIT QC step, the main 
reason for exclusion was enlarged ventricles in individuals. These individuals were 
excluded as in later steps in the pre-processing pipeline, a mean FA image would be 
compiled, which could be skewed due to enlarged ventricles. At the skeleton QC step, 














Individual white matter tracts included in global FA and MD PCA analyses 
White matter tract Abbreviation 
Cingulum (hippocampus) CGH 
Cingulum (cingulate gyrus) CGC 
Fornix* FX 
Fornix (cres) / Stria terminalis FX / ST 
Inferior fronto-occipital fasciculus IFO 
Superior fronto-occipital fasciculus SFO 
External capsule EC 
Superior longitudinal fasciculus SLF 
Sagittal striatum SS 
Uncinate fasciculus UNC 
Body of corpus callosum* BCC 
Genu of corpus callosum* GCC 
Splenium of corpus callosum* SCC 
Anterior corona radiata ACR 
Posterior corona radiata PCR 
Superior corona radiata SCR 
Corticospinal tract CST 
Anterior limb of internal capsule ALIC 
Posterior limb of internal capsule PLIC 
Posterior thalamic radiation PTR 
Retrolenticular limb of internal capsule RLIC 
Table S1. White matter tracts used as dependent variables in statistical analyses 
outlined below. * = unilateral tracts. 
 
The following tracts were excluded from the global FA and MD PCA derivation: (1) 
corpus callosum; (2) corona radiata; and (3) internal capsule. This is because TBSS 
outputs subsets of these three tracts, as well as the entire tract, as indicated below. 
Including the subsets as well as the entire tract output would have resulted in over-
inclusion of these regions; including the three sub-sets of tracts within these overall 
tracts aided in observing whether there is an association of the two risk scores with 
specific, individualised white matter tracts, rather than a more regional estimate 
comprising all three. 
1. For corpus callosum: body, genu, and splenium of corpus callosum. 
2. For corona radiata: anterior, posterior, and superior corona radiata. 





CpG site Beta CpG site Beta 
cg20116804 -0.015421634 cg18751657 0.027288385 
cg15971980 0.006942908 cg04821375 0.024358727 
cg01049205 0.067276206 cg02634584 0.757509208 
cg12736206 0.036873976 cg19143959 -0.266215326 
cg22225420 0.278735199 cg02203922 -0.053844111 
cg11044575 0.113164134 cg03903647 -0.353215677 
cg24254177 0.26284975 cg25610515 0.019056411 
cg22407822 0.001719539 cg02822381 0.069731732 
cg20984994 -0.028034876 cg18200311 -0.003902515 
cg26063721 -0.064925727 cg17943757 -0.13338057 
cg24173182 0.093449601 cg11463427 0.228010283 
cg10539371 -0.266530585 cg27653901 -0.21325932 
cg17250537 0.114100798 cg08744097 -0.075534229 
cg25985659 -0.016420323 cg13483916 0.113879106 
cg02576528 -0.008732521 cg25821785 0.045204034 
cg21124940 0.125069705 cg26621790 -2.09E-05 
cg01038738 0.09211571 cg10435816 -0.114915234 
cg21022949 -0.122922677 cg09490565 0.064310355 
cg18197594 -0.037357869 cg01170758 0.743479881 
cg18090197 0.275197436 cg13278241 -0.244617463 
cg14728380 0.000910739 cg17775332 -0.046708676 
cg15248828 0.004431601 cg27404676 0.08042557 
cg03859186 0.182232759 cg20528583 -7.91E-05 
cg13247663 -0.131885152 cg15770238 0.036076248 
cg13529291 0.172056972 cg07920739 -0.032823893 
cg14996929 -0.053869123 cg07861790 -0.064235819 
cg04191989 0.134906691 cg01950844 0.2704649 
cg09906991 -0.003536151 cg07971952 0.025230404 
cg06482498 -0.002781115 cg06157334 -0.05587217 
cg18035255 -0.234119678 cg05592146 -0.02029348 
cg22044566 -0.052043377 cg14210405 0.065082199 
cg02459042 -0.005130736 cg26579032 -0.03597194 
cg02055264 0.020186238 cg07323350 -0.322253068 
cg25242471 0.095306294 cg21562656 -0.073532389 
cg07548512 -0.389017708 cg10139443 -0.908790082 
cg10928544 0.00597106 cg03736774 0.181528807 
cg24072885 0.174686087 cg03827626 -0.495993086 
cg08464831 -0.077103695 cg09614389 0.001449656 
cg17054674 -0.109492909 cg25600478 -0.013482982 
cg26172211 -0.75833086 cg04029366 -0.08658678 
cg26038465 0.065443581 cg25394505 0.075190223 




cg16081176 0.099548626 cg26720682 0.032298882 
cg24601536 0.084188501 cg10401489 -0.01351181 
cg27332938 -0.075262664 cg12962542 -0.132560179 
cg20674014 0.204549134 cg26422761 -0.072979904 
cg23986470 0.110633334 cg12461092 0.012583705 
cg08873940 0.390595732 cg00298921 -0.025104852 
cg16605431 -0.067886882 cg21974358 -0.057762198 
cg26416971 0.017162464 cg04349815 -0.048879526 
cg10438391 0.017884374 cg19421526 0.059908283 
cg01305745 0.182066587 cg05924543 0.236377006 
cg18355902 -0.108723476 cg08912860 0.071151194 
cg26099134 0.049722806 cg22024931 0.007790324 
cg22237300 -0.078493498 cg23817627 0.035000194 
cg20545941 -0.214689878 cg13999210 0.105935225 
cg14443301 -0.070153977 cg21621114 -0.03694387 
cg10451078 -0.162129625 cg03839794 -0.028866007 
cg20984053 -0.13668675 cg12160741 0.012219106 
cg20273485 -0.119750057 cg08805821 0.044670337 
cg05176970 0.012997037 cg03055837 -0.053989788 
cg07244098 -0.067200919 cg24456846 0.066426026 
cg02613370 0.129967025 cg01297383 -0.065075788 
cg03079761 -0.105643912 cg25949304 0.07527537 
cg12138286 0.186379821 cg05621218 -0.018744792 
cg12654519 -0.218628548 cg21292008 -0.076694204 
cg24583766 0.042427484 cg15207669 0.063024294 
cg25707767 0.002092093 cg23214464 -0.011578311 
cg04772025 -0.007247445 cg04758026 0.007067428 
cg13463245 -0.104253112 cg09865955 -0.038167735 
cg19866673 -0.03368796 cg13751872 0.001763831 
cg16761754 0.01285452 cg15046935 0.067951209 
cg14375923 -0.039366583 cg12609526 0.13350385 
cg09910998 0.028668133 cg19698976 0.005413523 
cg24948792 -0.090876298 cg00828721 0.03947539 
cg17537844 0.00997141 cg01494348 0.033054139 
cg12140144 0.056099238 cg27168858 -0.028599887 
cg10515332 0.160491599 cg26146184 0.086514453 
cg02770534 -0.017156512 cg00555420 -0.022829456 
cg07296835 0.035630636 cg27129029 0.022538802 
cg06781788 -0.026267442 cg24367957 -0.030035942 
cg18944924 -0.068730008 cg11507780 -0.004280805 
cg03230711 -0.037727384 cg20821187 -0.030688714 
cg24185124 0.219559925 cg09552652 -0.060135871 

































cg17983217 0.070366023 cg22539189 -0.050789338 
cg20711828 0.163479128 cg09935388 -0.041843214 
cg07733920 -0.046450328 cg15849154 0.005918876 
cg00287370 -0.713805334 cg22738642 -0.017391434 
cg21601837 0.031436265 cg14157549 0.038867665 
cg22210337 0.01654544 cg06360820 -0.011082584 
cg09320113 0.192740454 cg08800396 -0.004683139 
cg07163389 -0.174219338 cg18815120 -0.002973236 
cg05828191 -0.085560334 cg02082929 0.008323224 
cg22430972 0.860620796 cg09557034 -0.093897544 
cg08821669 -0.014756084 cg00344422 -0.007259721 
cg24252746 -0.709664177 cg00318111 0.08602903 
cg00474840 -0.505416185 cg21549285 -0.060031127 
cg18811093 -0.054353706 cg05141400 -0.018150327 
cg23889772 0.028348977 cg24425727 -0.002068791 
cg04884395 -0.216310791 cg09768983 -0.002262711 
cg19047068 -0.07625118 cg19806221 0.005584262 
cg16088894 -0.019705825 cg07576632 -0.017198847 
cg15673187 -0.110154478 cg07801181 -0.011335721 
cg14337472 -0.237370309 cg02211983 0.000787545 
cg23878564 0.040093287 cg17542176 -0.087123853 
cg14959820 0.094109238 cg25189904 -0.052305954 
cg07076105 -0.080253123 cg16685388 0.005120511 
cg08747591 -0.171259744 cg07620573 -0.053164589 
cg06819963 0.060736712 cg15374515 -0.080333691 
cg24754199 0.244701222 cg17109042 -0.069025755 
cg02505588 0.045103077 cg16322792 0.0101152 
cg16442574 -0.118103539 cg14164492 0.027446766 
cg17517128 -0.02734914 cg16434510 -0.026626517 
cg23273834 0.103155906 cg22507558 -0.045030822 
cg02813644 -0.147179559 cg27304415 0.006514712 
cg21848117 0.067060087 cg21243459 -0.030101755 
cg24476033 0.028594309 cg17568934 -0.006180372 
cg07761822 0.066217342 cg24487940 -0.066777461 
cg14070323 0.036294258 cg01859717 -0.218157298 
cg13422261 0.225832858 cg08754268 -0.042172831 
cg01893681 -0.024661955 cg11864774 -0.048926955 
cg21033440 0.054716338 cg10185424 -0.017677734 
cg05544413 -0.057264219 cg14156792 -0.002430209 
cg25982965 -0.021451257 cg15611176 0.152441437 
cg14556303 -0.020044439 cg07211220 -0.105345409 
cg26326298 0.341406175 cg06754079 -0.002567777 
Table S2. CpG sites selected by the LASSO penalised regression model for the MDD 
DNAm predictor and their beta weights. 
 
